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Introduction 
It is with great pleasure that I 
present the annual report of the 
Health Protection Surveillance
Centre for 2010.
 
Once again, it was a busy year 
for surveillance and control of 
infectious diseases in Ireland. At 
the start of 2010 we witnessed 
the last remnants of the first 
influenza pandemic this century, and a moderately 
severe influenza season occurred at the end of 2010 and 
early 2011. While influenza-like-illness (ILI) rates in under 
15 year olds were lower than during the pandemic, 
ILI rates in the 15-64 year age group and those aged 
over 65 years were higher.  Overall, 121 patients with 
influenza were admitted to intensive care with the 
highest admission rate in the 55-64 year age group.  
Although 75% of the 107 adults admitted to ICU had 
pre-existing medical conditions, only 18 had been 
vaccinated during the 2010/2011 flu season.  Thirty two 
deaths occurred in people with laboratory confirmed 
influenza, yet only four of these people were known 
to have received influenza vaccine.  These statistics 
underline the message that influenza is a serious but 
preventable illness and reinforce the need for those 
in high risk groups and those aged over 65 to get 
vaccinated.
Measles cases continued to increase in 2010, following 
an upsurge in 2009.  Overall, 403 cases were notified in 
2010 and 108 of these cases were hospitalised.  Forty 
separate measles outbreaks were reported during the 
year.  Cases predominantly occurred in the traveller and 
Roma communities and amongst those who choose 
not to have their children vaccinated against vaccine 
preventable diseases.   
Mumps continued to circulate in 2010 and reported 
complications of this disease included orchitis, deafness, 
pancreatitis, encephalitis and appendicitis.   A catch-
up vaccination campaign is needed to control and 
eliminate the continued transmission of measles, 
mumps and rubella in Ireland.
Invasive pneumococcal disease continues to 
decline following the introduction of the conjugate 
pneumococcal vaccine.  We saw a 25% reduction in 
all types of invasive pneumococcal disease in 2010 
compared with 2008, when the vaccine was introduced. 
There also has been a reduction in the proportion of 
penicillin-non-susceptible S. pneumoniae isolates.  
Sadly, in 2010, one death occurred from pneumococcal 
meningitis in a young child who was unvaccinated.
There was a decline in the uptake of the third dose 
of Men C vaccine and the booster of Hib vaccine in 
2010. This decline coincided with the launch of a new 
immunisation schedule which introduced an extra visit 
for children at 13 months of age.  It appears that many 
parents may have missed this new appointment and 
did not realise that their child was not fully vaccinated. 
New information materials have since been developed 
by the Health Service Executive (HSE) to highlight the 
number of visits required to complete the childhood 
immunisation schedule.
Much of the data provided to calculate immunisation 
coverage in 2010 was incomplete, as many of the 
information providers did not have the immunisation 
information systems needed to submit the required 
data.  A new national immunisation information system 
is being planned which hopefully will rectify these 
inadequacies in the future. 
In 2010, we saw a decrease in the provisional number 
of tuberculosis cases.  However, TB continues to be a 
serious disease.  Thirty four people who were diagnosed 
with tuberculosis in 2009 died, with ten of these deaths 
deemed directly attributable to the disease.  The quality 
of TB surveillance data declined in 2009.  Outcome data 
were only reported on 82.5% of cases.  This may be a 
reflection of other pressures on surveillance systems, 
such as work associated with pandemic influenza 
during 2009.  It is critically important for TB control 
in Ireland that the surveillance is maintained at a high 
level.  New guidelines on the Prevention and Control 
of Tuberculosis in Ireland were published by the HPSC’s 
Scientific Advisory Committee in 2010. 
Campylobacter remains the most common bacterial 
cause of gastroenteritis. The Food Safety Authority of 
Ireland has recently published recommendations for 
a practical campylobacter control programme in the 
poultry production and slaughter chain during 2011 and 
it is hoped that these new recommendations will lead 
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to a fall in human cases of food borne campylobacter 
infection. 
There has been a continued decline in the number of 
cryptosporidiosis cases in Ireland. This is very welcome 
as the most recent European report from the European 
Centre for Disease Prevention and Control (ECDC) 
identified Ireland as the member state with the highest 
incidence of this disease among those countries which 
provided data to ECDC in their latest report (2008 data). 
The very high rate of verotoxigenic Escherichia coli 
(VTEC) reported in 2009 decreased by 17% in 2010. 
There is a marked urban / rural divide indicating once 
again that contact with farm animals and the use of 
private water supplies are potential sources of this 
infection. It is reassuring that new discriminatory typing 
performed in the Public Health Laboratory at Cherry 
Orchard did not detect any large clusters  that had 
not been clinically identified in 2010, which could have 
raised the possibility of unidentified food sources for the 
disease.
An outbreak of S. Typhimurium in 2010, associated 
with consumption of duck eggs, prompted excellent 
collaboration between the Department of Agriculture, 
Food and the Marine, the FSAI and HPSC, resulting in 
new legislative controls for prevention of salmonella 
contamination in ducks and duck eggs. 
Once again, very large numbers of cases of hepatitis C 
were reported in 2010, with over 1200 cases reported 
for the year.   A recent study has estimated that 
between 20,000 and 50,000 people in Ireland are now 
chronically infected with hepatitis C. This will have 
serious implications for health services in the future as 
a significant proportion will go on to develop cirrhosis, 
liver failure and hepatocellular carcinoma. In this regard, 
the anticipated publication of the National Hepatitis C 
Strategy in 2012 is to be welcomed.
The highest proportion of new HIV diagnosis in 2010 
were among men who have sex with men (MSM), with  
40.5% of 331 newly diagnosed HIV cases occurring in 
this category.  This trend has been observed in many 
European countries to such an extent that ECDC now 
recommends that interventions to control HIV among 
MSM should be the cornerstone of HIV prevention 
strategies in Europe. 
In 2010 there was an 11% decline in new cases of 
Clostridium difficile-associated disease (CDAD). 
Enhanced surveillance showed that 20% of cases were 
associated with onset in the community. All health care 
professionals must promote practices known to reduce 
the incidence of CDAD, whether working in hospital or 
community settings.
New studies in Irish critical care units on catheter-
related infection were initiated in 2010 and  continued 
surveillance is required to accurately target 
interventions. 
HPSC, in conjunction with the Infection Prevention 
Society, developed and piloted a national hand 
hygiene observation audit tool and standard operating 
procedures for use in acute hospitals in 2010. This will 
be rolled out in 2011 with a programme of hospital 
hand hygiene auditor training.
HPSC was the coordinating centre in Ireland for a 
European survey on healthcare associated infection 
and antimicrobial use in long term care facilities in 
the summer of 2010. The low rate of pressure sores 
and urinary catheter use, despite a high proportion of 
incontinent and/or immobile residents, reflects a high 
quality of nursing and medical care within the facilities 
that participated in the study. However the antimicrobial 
use was higher than the overall European use.
Overall outpatient antimicrobial consumption fell by 
2% in 2010 compared with 2009.  However, hospital 
antimicrobial consumption rose by 4% for the same 
period. These rates are mid-to-high in comparison with 
other European countries but the recently launched 
HSE initiative on reducing unnecessary antibiotic usage 
should improve our ranking in Europe. 
The proportion of S. aureus bloodstream infections 
which were meticillin resistant (MRSA) has been 
steadily decreasing since 2006, and decreased further 
from 27.1% in 2009 to 24.4% in 2010.   Despite this 
success, an increase in the numbers and proportions 
of vancomycin resistant E. faecium (VRE) is worrying.  
Ireland has by far the highest level of resistance in 
the European Union. Antimicrobial resistance among 
Gram-negative bacteria, such as E. coli, also increased 
in 2010, and there are continued threats posed by 
emerging resistance mechanisms in these bacteria, such 
as carbapenemases in Enterobacteriaceae.
I would like to thank our colleagues who work 
voluntarily on the HPSC Scientific Advisory Committee 
and its sub-committees, our partners throughout the 
country, and all of the staff at HPSC whose dedication 
throughout the year makes this report possible.
Dr Darina O’Flanagan
Director
Health Protection Surveillance Centre
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In 2010, 28 cases of invasive Haemophilus influenzae 
disease were notified in Ireland (0.7/100,000 total 
population). This is a marked decrease compared to 
2009 when 43 cases were notified in (figure 1). 
The main changes in 2010, when compared to 2009, 
are the reductions in the number of non-typeable/non-
capsular strains from 25 to 20, of other typed strains 
(excluding type b)  from eight to three and of non-typed 
strains from nine to two, but an increase of type b 
strains from one to three (figure 1). No other noteworthy 
change in the number of cases due to other serotypes 
has been observed in recent years.
Non-typeable/non-capsular cases accounted for the 
majority of the invasive H. influenzae cases notified in 
2010 (71.4%, n=20/28). The remaining cases were due 
to H. influenza type b (10.7%, n=3), type f (10.7%; n=3) 
and isolates that were not typed (7.1%; n=2). The cases 
ranged in age from four days to 88 years. The incidence 
rates were highest in infants <1 year (3.3/100,000) and 
those aged 65 years or more (2.6/100,000) (table 1).
Cases occurring in children <10 years of age (n=5) and 
elderly adults over 65 years of age (n=12) accounted for 
60.7% of all invasive H. influenzae notifications in 2010 
(table 1).
The clinical manifestations of invasive H. influenzae 
disease in the five children <10 years of age in 2010 
were three cases of septicaemia and one case of 
pneumonia. Clinical diagnosis was not reported in the 
remaining case. A breakdown by clinical diagnosis 
for all age groups by year between 2004 and 2010 is 
presented in table 2.
No imported cases were reported in 2010, nor were 
there any invasive H. influenzae related deaths reported.
 
In 2010 three cases of H. influenzae type b (Hib) 
occurred, one in a completely vaccinated ten year-old 
child who had received three doses of Hib vaccine and 
in two unvaccinated adults (age range 23-76 years). In 
contrast, in 2009, there was only one Hib case reported: 
an incompletely vaccinated four year old who received 
three doses of the 5 in 1 vaccine but not the Hib 
booster dose.
In 2010, one true Hib vaccine failure was reported; 
the first since 2007 highlighting the positive impact 
the Hib booster catch up campaign has had in Ireland. 
Back in 2007, two true Hib vaccine failures occurred in 
children aged 14 years or less, one of whom died from 
1.1 Haemophilus influenzae (invasive) 
Number of cases, 2010: 28
Number of cases, 2009: 43
Number of cases, 2008: 22
Crude incidence rate, 2010: 0.7/100,000
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Figure 1. Annual number of invasive Haemophilus influenzae cases 
notified in Ireland, 2004-2010
septicaemia. Both children received three doses of 
Hib vaccine when they were less than one year of age. 
Similar to the Hib vaccine failure reported in 2010, one 
of the two true vaccine failures in 2007 occurred in a 10-
14 year old child who would not have been targeted by 
the catch-up programme, which ran between 2005 and 
2006 and was aimed (at the time) at children under four 
years of age.
Since September 2008, the, Hib booster dose has been 
administered at 13 months of age as part of the routine 
childhood immunisation schedule in addition to the 
three doses at 2, 4 and 6 months of age. Vaccination is 
routinely recommended for those at increased risk of 
Hib disease.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 4th August 
2011. These figures may differ from those published 
previously due to ongoing updating of notification data 
on CIDR.
Table 1. Number and incidence rates of invasive Haemophilus influenzae cases by serotype plus number of Hib vaccine failures 
by age group, 2010
Age Group Type b Type e Type f
Non-typeable/
non-capsular
Not 
Typed
Total
ASIR of 
Hib
ASIR of all H. 
influenzae
Type b 
TVFs
<1 0 0 0 2 0 2 0.00 3.27 0
1-4 0 0 0 2 0 2 0.00 0.83 0
5-9 0 0 0 1 0 1 0.00 0.35 0
10-19 1 0 0 1 0 2 0.18 0.35 1
20-34 1 0 0 3 1 5 0.09 0.47 0
35-54 0 0 2 2 0 4 0.00 0.35 0
55-64 0 0 0 0 0 0 0.00 0.00 0
65+ 1 0 1 9 1 12 0.21 2.56 0
All Ages 3 0 3 20 2 28 0.07 0.66 1
CIR 0.07 0.00 0.07 0.47 0.05 0.66 - - -
CIR, crude incidence rate per 100,000 total population
ASIR, age specific incidence rate per 100,000
TVFs, true Hib vaccine failures
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Table 2. Number of invasive Haemophilus influenzae cases by clinical diagnosis, 2004- 2010 
Clinical Diagnosis 2004 2005 2006 2007 2008 2009 2010
2004-
2010
% of 
Total
Septicaemia 8 14 13 6 3 9 8 61 26.1%
Pneumonia 5 0 3 6 3 8 5 30 12.8%
Meningitis 3 9 3 2 2 2 1 22 9.4%
Epiglottitis 1 3 3 1 1 0 2 11 4.7%
Cellulitis 1 1 2 1 1 0 0 6 2.6%
Meningitis & septicaemia 1 0 1 0 1 1 1 5 2.1%
Osteomyelitis 1 0 0 0 0 0 0 1 0.4%
Septic arthritis 0 1 0 0 1 0 0 2 0.9%
Unknown 18 6 13 15 10 23 11 96 41.0%
Total 38 34 38 31 22 43 28 234 100%
Table 3. Incidence rates of invasive Haemophilus influenzae by HSE area, 2004-2010
HSE Area 2004 2005 2006 2007 2008 2009 2010
E 1.1 1.0 0.9 0.8 0.5 0.8 0.6
M 0.5 0.5 0.2 0.5 0.3 0.5 0.2
MW 0.8 0.3 0.8 0.6 0.8 2.2 0.6
NE 0.2 1.1 0.2 0.0 0.0 0.2 0.4
NW 0.4 0.0 2.0 0.4 0.0 0.4 0.4
SE 1.3 0.5 1.0 1.3 0.8 1.3 1.3
S 3.0 0.8 3.4 0.8 1.7 3.4 3.0
W 0.5 1.4 0.7 1.4 0.5 1.2 0.2
Ireland 0.9 0.8 0.9 0.7 0.5 1.0 0.7
In 2010, there were 403 measles cases (9.5/100,000) 
notified in Ireland.  This is a 2.5-fold increase compared 
to 2009 when 162 cases were notified and a seven-
fold increase compared to 2008 when 55 cases were 
notified.  This increase is a result of a national measles 
outbreak that was first identified in August 2009 and 
continued into early May 2010.  Measles cases by week 
and month of notification from July 2009 to December 
2010 are shown in figure 1.  Eight-one percent 
(n=328/403) of cases in 2010 were notified between 
January and early May (Weeks 1-18).
In Week 31 2009 (week ending 8th August 2009), a 
confirmed measles case, in an adult who worked in a 
general practice, was notified in the HSE-S.  In Week 33 
2009, a measles case in a Roma child was notified in the 
same Area, this case’s general practitioner worked in the 
same building as the previous case.  In Week 37, 2009, 
two measles cases, one in a child from the Irish Traveller 
community and one in a hospital contact of this case, 
were notified in the HSE-S.  During Weeks 38 and 39, six 
cases in Irish Travellers were notified in the HSE-S.  From 
then on measles continued to circulate and spread to 
other HSE Areas.  The measles outbreak continued into 
early May 2010.  
At the start of the outbreak, a national outbreak control 
team was convened, which included health professionals 
from the departments of public health in the HSE 
Areas, HSE-Health Protection Surveillance Centre, HSE-
National Immunisation Office, HSE Population Health, 
HSE Social Inclusion, the Institute of Obstetricians and 
Gynaecologists, the National Virus Reference Laboratory 
and the field of Paediatric Infectious Disease. This 
group agreed public health strategies (vaccination and 
management of cases and close contacts, awareness-
1.2 Measles 
Summary
Number of cases, 2010: 403
Number of confirmed cases, 2010: 299                                                                       
Crude incidence rate, 2010: 9.5/100,000
Crude confirmed incidence rate, 2010: 7.1/100,000
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Figure 1. Number of measles cases notified by week and month July 2009 to December 2010
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raising among clinicians and in the community) to 
control the outbreak at national and local level.
Of the 403 measles cases notifed in 2010, 26% (n=104) 
were classified as possible while 74% (n=299) were 
classified as confirmed, giving a crude confirmed 
incidence rate of 7.1 per 100,000 population.  Of 
the confirmed cases, it was known that 76% (n=228) 
were laboratory confirmed and 24% (n=71) were only 
epidemiologically linked to a laboratory confirmed case. 
The largest number of cases notified in 2010 was in the 
HSE-E while the highest crude incidence rate was in the 
HSE-S (table 1).
In 2010, measles cases ranged in age from one month 
to 50 years.  The number of cases by age group and the 
age specific incidence rates are shown in figures 2 and 
3.  The highest age specific incidence rate was in those 
aged <1 year (figure 3).  Of the 403 measles cases 50% 
(n=203) were male and 50% (n=200) were female.
Laboratory results were provided for 272 (67%, 
n=272/403) cases in 2010.  Two hundred and twenty 
eight cases (57%, n=228/403) were laboratory positive 
for measles.  Two further cases were laboratory positive 
(based on serology) for measles, however, the positive 
results may have represented responses to recent 
vaccinations.  The laboratory results for eight cases 
were recorded as inconclusive.  Thirty-four cases were 
laboratory negative for measles, however, for 29 of 
these the specimens were not taken at the optimal 
time following disease onset or the date of specimen 
collection in relation to disease onset was unknown (the 
optimal time following disease onset for collecting oral 
fluid specimens for measles IgM testing is greater than 
seven days to two months and the optimal time for 
collecting serum specimens for measles IgM testing is 
greater than four days to two-three months).  The five 
cases that were laboratory negative for measles and 
were known to have a specimen collected at the optimal 
time were classified as possible cases.
Measles vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR is 
routinely recommended at twelve months of age and 
the second dose at four to five years of age.
Vaccination data were reported for 82% (n=332/403) of 
measles cases in 2010.  Sixty-four percent (n=257/403) 
of cases were unvaccinated; only 28% (n=73/257) of 
these were less than 12 months of age.
Sixteen percent (n=64/403) had one dose of MMR 
vaccine; 81% (n=52/64) of these were less than six years 
of age.  Fifty-two percent (n=33/64) of those reported 
to have one dose of MMR were classified as confirmed.  
Seventy-five percent (n=48/64) with one dose of MMR 
had a vaccination date reported, 29% (n=14/48) of 
these were vaccinated ≤16 days before onset of illness 
and were probably incubating measles at the time of 
vaccination.
Three percent (n=11/403) were reported as having 
received two doses of MMR.  Only four of these cases 
were laboratory confirmed and only one of these four 
laboratory confirmed cases had both vaccination dates 
reported. 
One hundred and eight cases were reported as 
hospitalised, representing 27% (n=108/403) of all 
cases.  The hospitalised cases ranged in age from one 
month to 50 years with 94% (n=101/108) classified as 
confirmed cases and six percent (n=7/108) classified as 
possible cases.  Length of hospitalisation was reported 
for 71% (n=77/108) with a median duration of stay of 
three days (range one to nineteen days); 18% (n=14/77) 
were reported as hospitalised for one day.  Of the 108 
hospitalised cases, 22% (n=24) had no MMR details 
reported while 68% (n=73) were unvaccinated.  Nine 
percent (n=10/108) were reported to have one dose 
of MMR; 60% (n=6/10) of these had a vaccination 
date recorded, 50% (n=3/6) of these were vaccinated 
less than 10 days prior to onset and may have been 
incubating measles at the time of vaccination.  The 
remaining hospitalised case (1%) was reported to have 
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Figure 3. The age specific incidence rate (per 100,000) of 
notified measles cases in 2010 by case classification
Figure 2. Number of notified measles cases in 2010 by age 
group and case classification
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had two doses of MMR; however the vaccination dates 
and other vaccination details were only reported for one 
of the doses. 
Information on measles associated complications was 
reported for 52% (n=208/403) of cases.  Complications 
included pneumonia (n=14), otitis media (n=2), 
tonsillitis (n=2; one of these was also reported to have 
pneumonia), chest infection (n=1), dehydration (n=1), 
dehydration /nausea/vomiting (n=1), lower respiratory 
tract infection (n=1), pharyngitis (n=1) and seizures 
(n=1). The remaining 185 cases had no complications.
The setting where the case most likely acquired measles 
was reported as home (n=105, 26%), school (n=30, 
7%), daycare/pre-school (n=17, 4%), prison (n=7, 2%), 
hospital in-patient/hospital out-patient (n=5, 1%), work 
(n=5, 1%), overseas (n=2, 0.5%), third level (n=1, 0.2%) 
and was unknown/unreported for the remainder (n=231, 
57%).  For an additional two cases where the case most 
likely acquired measles was recorded as unknown but 
hospitalisation was considered a possible risk factor as 
both attended hospital prior to onset and during the 
incubation period.
Although ethnicity is not routinely collected as part 
of notification data and may be difficult to establish 
and report on, it was evident in the early stages of the 
outbreak that a substantial number of cases were linked 
to the Irish Traveller community. Based on available 
data, 16% (n=54/328) of the cases notified from week 1 
to week 18 2010 were recorded as Irish Travellers while 
1.8% (n=6/328) belonged to the Roma community.  In 
contrast, only 0.5% of the population of Ireland are 
Irish Travellers and approximately 0.1% belongs to the 
Roma community.  Although information on objectors to 
vaccination is not routinely collected there were reports 
from the HSE-S that highlighted transmission was also 
among children whose parents objected to vaccination, 
either for perceived safety reasons or for philosophical 
reasons.  During the course of the outbreak a small 
number of cases were also reported in other citizens 
from Eastern Europe and Russia.
 
Forty localised measles outbreaks were notified during 
2010, with 149 associated cases of illness.  The outbreak 
locations included 21 private houses (with 63 ill), three 
community outbreaks (with 19 ill), four crèche outbreaks 
(with 17 ill), three outbreaks occurring among extended 
families  (with 10 ill), one outbreak in a residential 
institution (with nine ill), one hospital outbreak (with four 
ill), six school outbreaks (with 25 ill) and one outbreak 
associated with day care (with two ill).
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system.  These figures may 
differ slightly from those published previously due to 
ongoing updating of notification data on CIDR. 
 
Table 1. Number of measles cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2010
HSE Area Number CIR
HSE-E 150 10.0
HSE-M 6 2.4
HSE-MW 51 14.1
HSE-NE 6 1.5
HSE-NW 12 5.1
HSE-SE 12 2.6
HSE-S 117 18.8
HSE-W 49 11.8
Total 403 9.5
In 2010, 114 cases (2.7/100,000) cases of invasive 
meningococcal disease (IMD) were notified in Ireland. 
This continues the downward trend from the previous 
two years when 147 cases (3.5/100,000) and 168 
cases (4.0/100,000), were reported in 2009 and 2008, 
respectively (figure 1). When compared with rates 
reported in 1999 and 2000, incidence rates have 
substantially declined in recent years (figure 1).
Based on the current meningococcal disease case 
definition, 98 of the 114 cases (86.0%) notified in 
2010 were case classified as definite, none (0.0%) 
as presumed and 16 (14.0%) as possible. The vast 
majority of the cases (86.0%; n=98/114) were laboratory 
confirmed by means of blood/CSF culture testing, PCR 
testing, blood serology, detection of gram negative 
diplococci in skin lesions/culture or in CSF specimens, 
and by screening of nasal, throat and eye swabs. Over 
half of all definite cases were confirmed by PCR alone 
(57.1%, n=56/98). Confirmation of the remaining 42 
definite cases was by blood or CSF culture only (7.1%; 
n=7/98); by blood or CSF PCR and/or culture (42.8%; 
n=42/98). None were confirmed by detection of Gram 
negative diplococci in skin lesion microscopy exclusively 
or by serology exclusively. 
In 2010, male cases (n=68) exceeded female cases 
(n=46), resulting in a male to female ratio of 1.47:1.0. 
Cases ranged in age from two months to 82 years 
(median age of 2.2 years). The incidence of IMD was 
highest in infants and young children. Age specific 
incidence rate (ASIR) was highest among infants <1 year 
of age (49.1/100,000), followed by children in the 1-4 
year age group (18.2/100,000), and the 15-19 year age 
group (4.1/100,000) (table 1). 
In 2010 the overall incidence of IMD in Ireland was 
highest in the HSE-NW area (4.6/100,000) with the 
lowest in the HSE-W area (1.0/100,000) (table 2). There 
were no imported cases in 2010.
Neisseria meningitidis serogroup B was the pathogen 
most commonly associated with IMD in 2010 and 
accounted for 93 (81.6%) of the 114 notifications (figure 
1). Since 2003 serogroup B has accounted for 80% or 
more of annual IMD notifications (figure 1). 
IMD due to serogroup C has remained at very low 
levels over the last eight years with no more than five 
cases occurring annually. In 2010, four (0.09/100,000) 
1.3  Meningococcal Disease     
Summary
Number of cases, 2010: 114
Number of cases, 2009: 147
Number of cases, 2008: 168
Crude incidence rate, 2010: 2.7/100,000
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Table 1. Number of cases, deaths, age-group specific incidence rates per 1000,000 population and case fatality ratios of IMD in 
Ireland, 2010
Age Group No. Cases ASIR No. Deaths CFR (%)
<1 30 49.1 2 6.7%
1-4 44 18.2 1 2.3%
5-9 8 2.8 1 12.5%
10-14 4 1.5 0 0.0%
15-19 12 4.1 0 0.0%
20-24 1 0.3 0 0.0%
25+ 15 0.5 1 6.7%
All ages 114 2.7 5 4.4%
ASIR, age specific incidence rate per 100,000 population
CFR, case fatality ratio
serogroup C cases occurred, none of whom were 
reported to have died (figure 1). Two of these four cases 
were aged 5-9 years, one was aged 15-19 years and 
the remaining case was aged 65 years or more. Three 
of these cases were unvaccinated, but the fourth, aged 
5-9 years, who had been in Poland where the Men C 
vaccine is not on national vaccination schedule, only 
ever received one dose. In contrast, three MenC vaccine 
failures occurred in 2009 whilst there was one each in 
2008, 2007, 2006 and 2005, with no failures arising in 
either 2004 or 2003.
The presence of small numbers of MenC vaccine failures 
in recent years is a reminder of the need for vigilance 
and monitoring of IMD due to serogroup C following 
the introduction of the MenC conjugate vaccine back in 
October 2000. Prior to the introduction of this vaccine, 
the serogroup C incidence rate in 1999 was 3.7 per 
100,000 total population. The National Immunisation 
Advisory Committee (NIAC) has recommended a 
booster dose of the MenC vaccine for close contacts 
of cases that have completed a course more than one 
year before, details of which are available at http://
www.ndsc.ie/hpsc/A-Z/VaccinePreventable/Vaccination/
Guidance/
There were five IMD related notified deaths in 2010 
(case fatality ratio (CFR) of 4.4%) compared to an 
average of 6.4 deaths between 2005 and 2009. In 2010, 
the CFR was highest amongst cases 5-9 years of age 
(12.5%) as a result of one death among eight cases 
(table 1). The next highest CFR occurred in children 
aged <1 year and adults aged 25 years or more (6.7% in 
each age group) (table 1).
Four of the five IMD deaths in 2010 were due to 
serogroup B disease (age range two months to 82 
years). This is in marked contrast to the 25 deaths 
reported in 2000 due to serogroup B. In the same 
year, 11 deaths were due to serogroup C disease (out 
of a total of 139 cases). In 2001, three deaths from 
serogroup C disease were reported, one in a child <15 
years of age and two in adults aged between 20 and 64 
years. One death from serogroup C disease occurred 
in 2003, 2004 and again in 2008, all in adults over 45 
year of age. Since 2001 however, the decline in the 
annual number of serogroup C deaths has been quite 
significant, especially in those aged less than 25 years of 
age, with no deaths being reported during this period 
of time (table 3).
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Figure 1. Number of invasive meningococcal disease (IMD) notifications in Ireland by serogroup, 1999-2010
Table 2. Number of cases and age specific incidence rates per 100,000 population of IMD by HSE area, 2010
HSE area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
E 51.4 19.4 3.2 0.0 7.1 0.0 0.5 2.8
M 52.8 6.3 5.3 0.0 0.0 0.0 0.0 1.6
MW 19.6 19.9 4.0 4.2 3.9 3.5 0.4 2.8
NE 62.9 15.8 0.0 3.7 0.0 0.0 0.4 2.5
NW 59.4 51.2 0.0 5.9 5.8 0.0 0.0 4.6
SE 74.1 29.6 6.1 0.0 0.0 0.0 1.0 3.9
S 46.6 8.9 2.4 2.5 4.7 0.0 1.0 2.4
W 17.4 4.4 0.0 0.0 3.4 0.0 0.4 1.0
Ireland 49.1 18.2 2.8 1.5 4.1 0.3 0.5 2.7
Despite a reduction in the overall incidence in recent 
years, IMD continues to be treated as a serious public 
health concern due to its associated severity, high 
mortality rate and serious adverse sequelae. 
Effective vaccination is necessary for the complete 
prevention and control of IMD. Although effective 
vaccines are available against serogroups A, C, W135 
and Y forms of the disease, a suitable vaccine against 
serogroup B disease, the most common form of IMD 
in Ireland, is not yet available. Until such time that an 
effective meningococcal serogroup B vaccine, suitable 
for use in infants, is on the market, IMD will remain a 
significant cause of morbidity and mortality in children 
and young adults in Ireland.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 4th August 2011. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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Table 3. Number of cases, deaths and case fatality ratios by year of meningococcal serogroups B and C disease in Ireland,  
1999-2010
Meningococcal B Meningococcal C
Year No. Cases No. Deaths CFR% No. Cases No. Deaths CFR%
1999 292 12 4.1% 135 5 3.7%
2000 258 13 5.0% 139 11 7.9%
2001 245 8 3.3% 35 3 8.6%
2002 199 8 4.0% 14 0 0.0%
2003 206 11 5.3% 5 1 20.0%
2004 163 7 4.3% 5 1 20.0%
2005 169 5 3.0% 5 0 0.0%
2006 168 5 3.0% 4 0 0.0%
2007 157 6 3.8% 2 0 0.0%
2008 149 6 4.0% 4 1 25.0%
2009 119 6 5.0% 5 0 0.0%
2010 93 4 4.3% 4 0 0.0%
In total, there were 293 (6.9/100,000) mumps cases 
notified in 2010.  This is a large decline compared to the 
years 2008/2009 and 2004/2005 when large outbreaks 
occurred (figure 1).  The number of cases notified in 
2010, however, is still considerably higher compared to 
the years 1998 to 2003 when there was an average of 
43 cases notified each year.
In 2010, of the 293 mumps cases notified 37% (n=109) 
were classified as confirmed, four percent (n=11) were 
classified as probable and 59% (n=173) were classified 
as possible.
The largest number of cases was notified in the HSE-E 
followed by the HSE-W, while the highest crude 
incidence rates were in the HSE-W, HSE-E and HSE-MW 
(table 1).
Table 1. Number of mumps cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2010
HSE Area Number CIR
HSE-E 141 9.4
HSE-M 12 4.8
HSE-MW 34 9.4
HSE-NE 14 3.6
HSE-NW 10 4.2
HSE-SE 25 5.4
HSE-S 17 2.7
HSE-W 40 9.7
Total 293 6.9
In 2010, cases ranged in age from one year to 87 years; 
with a mean age of 24 years and a median age of 20 
years (age was unknown for three cases).  The number 
of cases by age group and the age specific incidence 
rates are shown in figures 2 and 3.  The highest age 
specific incidence rates were in those 15-19 years 
followed by those 20-24 years.  Of the 293 mumps 
cases, 54% (n=158) were male and 45% (n=133) were 
female (gender was unreported for two cases).
1.4 Mumps 
Summary
Number of cases, 2010: 293
Number of cases, 2009: 3,620
Crude incidence rate, 2010: 6.9/100,000
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Figure 1. Number of mumps notifications by year and year of introduction of the measles-mumps-rubella (MMR) 
vaccine in Ireland
MMR1- first dose of MMR
MMR2- second dose of MMR
1988-June 2000 data collated by DoHC
July 2000-2010 data collated by HPSC
Of the 293 mumps cases, 17% (n=50) were 
unvaccinated, 16% (n=47) had one dose of the measles-
mumps-rubella vaccine (MMR), 19% (n=56) were 
reported to have received two doses of MMR while for 
48% (n=140) of cases the number of doses of MMR was 
not reported.  The vaccination date was reported for 
53% (n=25/47) of cases reported to have received one 
dose of MMR.  Both vaccination dates were reported 
for 23% (n=13/56) of cases vaccinated with two doses of 
MMR.  One of the cases where both vaccination dates 
were reported was vaccinated 25 days prior to onset 
and potentially was exposed just prior to or shortly 
after vaccination; another mumps case that only had 
the second MMR date reported was vaccinated three 
days prior to onset.  Nine percent (n=5/56) of the cases 
reported to have received two doses of MMR were 
classified as confirmed; only one of these had MMR 
vaccination dates reported.
Eight cases were hospitalised, representing three 
percent (n=8/293) of all cases and five percent 
(n=8/146) of cases where hospitalisation data were 
provided.  The number of days hospitalised was 
reported for five of the hospitalised cases and ranged 
from one to 10 days with a median of two days.  
Reported complications of mumps included orchitis 
(14%, n=10/72), deafness (1.6%, n=2/125), mastitis 
(1.6%, n=2/124), pancreatitis (1.6%, n=2/122), 
encephalitis (0.8%, n=1/126) and appendicitis (n=1).
The setting where the case most likely acquired mumps 
was reported for 24% (n=69/293) of cases.  Social 
setting was reported as the setting where the case most 
likely acquired mumps for 51% (n=35/69) of cases where 
this information was provided, school/university/college 
was reported for 23% (n=16/69) and family/household 
was reported for 14% (n=10/69) of these cases.
Five localised outbreaks of mumps were notified during 
2010 with 17 associated cases of illness.  The outbreak 
locations included two private houses (with 7 ill), two 
schools (with 7 ill) and one university/college (with 3 ill).  
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 13th October 2010.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.  
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Figure 2. Number of notified mumps cases in 2010 by age 
group and case classification
Figure 3. The age specific incidence rates (per 100,000) of 
notified mumps cases in 2010 (age is unknown for three cases)
Figure 3
0 
10 
20 
30 
40 
50 
0-
4 
 
5-
9 
10
-1
4 
15
-1
9 
20
-2
4 
25
-3
4 
35
-4
4 
45
-5
4 
55
-6
4 
65
+
 
U
nk
no
w
n 
N
um
b
er
 o
f 
ca
se
s 
no
ti
fie
d
 
Age group (years) 
Possible Probable Confirmed Possible Probable Confirmed 
0 
5 
10 
15 
20 
0-
4 
 
5-
9 
10
-1
4 
15
-1
9 
20
-2
4 
25
-3
4 
35
-4
4 
45
-5
4 
55
-6
4 
65
+
 
R
at
e 
p
er
 1
00
,0
00
 
Age group (years) 
Figure 3
0 
10 
20 
30 
40 
50 
0-
4 
 
5-
9 
10
-1
4 
15
-1
9 
20
-2
4 
25
-3
4 
35
-4
4 
45
-5
4 
55
-6
4 
65
+
 
U
nk
no
w
n 
N
um
b
er
 o
f 
ca
se
s 
no
ti
fie
d
 
Age group (years) 
Pos ible Probable Confirmed Pos ible Probable Confirmed 
0 
5 
10 
15 
20 
0-
4 
 
5-
9 
10
-1
4 
15
-1
9 
20
-2
4 
25
-3
4 
35
-4
4 
45
-5
4 
55
-6
4 
65
+
 
R
at
e 
p
er
 1
00
,0
00
 
Age group (years) 
Apart from Neisseria meningitidis, which is considered 
the most common cause of bacterial meningitis in 
Ireland, other forms of the disease do occur including 
those caused by non-notifiable organisms, details of 
which are presented below. For information on invasive 
meningococcal disease (Neisseria meningitidis), see 
a separate chapter within this report. The figures 
presented in this chapter are based on data extracted 
from the Computerised Infectious Disease Reporting 
(CIDR) system on 4th August 2011. These figures may 
differ from those published previously due to ongoing 
updating of notification data on CIDR.
Haemophilus influenzae
In 2010, two cases of meningitis due to H. influenzae 
were notified. One was aged between 20 and 24 years, 
was infected with a type b strain and was unvaccinated. 
The other was aged between 40-44 years and was 
infected with a type f strain. No deaths were reported. 
See a separate chapter on invasive H. influenzae disease 
for further details.
Leptospira species
No case of leptospirosis meningitis was reported in 
2010. See a separate chapter on non-IID zoonotic 
diseases for further details.
Listeria species
Three cases of listeriosis meningitis were notified in 
2010: two in women aged between 70 and 74 years, 
and in a man aged between 55 and 59 years (for whom 
the country of infection was France). See a separate 
chapter on listeriosis disease for further details.
Streptococcus pyogenes (Streptococcus group A 
infection (invasive) (iGAS))
One probable case of iGAS causing meningitis was 
notified in a 35-39 year old male in 2010. See a separate 
chapter on iGAS infection for further details.
Streptococcus pneumoniae
In 2010, 20 cases of pneumococcal meningitis were 
notified, compared to 28 in 2009 and 32 in 2008. 
Cases in 2010 ranged in age from two months to 67 
years. One pneumococcal meningitis related death in 
2010 was reported in a child aged between one and 
four years. This child had not been vaccinated and 
developed a serotype 6B infection (a serotype that is 
included in the PCV7 vaccine). See a separate chapter 
on invasive pneumococcal disease for further details.
1.5 Other forms of Bacterial Meningitis
Summary
Bacterial meningitis, Not Otherwise Specified
Number of cases, 2010: 42
Number of cases, 2009: 40
Number of cases, 2008: 40
Crude incidence rate, 2010: 1.0/100,000
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Mycobacterium species
In 2010, eight tuberculosis meningitis cases were 
notified (provisional). Cases ranged in age from 28 to 78 
years. One tuberculosis meningitis death was reported. 
See a separate chapter on tuberculosis for further 
details.
Bacterial meningitis by other specified notifiable 
diseases
No cases of meningitis caused by other specified 
notifiable diseases were reported in 2010.
Bacterial meningitis (not otherwise specified)
In total, 42 cases of meningitis under this disease 
category were notified in 2010, among which three 
patients died. The causative pathogens were identified 
in 21 of the cases. No causative pathogen was identified 
in the remaining 21 (50%) cases in 2010, a decrease 
compared to 2009 when 25 cases had no organism 
identified (62.5%; n=25/40).
Among the bacterial meningitis (not otherwise specified) 
cases notified in 2010 were 10 cases of Beta Haemolytic 
Streptococcus Group B (Streptococcus agalactiae) 
occurring in eight infants aged six months or less and 
in two adults aged between 35 and 67 years, all of 
whom recovered. Staphylococcus aureus occurred in six 
patients, two of whom died, (age range two weeks to 
81 years). Escherichia coli meningitis, was reported in 
two cases (age range 1 week to 61 years), both of whom 
recovered. Other meningitis notifications include one 
each caused by Mycoplasma pneumoniae in a 5-9 year 
old, by Staphylococcus capitis in a one month old infant 
and by Streptococcus species in a three week old infant, 
all of whom recovered.
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Table 1. Annual notifications of bacterial meningitis other than meningococcal disease, 2008-2010
Notified under Causative organism 2008 2009 2010 2008-2010
Haemophilus influenzae disease (invasive) Haemophilus influenzae 3 3 2 8
Leptospirosis Leptospira species 1 1 0 2
Listerosis Listeria species 3 1 3 7
Salmonellosis Salmonella enteritidis 0 1 0 1
Streptococcus pneumoniae infection (invasive) Streptococcus pneumoniae 32 28 20 80
Streptococcus Group A infection (invasive) Streptococcus Group A (S. pyogenes) 2 0 1 3
Tuberculosis* Mycobacterium species 6 8* 8* 22
Beta Haemolytic Streptococcus Group B 6 7 10 23
Escherichia coli 11 3 2 16
Staphylococcus aureus 3 2 6 11
Enterococcus faecalis 1 1 0 2
Bacterial meningitis, NOS Citrobacter koseri 1 0 0 1
(not otherwise specified) Mycoplasma pneumoniae 0 0 1 1
Serratia liquefaciens 1 0 0 1
Staphylococcus capitis 0 0 1 1
Streptococcus bovis 0 1 0 1
Streptococcus Group D 0 1 0 1
Streptococcus species 0 0 1 1
Unknown 17 25 21 63
Total Bacterial Meningitis, NOS 40 40 42 122
Total 87 82 76 245
Notes
* Tuberculosis meningitis figures for 2009 and 2010 are provisional
One hundred and fourteen cases (2.7/100,000) of 
pertussis were notified in 2010 compared to 78 cases in 
2009.  Of the 114 cases in 2010 45 (39%) were classified 
as confirmed, 11 (10%) as probable and 58 (51%) were 
classified as possible.
In 2010, the largest number of cases (n=36, 32%) and 
the highest age-specific incidence rate (58.9/100,000) 
were in children aged less than one year with 27% 
(n=31) of all cases aged less than six months (figures 1 
and 2).  Sixty-two cases (54%) were female and 52 (46%) 
were male.
In Ireland it is recommended that children be vaccinated 
with an acellular pertussis-containing vaccine at two, 
four and six months of age and a booster dose at four 
to five years of age.  The vaccine provides protection 
in over 80% of children who are fully vaccinated. 
However, protection declines over time, with little or 
no protection 10-12 years after primary immunisation, 
if no booster doses are administered.  In 2008 the 
National Immunisation Advisory Committee (NIAC) 
recommended a booster with low dose acellular 
pertussis vaccine for children aged 11-14 years. The 
adolescent booster dose will commence through the 
schools immunisation programme in the academic year 
of 2011-2012. 
In 2010, the vaccination status was reported for 58 
(51%) pertussis cases.  Seventeen (n=17/114, 15%) cases 
were unvaccinated; these cases ranged in age from 
three weeks to 11 years, with 15 cases aged less than 
six months.  Nine unvaccinated cases (n=9/17, 53%) 
were less than two months of age and were therefore 
not eligible for pertussis vaccine in the Irish schedule.  
Fifteen (n=15/114, 13%) cases were reported as 
incompletely vaccinated, but these included eight cases 
(n=8/15, 53%) who were less than six months of age and 
were therefore not eligible for three doses of pertussis 
vaccine in the Irish schedule.  Twenty six (n=26/114, 
23%) cases were reported as completely vaccinated for 
1.6 Pertussis
Summary
Number of cases, 2010: 114
Number of cases, 2009: 78
Crude incidence rate, 2010: 2.7/100,000
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Figure 1. Number of notified pertussis cases in 2010 by age group and case 
classification. “Mo” in graph indicates months i.e. 0-5 months and 6-11 
months, the remaining age groups are in years
their age; four of these were reported to have had three 
doses of pertussis vaccine, two were reported as having 
four doses while the number of doses was not specified 
for the remainder.  Five of the 26 cases reported as 
completely vaccinated for their age were classified as 
confirmed.
Of the notifications in 2010, 65 (57%) were linked to 
a community outbreak in the HSE-NW.  Of these 65 
cases, seven were classified as confirmed, seven as 
probable and 51 as possible.  The largest number of the 
cases in the outbreak were in the age groups 1-4 years 
(n= 16) followed by 10-14 years (n=15).  The outbreak 
is described in detail in Eurosurveillance.1  Three other 
localised outbreaks of pertussis were notified during 
2010; all three were outbreaks in private houses with 
seven associated cases of illness in total.
Laboratory confirmation of pertussis is recommended, 
but it can be difficult to confirm the diagnosis as the 
sensitivity of the test is dependent on obtaining a 
nasopharyngeal aspirate or pernasal swab early on in 
the illness and rapid transfer to the hospital laboratory 
is required.  Cultures are unlikely to be positive 
more than two weeks after onset of the catarrhal 
stage or one week after onset of cough or for more 
than a few days after commencing antibiotics. In 
Ireland laboratory confirmation is usually obtained by 
isolating the Bordetella pertussis organism through 
culture from nasopharyngeal aspirates or pernasal 
swabs. Increasingly PCR testing is being used to 
diagnose pertussis infection.  Serology tests are not 
routinely done in Ireland. The establishment of a 
national pertussis reference laboratory would improve 
the quality of pertussis surveillance in Ireland and 
discussions have commenced to assess the feasibility of 
supporting this work.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 28th October 2011.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
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Figure 2. The age specific incidence rate (per 100,000 population) of notified 
pertussis cases in 2010 by case classification.
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In 2010, 24 cases (0.6/100,000) of rubella were notified 
in Ireland compared to 19 cases in 2009. Thirteen cases 
(54%) were notified in the HSE-E (table 1). 
One of the cases in 2010 was classified as confirmed 
(based on specific antibody response and compatible 
clinical presentation) giving a crude confirmed incidence 
rate of 0.02 per 100,000 total population.  The 
confirmed case was in the age group 1-2 years (figure 1). 
Twenty-three cases in 2010 were classified as possible; 
the majority (n=18/23, 78%) of these were less than 
three years of age (figure 1).  The age specific incidence 
rates by case classification are shown in figure 2.
Of the 24 rubella cases 11 (46%) were male and 13 
(54%) were female.  The confirmed case was female.
Rubella vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR 
is routinely recommended for all children at twelve 
months of age and the second dose at four to five 
years of age.   Vaccination status was reported for 
22 (92%) of the rubella cases in 2010.  Thirteen cases 
(n=13/24, 54%) were unvaccinated; eight of these were 
<12 months of age.  Nine cases (n=9/24, 38%) were 
reported as completely vaccinated for their age, only 
two of these were greater than five years of age (neither 
of these cases were confirmed). The confirmed case was 
reported as completely vaccinated for their age. 
The diagnosis of rubella based solely on clinical signs 
and symptoms is unreliable because there are many 
other causes of rash that may mimic rubella infection 
and up to 50% of rubella infections may be subclinical. 
Therefore, samples should always be obtained for 
the accurate diagnosis of rubella. Serology tests are 
routinely carried out in Ireland (rubella IgM antibodies 
or IgG seroconversion or a fourfold or greater rise in 
titre to rubella virus) except if the individual has received 
a rubella-containing vaccine eight days to eight weeks 
before sample collection. Detection of rubella virus RNA 
in an appropriate specimen or a positive culture for 
rubella virus (not routinely performed) can also be done 
(following consultation with the laboratory). 
1.7 Rubella
Summary
Number of cases, 2010: 24
Number of confirmed cases, 2010: 1
Crude incidence rate, 2010: 0.6/100,000
Crude confirmed incidence rate, 2010: 0.02/100,000
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Table 1. Number of rubella cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2010
HSE Area Number CIR
HSE-E 13 0.9
HSE-M 0 0.0
HSE-MW 1 0.3
HSE-NE 0 0.0
HSE-NW 1 0.4
HSE-SE 5 1.1
HSE-S 2 0.3
HSE-W 2 0.5
Total 24 0.6
The only confirmed case reported in 2010 was 
laboratory confirmed based on serological response. 
This case was reported to have received one MMR 
dose, but the date of vaccination could not be 
obtained. Accurate information on vaccination dates 
in relation to disease onset is needed to accurately 
interpret serology test results. 
Accurate and detailed information on all notified rubella 
cases is needed to monitor progress towards the WHO 
European Measles and Rubella Elimination Strategy (for 
2015). HPSC is currently working with the HSE Areas to 
improve rubella surveillance data.  
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 3rd November 
2011.  These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.
Guidance on tests used to diagnose rubella is available 
on the NVRL website at http://www.ucd.ie/nvrl and 
on the HPSC website www.hpsc.ie/ under the disease 
name, see Topics A-Z. 
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Figure 2. The age specific incidence rate (per 100,000 
population) of notified rubella cases in 2010 by case 
classification
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Figure 1. Number of notified rubella cases in 2010 by age 
group and case classification
Background
Since January 2004, invasive Streptococcus pneumoniae 
infection is a notifiable disease in Ireland, clinicians 
and laboratories are legally obliged to notify.  For the 
purposes of this report the term invasive pneumococcal 
disease (IPD) will be used to describe these infections.  
A number of surveillance initiatives are in place in 
Ireland for IPD. Data on IPD notifications are collated in 
the Computerised Infectious Disease Reporting (CIDR) 
system.  Enhanced surveillance on IPD notifications is 
undertaken by Departments of Public Health particularly 
on children born since 2000.  A separate surveillance 
strand (EARS-Net project) involving the microbiology 
laboratories and HPSC is used to monitor in 
detail the antimicrobial resistance profiles of invasive    
S. pneumoniae isolates from blood and/or CSF.  
Since April 2007, the National Pneumococcal Typing 
Project has been offering a typing service to Irish 
laboratories for all invasive S. pneumoniae isolates 
submitted.  This is a collaborative project involving 
Beaumont Hospital, the Children’s University Hospital, 
Temple Street and HPSC.
In September 2008, the 7-valent pneumococcal 
conjugate vaccine (PCV7) was introduced in Ireland to 
the infant immunisation schedule at 2, 6 and 12 months 
of age.  A catch-up campaign was also implemented 
at that time, targeting all children <2 years of age.  In 
December 2010, PCV13 replaced PCV7 for new entrants 
to the infant schedule (i.e. for children born on or after 
1st October 2010).
Notifications
In 2010, 391 cases of IPD (9.2/100,000) were notified in 
Ireland.  This was a 9.5% decrease compared with 2009 
when 432 cases were notified (10.2/100,000).  Seventy 
seven percent (n=302) of notifications in 2010 were 
classified as confirmed, 1.0% (n=2) as probable and 
22% as possible (n=87).  The majority of the possible 
cases (80%, n=70/87) were notified by HSE-SE and most 
related to cases that were urinary antigen positive for S. 
pneumoniae (figure 1).  These figures do not  necessarily 
indicate  a higher burden of IPD  in this area relative to 
other areas,  but rather more consistent reporting of 
urinary antigen positive cases from that area. Comparing 
the crude incidence rate of confirmed IPD cases by HSE 
area, the incidence rate in HSE-SE (8.9/100,000; 95% CI 
1.8 Streptococcus pneumoniae (invasive)
Summary
Number of cases, 2010: 391
Number of cases, 2009: 432
Number of deaths, 2010: 13
Number of deaths, 2009: 18
Crude incidence rate, 2010: 9.2/100,000
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Figure 1.  Number of IPD cases notified by case classification and HSE area and crude incidence rate (CIR) of 
confirmed cases by HSE area, 2010
Data source: CIDR
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6.1-11.6/100,000) was not statistically different from the 
national rate (7.1/100,000; 95% CI 6.3 – 7.9/100,000).  
In fact the IPD incidence rates for confirmed cases in 
seven out of the eight HSE areas were not statistically 
different from the national rate.  The only exception was 
HSE-NE where the incidence rate was significantly lower 
(4.1/100,000; 95% CI 2.1 – 6.1/100,000) (figure 1).
Clinical diagnosis was reported for just 125 of the 
391 cases (32%), which included bacteraemia with 
pneumonia (n=63), bacteraemia without focus (n=35), 
meningitis (n=20), peritonitis (n=3), muscoskeletal (n=3) 
and abscess (n=1).  More cases occurred in males (55%; 
n=215) than in females (45%; n=176), giving a male to 
female ratio of 1.2:1.0.  Cases ranged in age from 6 
days to 96 years, with an average age of 58.3 years and 
a median age of 66 years.  Those aged 65 years and 
older accounted for over half of the cases (51%, n=201). 
The age specific incidence rate was highest  in those 85 
years of age and older (106.2/100,000; n=51), followed 
by 75-84 years age group (48.3/100,000; n=76) and then 
those aged between 65 and 74 years (28.2/100,000; 
n=74) (figure 2).  In children < 2 years of age the age 
specific incidence rate was 18.9 cases per 100,000 
population (n=23).  In this age group the incidence has 
dropped by more than half when compared with 2008 
(42.8/100,000; n=52), highlighting the positive impact 
the introduction of PCV7 to the infant schedule in 
September 2008 has had on reducing the burden of IPD 
in young children (figure 2).
Medical risk factor information was reported for 82 
cases (21%), with some patients having multiple risk 
factors.  For those where this information was reported, 
the main risk factors included immunosuppressive 
condition or therapies (n=37), chronic lung disease 
(n=21), diabetes mellitus (n=12) and chronic liver 
disease (n=12).  It should also be noted that being 
elderly, aged 65 years and older is also a recognised IPD 
risk factor; 201 cases in 2010 were in this age group.
Outcome was reported on just 27% (n=107) of the IPD 
notifications in 2010.  Therefore, figures presented 
underestimate IPD mortality in Ireland. Based on the 
data available, 16 deaths in individuals with IPD in 2010 
were reported.  The cause of death was reported as 
directly due to IPD in five cases, not due to IPD in three 
cases and for the remaining eight the cause of death 
was not reported.  Therefore, based on the outcome 
data available 13 deaths potentially associated with IPD 
infection occurred in 2010, giving an IPD case fatality 
rate of 12%.  One death was in a child <5 years of age 
and 12 deaths were in adults >35 years of age. 
IPD notification data was extracted from CIDR on 30th 
August 2010. These figures may differ slightly from 
those previously published due to ongoing updating of 
notification data on CIDR.
Impact of PCV7
Data from the National IPD Typing Project was used 
to assess the impact of introducing PCV7 on the 
distribution of S. pneumoniae serotypes associated with 
IPD and on the burden of IPD in Ireland.  
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Figure 2.  Age specific incidence rate of invasive pneumococcal disease by age group, 2008-2010
Table 1.  Number of IPD cases in 2008 and 2010 and percentage change in burden of IPD since introducing PCV7 in September 
2008
PCV7 serotypes Non-PCV7 serotypes All IPD serotypes
<2 yrs ≥2 yrs All ages <2 yrs ≥2 yrs All ages <2 yrs ≥2 yrs All ages
2008 34 145 179 15 180 195 49 325 374
2010 3 73 76 17 186 203 20 259 279
% change -91.2 -49.7 -57.5 13.3 3.3 4.1 -59.2 -20.3 -25.4
Date source: National IPD Typing Project
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In 2010, isolates relating to 279 cases of IPD were 
typed, compared to 314 in 2009 and 374 in 2008.  
In 2010, 27% of IPD infections were due serotypes 
covered by PCV7, 11% of infections were associated 
with the three additional serotypes covered by PCV10 
(1, 5 and 7F) and a further 17% of IPD infections were 
due to the other three serotypes covered by PCV13 
(3, 6A and 19A) (figure 3).  Forty five percent of IPD 
infections in 2010 were associated with non-vaccine 
types (NVTs, serotypes excluding the 13 covered by 
PCV13) (figure 3).
The introduction over two years ago of PCV7 to the Irish 
immunisation schedule has had a dramatic impact in 
reducing the burden of IPD, particularly in disease due 
to the serotypes covered by PCV7.  Most impressively 
disease burden due to PCV7 serotypes has declined 
by 91% in children under 2 years of age (figure 4 and 
table 1), by 50% in children 2 years of age and older 
and by 58% in all age groups (table 1) .  An increase 
in incidence of disease due to non-PCV7 serotypes 
has been seen, a 13% increase in <2 year olds and 4% 
increase when all age groups are taken into account 
(table 1).  Overall the incidence of IPD has declined 
by a quarter when all serotypes and ages are taken 
into consideration (table 1). For ongoing updates, see 
“Slides – Impact PCV in Ireland” at http://www.hpsc.ie/
hpsc/A-Z/VaccinePreventable/PneumococcalDisease/
PostersPresentations/
The predominant serotypes associated with IPD 
infection in 2010 were 8, 22F, 7F and 19A. In children 
<2 years of age, the predominant serotype was 7F and 
this accounted for one third of the cases in this age 
group.
PCV7 vaccine failures
Based on data obtained through the IPD enhanced 
surveillance system, two PCV7 vaccine failures occurred 
in 2010. One was in a 2 year old with serotype 14 S. 
pneumoniae infection; the other in 3 year old due to 
serotype 19F infection.  Both had received one dose of 
PCV7 vaccine at >12 months of age and therefore were 
considered fully vaccinated.  Two PCV7 vaccine failures 
also occurred in 2009, also associated with serotype 14 
and 19F infections.
Penicillin non-susceptible S. pneumoniae (PNSP)
The proportion of penicillin-non-susceptible S. 
pneumoniae (PNSP) decreased from 23.1% in 2008 to 
20.2% in 2009, followed by a further decline in 2010 
to 18.2% (Data source: EARS-Net).  For details on the 
antimicrobial resistance patterns of S. pneumoniae, 
please see the chapter on Antimicrobial Resistance 
within this report.
Discussion
The incidence of IPD continued to decline in Ireland, in 
2010.  Introducing PCV7 has been a major contributory 
factor in this decline.  Compared with 2008, there has 
been an impressive 91% reduction in IPD in young 
children due to serotypes covered by PCV7 and the 
burden of all types of IPD in the total population 
has been reduced by a quarter.  In 2010, 28% of 
IPD infections were due to one or other of the six 
additional serotypes covered by PCV13.  The impact of 
introducing PCV13 at the end of 2010 on the burden of 
IPD and in particular on the burden of disease due to 
the additional six serotypes covered by PCV13 should 
become evident over the next year or two.
Considerable progress has been made in recent years 
in improving the various IPD surveillance initiatives in 
Ireland.  Data from these surveillance systems provide 
invaluable information in monitoring the incidence 
of this disease and in determining the impact of 
interventions such as the introduction of PCV7.  The 
establishment of the National IPD Typing Project and 
the data available from this project has been vital in this 
regard, as has the enhanced surveillance undertaken 
by Departments of Public.  Not only can the impact 
of various interventions be monitored but changes 
in serotype distribution patterns can also be studied.  
The data obtained through such initiatives are all vital 
elements when informing public health decisions on 
vaccination policy and immunisation schedules.
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Figure 4.  Cumulative number of IPD cases due to PCV7 
serotypes in children <2 years of age, 2008 – 2010
Data source: National IPD Typing Project
Figure 3.  Proportion of IPD cases in 2010 due to serotypes 
covered by PCV7, the additional serotypes in PCV10 and 
PCV13 and due to the non-vaccine types (NVTs)
PCV7:  4, 6B, 9V, 14, 18C, 19F and 23F; PCV10: 1, 5 and 7F; 
PCV13: 3, 6A and 19A
Data source: National IPD Typing Project
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HPSC is working in collaboration with the NVRL, the
ICGP and the Departments of Public Health on the 
influenza sentinel surveillance project. Sixty general 
practices (located in all HSE-Areas) were recruited to 
report electronically, on a weekly basis, the number of 
patients who consulted with influenza-like illness (ILI)1. 
Sentinel GPs were requested to send a combined nasal 
and throat swab on 1 to 2 ILI patients per week to the 
NVRL. Other surveillance systems set up to monitor ILI/
influenza activity include a network of sentinel hospitals 
reporting admissions data, sentinel schools reporting 
absenteeism and enhanced surveillance of hospitalised 
influenza cases aged 0-14 years.  
Several surveillance projects that were initiated/
augmented during the 2009 influenza pandemic were 
continued during the 2010/2011 influenza season: 
•  Surveillance of all calls to GP out-of-hours (OOHs) 
centres were monitored for self-reported influenza. 
•  Surveillance of all confirmed influenza notifications, 
including hospitalisation status.
•  Surveillance of all confirmed influenza adult and 
paediatric cases admitted to critical care.
•  Enhanced surveillance of all confirmed influenza 
deaths.
Sentinel GP Clinical Data
Influenza activity in Ireland was moderate during the 
2010/2011-influenza season, peaking during week 1 
2011 at 202.1 per 100,000 population, the highest 
recorded ILI rate since influenza surveillance began in 
2000 (figure 1). ILI rates first increased above baseline 
levels (17.8 per 100,000) during week 50 2010 and 
remained above baseline levels until week 10 2011. 
The highest age specific ILI rates were in the 5-14 year 
age group (peaking at 254.1/100,000), followed by 
the 15-64 year age group (244.9/100,000), 0-4 year 
olds (193.6/100,000)  and those aged 65 years or older 
(66.0/100,000). ILI rates in those under 15 years were 
lower than during the pandemic period, however ILI 
rates in the 15-64 year age group and those aged 65 
years or older were higher than the pandemic period. 
Virological Data
The NVRL tested 1054 sentinel specimens for influenza 
virus during the 2010/2011 season. Five hundred and 
thirteen (48.7%) sentinel specimens were positive for 
influenza: 279 influenza A (267 A (H1) 2009, 9 A (H3) 
and 3 A (unsubtyped) and 234 influenza B. At the peak 
of influenza activity, the proportion of influenza positive 
specimens reached 72.4% (during week 1 2011).
The NVRL tested 7,114 non-sentinel respiratory 
specimens during the 2010/2011 season, 1518 (21.3%) 
of which were positive for influenza: 1157 influenza A 
(1099 A (H1) 2009, 31 A (H3) and 27 A unsubtyped) 
and 361 influenza B. Eight influenza A cases were co-
infected with influenza B: 7 with influenza A (H1) 2009 
and one with influenza A (unsubtyped). One influenza B 
case was also co-infected with respiratory syncytial virus 
(RSV).
Influenza A (H1) 2009 was the dominant influenza 
type/subtype detected during the first half of the 
season, with influenza B dominating during the latter 
half. Influenza A accounted for 70.7% of all influenza 
positive specimens and influenza B for 29.3% during the 
2010/2011 season. Influenza A (H1) 2009, accounted for 
67.3% of all positive influenza specimens.
The NVRL tested eight non-sentinel specimens from 
six confirmed influenza A (H1) 2009 cases for antiviral 
resistance. All six patients were hospitalised and 
admitted to critical care.  One (12.5%) of the eight 
specimens tested was resistant to oseltamivir, carrying 
the H275Y mutation. As part of the WHO Global 
Influenza Surveillance Programme, a proportion of 
influenza viruses (10 A (H1N1) 2009 and 2 B viruses) 
circulating in Ireland during the 2010/2011 season 
2.1 Influenza
Summary
2010/2011 influenza season summary:
Peak influenza-like illness rate: 202.1/100,000
Total confirmed influenza cases hospitalised: 945
Total confirmed influenza cases admitted to ICU: 121
Total deaths associated with influenza: 38
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were submitted to the WHO Collaborating Centre for 
Reference and Research on Influenza (Mill Hill, London) 
for characterisation. Antigenic characterisation results 
for the circulating influenza A (H1N1 2009) and for 
the influenza B isolates showed good reactivity with 
the A/California/7/2009 and the B/Brisbane/60/2008 
2010/2011 influenza vaccine strains, respectively. 
Therefore, indicating a good match between the 
circulating and vaccine strains.
Outbreaks, GP OOHs, Sentinel hospital & school data
Fourteen general ILI/influenza outbreaks were reported 
to HPSC: eight ILI outbreaks, five influenza A (H1) 2009 
outbreaks and one outbreak associated with both 
influenza A (H1) 2009 and influenza B. Five outbreaks 
were reported from HSE-E, seven from HSE-S and two 
from HSE-W. Two outbreaks were in healthcare settings 
(one of which was a maternity hospital), seven in 
schools, one in a community setting, one in a residential 
institution, one in a prison, one travel related outbreak 
and one outbreak reported as ‘Other’ setting. 
The percentage of influenza-related calls to GP out-of-
hours services in Ireland, peaked during week 1 2011 
at 14.7%. This is higher than the proportion recorded 
during the pandemic period. During the peak of activity, 
each service received on average, five calls per hour 
relating to influenza.
Hospital respiratory admissions in sentinel hospitals 
peaked during week 52 2010 (figure 2), one week 
prior to the peak in sentinel GP ILI consultation rates. 
Sentinel school absenteeism data are not presented in 
this report, as most sentinel schools were closed for an 
extended period of time due to severe weather and 
road conditions coinciding with the peak of influenza 
activity. 
Influenza notifications
A total of 2233 influenza notifications were reported 
on CIDR during the 2010/2011 influenza season. The 
peak of influenza notifications occurred during week 2 
2011, one week following the peak in ILI consultation 
rates and GP OOHs flu calls. Of the 2233 notifications, 
1324 (59.3%) were influenza A (H1) 2009, 23 (1.0%) 
were influenza A (H3), 203 (9.1%) were influenza A 
(unsubtyped) and 683 (30.6%) were influenza B. 
Hospitalisation 
Nine-hundred and forty-five cases with confirmed 
influenza were hospitalised during the 2010/2011 
influenza season. Similar to the pandemic period, the 
highest age specific rate in hospitalised cases was in the 
0-4 year age group (61.9 per 100,000 population) (table 
1). Of the 945 hospitalised cases, 602 (63.7%) were 
influenza A (H1) 2009, 7 (0.7%) were influenza A (H3), 
109 (11.5%) were influenza A (unsubtyped) and 227 
(24.0%) were influenza B.
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Figure 1. ILI sentinel GP consultation rates per 100,000 population, baseline ILI threshold rate, and number of positive influenza 
A and B specimens tested by the NVRL2 , by influenza week and season. 
Source: Clinical ILI data from ICGP and virological data from the NVRL.
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Pregnancy 
A total of 81 laboratory confirmed influenza cases were 
reported as pregnant during the 2010/2011 season. 
Fifty-one (63.0%) of these cases were hospitalised: 
influenza A (H1) 2009 was detected from 42 of these 
cases, influenza A (unsubtyped) from two cases and 
influenza B from seven cases. Eight (15.7%) of all 
reported hospitalised pregnant cases were admitted to 
ICU, one of whom died.
Enhanced surveillance hospital data on 0-14 year age 
group
A total of 547 confirmed influenza cases aged 
between 0 and 14 years were notified on CIDR for 
the 2010/2011 influenza season, 275 (50.3%) of these 
cases were hospitalised. Enhanced surveillance data 
was available on 266 (96.7%) cases. One hundred 
and seventy-four cases (65.4%) were positive for 
influenza A (144 influenza A (H1) 2009, 1 A (H3) and 
29 A (unsubtyped)) and 92 (34.6%) were positive for 
influenza B. The predominant influenza type/subtype 
was influenza A (H1) 2009, accounting for 54.1% of all 
cases. The median age was 2 years, ranging from 6 days 
to 14 years. The majority of cases, 66.5% were aged 
between 0 and 4 years. The most frequently reported 
symptoms included: fever (74.8%), cough (65.8%) 
and gastrointestinal symptoms (33.8%). The most 
frequently reported complications included: secondary 
bacterial pneumonia, primary influenza viral pneumonia, 
bronchitis and other respiratory complications, such as 
bronchiolitis and chest infections. The median length 
of stay in hospital was 3 days (ranging from 1 - 35 
days).  Eighty-one (35.4%, n=229) cases had underlying 
medical conditions. Chronic respiratory disease was the 
most frequently reported underlying medical condition 
(33/229, 14.4%). Fourteen (6.1%) cases had more than 
one underlying medical condition. Vaccination status 
was known for 175 (65.8%) children. Five (2.9%) cases 
were vaccinated with the 2010/2011 influenza vaccine 
and 97.1% (170/175) were not vaccinated. Three of the 
five vaccinated cases had also received the pandemic 
influenza vaccine. Thirty-eight percent (73/194) of cases 
commenced antiviral treatment and 62.4% (121/194) 
of cases did not. Fourteen percent of cases were 
associated with an ILI/influenza outbreak. Fourteen 
cases were admitted to critical care and two cases died 
(see further details on disease severity below). 
Critical care
Of the 945 hospitalised cases, 121 (12.8%) were 
admitted to critical care (107 adults and 14 paediatric 
cases). The highest age specific rate for patients 
admitted to ICU was in the 55-64 year age group (5.9 
per 100,000 population) (table 1). The median age of 
paediatric cases was one year of age and the median 
age of adult cases was 51 years. Eighty-one (81/107, 
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Figure 2. Total hospital respiratory admissions in nine sentinel hospitals and ILI sentinel GP consultation rate per 100,000 
population by week for the 2010/2011 influenza season. It should be noted that admissions data from one sentinel hospital 
were not available for weeks 40-50 2010. 
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75.7%) adults and nine (9/14, 64.3%) paediatric 
cases had pre-existing medical conditions.3 The most 
frequently reported underlying medical conditions for 
adults included chronic respiratory disease (n=42/107, 
39.3%) and chronic heart disease (n=26/107, 24.3%). 
The most frequently reported underlying medical 
conditions for paediatric cases included chronic 
neurological disease (n=4/14, 28.6%) and chronic 
respiratory disease (n=3/14, 21.4%). Nine (64.3%) 
paediatric and 98 (91.6%) adults were ventilated during 
their stay in ICU. The median length of stay in ICU for 
paediatric cases was 6.5 days (ranging from 1 - 20 days) 
and for adult cases was 13.5 days (ranging from 1 - 135 
days). Eighteen (n=121, 14.9%) cases were vaccinated 
during the 2010/2011 influenza season. Clinical 
outcome data are presented below. 
Mortality data
During the 2010/2011 influenza season, 38 influenza-
associated deaths4 were reported, compared to 295 
during the pandemic period. The median age of cases 
that died during the 2010/2011 influenza season 
was 57 years, ranging from 2 – 83 years. Thirty-two 
(84.2%) cases had underlying medical conditions. 
Thirty-two (84.2%) cases were admitted to ICU. Of the 
38 cases that died, one was infected with influenza 
A (unsubtyped), one with influenza A (H3), 32 with 
influenza A (H1) 2009, one co-infection of influenza 
A (H1) 2009 and influenza B and three with influenza 
B. Vaccination status was known for 33 of the 38 
(86.8%) deaths. Eighty-eight percent (29/33) were not 
vaccinated and 12.1% (4/33) were vaccinated with the 
2010/2011 influenza vaccine. 
A summary table of confirmed influenza hospitalised 
and critical care cases and influenza-associated deaths 
for all ages is detailed in table 2.
 
Seasonal influenza vaccine uptake6 
The average uptake for seasonal influenza vaccination 
nationally during the period September 2010 to July 
2011 in those aged 65 years and older was 60.1%. 
This is the highest recorded rate for this period since 
the 2006/2007 influenza season when uptake reached 
60.6%. Variation in vaccination coverage was observed 
between age groups, with the highest uptake (64.0%) 
in those aged 75 years or older. A slight variation in 
vaccination coverage was also observed between HSE 
areas, ranging from 57.7% in HSE-NW to 62.7% in  
HSE-SE.
Overview of the 2010/2011 influenza season 
Based on all influenza/ILI data available at HPSC, 
influenza activity during the 2010/2011 was regarded 
as moderate, with the highest ILI rates reported since 
the GP sentinel surveillance scheme began. ILI/influenza 
activity was very intense during the peak of influenza 
activity (week 1 2011). The predominant circulating 
influenza virus was influenza A (H1) 2009, however 
for the latter part of the influenza season, influenza B 
predominated. Fewer cases were admitted to hospital 
during the 2010/2011 influenza season than during the 
pandemic period, however more cases were admitted 
to critical care and more influenza-associated deaths 
were reported. The median age of severe cases was 
higher during the 2010/2011 influenza season than 
during the pandemic period. Similarly, the proportion 
of severe cases with underlying medical conditions, 
although still high, was less than that reported during 
the pandemic period. Critical care and hospitalisation 
rates were similar to the pandemic period; however, the 
intensity was greater at the peak of influenza activity 
during the 2010/2011 season and activity was spread 
over a longer period of time during the pandemic.
2011/2012 influenza season
For the 2011/2012 influenza season, existing 
surveillance systems have been strengthened and a 
number of additional measures have been put in place 
in Ireland to improve surveillance of ILI/influenza. At 
HPSC, initiatives have been implemented to streamline 
reporting and to capture additional data on influenza 
vaccination status, underlying medical conditions 
and antiviral treatment. The NVRL has improved 
standardisation of procedures, testing and reporting 
algorithms for characterising influenza viruses. They 
Table 1. Age specific rate for confirmed influenza cases hospitalised and admitted to critical care during the 2010/2011 influenza 
season. Age specific rates are based on the 2006 CSO population census.
Hospitalised Admitted to ICU
Age (years) Number Age specific rate per 100,000 pop. Number Age specific rate per 100,000 pop.
0-4 187 61.9 12 4.0
5-14 91 16.2 2 0.4
15-24 102 16.1 3 0.5
25-34 173 23.9 21 2.9
35-44 104 16.7 18 2.9
45-54 88 16.9 23 4.4
55-64 101 24.8 24 5.9
65+ 98 20.9 18 3.8
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have also introduced multiplex PCR (swabs) for influenza 
A, B, RSV, adenovirus, parainfluenza virus types -1 and 
-3 and human metapneumovirus. The NVRL will also 
continue monitoring for oseltamivir resistance. 
All influenze surveillance projects described for the 
2010/2011 season will continue for the 2011/2012 
influenza season. A review of the influenza surveillance 
system in critical care units was conducted at the end 
of the 2010/2011 influenza season and improvements 
were made. A pilot project to monitor morbidity 
and mortality from all severe acute respiratory 
infections (SARI) admitted to two critical care units 
is being implemented for the 2011/2012 influenza 
season. Additional projects not detailed in this report 
include participation in a European influenza vaccine 
effectiveness study (I-MOVE project) and an all-cause 
mortality monitoring project associated with the 
European mortality monitoring group (EuroMOMO). 
Data from all of these surveillance systems will assist in 
guiding the management and control of influenza and 
any future epidemics or pandemics. 
Table 2. Summary table of confirmed influenza hospitalised and critical care cases and influenza-associated deaths for all ages. Rates 
are based on the 2006 CSO population census. 
Hospitalised  Admitted to ICU Influenza associated deaths
Pandemic period 2010/2011 Pandemic period 2010/2011 Pandemic period 2010/2011
    Total cases 1059 945 100 121 27 38
     Crude rate per 100,000 pop. 25.0 22.3 2.4 2.9 0.6 0.9
    Age range (years) 0-84 0-97 0-79 0-80 8-83 2-83
    Median age (years) 17 29 34 49 52 57
    Females 
533 513 50 64 15 18
50.3% 54.3% 50.0% 52.9% 55.6% 47.4%
    Cases with risk factor
507
No data*
81 90 25 32
47.9% 81.0% 74.4% 92.6% 84.2%
*It should be noted: that risk factor data was not available for all age groups for the 2010/2011 season.
References
1.  ILI is defined using the EU case definition which is sudden onset 
of symptoms AND at least one of the following four systemic 
symptoms: fever, malaise, headache, myalgia; AND at least one 
of the following three respiratory symptoms: cough, sore throat, 
shortness of breath. 
2.  In addition to the NVRL, Cork University Hospital (CUH) and Galway 
University Hospital(s) (GUH) also tested for influenza A (H1) 2009 
during the pandemic period.
3.  Some cases had more than one underlying condition.  
4.  Influenza-associated deaths include: deaths with influenza as the 
primary/main cause of death on the death certificate or as reported 
by the clinician or deaths with influenza listed anywhere on the 
death certificate.
5.  This is an increase to previously reported deaths for the pandemic 
period, following extensive searches of the General Registrar’s Of-
fice registered deaths data.
6.  Seasonal influenza vaccine uptake data for the 2010/2011 influenza season 
are provisional. 
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In 2010, there were eleven cases of legionnaires’ disease 
notified in Ireland, a rate of 2.6 per million population. 
No deaths associated with legionnaires’ disease were 
reported.
Seven cases were reported from HSE East, two from 
HSE South East, and one each from HSE Mid-West and 
HSE North East.
Just over half the cases were male (54.5%). The median 
age was 63 with a range from 21 to 75 years.
All cases were confirmed by urinary antigen test. The 
organism involved in all eleven cases was Legionella 
pneumophila serogroup 1. 
Seven cases were travel-associated. Countries of travel 
included Spain (2), Ireland (2), Germany (1), Bulgaria (1), 
and Cuba (1). Four cases were community-associated, 
two in Ireland and one each in Spain and the United 
Arab Emirates. 
The peak month for notifications was August when five 
cases were notified.
2.2 Legionellosis
Summary
Number of cases, 2010: 11
Crude incidence rate: 2.6 per million
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Table 1. Number of legionnaires’ disease cases per million population in Ireland, 2003-2010
Age group 
(years)
2003 2004 2005 2006 2007 2008 2009 2010
<30 1 0 0 0 1 0 0 1
30-39 0 0 2 0 3 0 0 0
40-49 0 1 3 7 4 2 0 2
50-59 0 1 1 2 2 3 2 1
60-69 2 1 1 1 3 4 3 3
70+ 3 1 1 2 2 2 2 4
Total 6 4 8 12 15 11 7 11
CIR 1.5 0.9 1.9 2.8 3.5 2.6 1.7 2.6
Invasive Group A Streptococcal Disease
Notifications
Sixty-eight cases of invasive Group A streptococcal 
(iGAS) disease were notified in 2010.  This corresponds 
to 1.60 iGAS cases per 100,000 population [95% 
confidence interval (CI), 1.25 to 2.03 per 100,000] and 
represents an increase since 2009 when the iGAS rate 
was 1.42 per 100,000 population (95% CI, 1.08 to 1.82 
per 100,000).  
Sixty-five cases were confirmed, defined as patients 
with Group A streptococcus (GAS), or Streptococcus 
pyogenes, isolated from a sterile site. Three cases were 
probable, defined as patients with streptococcal toxic 
shock syndrome (STSS) and GAS isolated from a non-
sterile site (e.g. throat, sputum, vagina).
Patient demographics
Of the 68 cases, 36 (53%) were males and 32 (47%) were 
females, with ages ranging from 3 months to 97 years 
(mean, 49 years; median, 49 years). iGAS was more 
common in young children and older adults (Figure 1). 
Geographic spread and seasonal variation
Table 1 outlines the numbers and crude incidence 
rates (CIRs) of iGAS disease by HSE area from 2004 to 
2010. Of note, the highest number of cases in 2010 
occurred in the HSE-East (n=22; CIR, 1.47 per 100,000 
population) while the highest CIR occurred in the HSE-
North West (n=8; CIR, 3.37 per 100,000 population). 
As in 2009, the peak period in 2010 occurred between 
April and July accounting for 29 cases, with other 
peaks in January (n=7) and October (n=6). Note, the 
number of monthly cases (based on the date the case 
was positive for GAS and not the date the case was 
reported) is small, ranging from three to nine.
Enhanced surveillance data 
Enhanced data fields were entered for 57 (84%) of the 
iGAS cases, which is similar to 2009 (83%, 50 of 60 
cases). The source laboratory could not be ascertained 
for three of the cases. As in previous years, a wide 
variation in completed fields was observed. 
2.3  Invasive Group A Streptococcal 
 Disease
Summary
Number of cases, 2010: 68
Crude incidence rate, 2010: 1.60 per 100,000 
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Figure 1. Age and sex specific rates of iGAS disease in 2010
Isolate details
GAS was isolated from a sterile site in 53 of 65 
confirmed cases (no data on the source were available 
for 12 cases), primarily from blood cultures (n=51 
isolates, 96%) but also deep tissue (n=1) and a 
ventriculoperitoneal shunt tip (n=1). For the three 
probable cases, GAS source was provided for two of 
these: vaginal swab (n=1) and caesarean section wound 
(n=1). The third probable case was from a patient with 
meningitis.
Serological typing data, based on the detection of M 
and T-proteins, were available on only nine isolates from 
five laboratories: emm/M3, M11, M12, M13, M25, M28, 
M48, M49 and M78 (one isolate of each, respectively). 
Of these, enhanced data were available on eight 
patients with iGAS, two of whom presented with STSS 
(emm/M12 and M25). 
Clinical details
As in 2009 and previous years, bacteraemia (n=51 cases, 
including cases where bacteraemia was not specifically 
stated but GAS was isolated from blood) and cellulitis 
(n=20) were the most common clinical presentations, 
followed by pneumonia (n=10), STSS (n=9; one of 
which was implied based on the clinical presentation 
given), necrotising fasciitis (n=4), puerperal sepsis (n=3), 
myositis (n=2), septic arthritis (n=2), meningitis (n=1) 
and peritonitis (n=1). Note that cases could have more 
than one clinical presentation.  
Risk factors
Risk factors associated with iGAS disease included age 
65 years and over (n=22), presence of skin and wound 
lesions (n=16), diabetes mellitus (n=8), intravenous 
drug use (IVDU) (n=6), malignancy (n=6), non-steroidal 
anti-inflammatory drug (NSAID) use (n=5), childbirth 
(n=4), alcoholism (n=3), steroid use (n=2) and varicella 
infection (n=2). Note that cases could have one or more 
associated risk factors: 31 cases had one risk factor, 10 
had two risk factors, five had three risk factors and two 
had four risk factors. No risk factors were identified 
for seven cases. Among the nine cases with STSS, all 
of whom had at least one risk factor recorded, NSAID 
use was identified as a risk factor in three cases, age 
65 years and over was identified in two cases, and 
alcoholism in two cases. 
Clinical management
Surgical intervention was required for 12 patients 
(compared with 8 in 2009) ranging in age from one to 
71 years, including the four cases that presented with 
necrotising fasciitis.
Thirteen patients ranging in age from two to 72 
years were admitted to an intensive care unit (ICU) 
(compared to 16 in 2009). This included three patients 
with pneumonia, three with STSS, one with necrotising 
fasciitis, one with STSS and necrotising fasciitis, one with 
STSS and septic arthritis and one with STSS, necrotising 
fasciitis, septic arthritis and puerperal sepsis (some of 
these cases also presented with bacteraemia and/or 
cellulitis).
Risk factors for patients admitted to an ICU included 
skin and wound lesions (n=4), age over 65 years (n=3), 
diabetes mellitus (n=3), NSAID use (n=3), alcoholism 
(n=2), childbirth (n=2), steroid use (n=1) and varicella 
infection (n=1). Six patients had one, three had two, one 
had three and one had four risk factors. No risk factors 
were identified in one patient. 
Length of ICU stay was provided for nine cases ranging 
from one to eight days (mean, 4.3 days; median, 3 days). 
Other epidemiological information
Three cases (all bacteraemia, including one with 
cellulitis) were reported as hospital-acquired, which is 
the same as in 2009. 
As in 2009, no outbreaks of iGAS were notified in 2010.
Table 1. Numbers (n) and Crude Incidence Rates (CIRs) per 100,000 population of iGAS disease by HSE Area, 2004-2010
HSE Area 2004 2005 2006 2007 2008 2009 2010
 n CIR  n CIR n  CIR   n   CIR    n   CIR    n   CIR    n   CIR    
HSE-E 25 1.67 19 1.27 37 2.47 28 1.87 31 2.07 32 2.13 22 1.47
HSE-M 0 0.00 1 0.40 2 0.79 0 0.00 0 0.00 2 0.79 2 0.79
HSE-MW 1 0.28 3 0.83 2 0.55 2 0.55 3 0.83 5 1.38 6 1.66
HSE-NE 1 0.25 3 0.76 5 1.27 3 0.76 10 2.54 3 0.76 7 1.78
HSE-NW 0 0.00 3 1.27 1 0.42 3 1.27 3 1.27 1 0.42 8 3.37
HSE-SE 7 1.52 1 0.22 4 0.87 10 2.17 8 1.74 8 1.74 5 1.08
HSE-S 1 0.16 1 0.16 3 0.48 4 0.64 5 0.80 5 0.80 12 1.93
HSE-W 0 0.00 18 4.34 7 1.69 7 1.69 10 2.41 4 0.97 6 1.45
IRELAND 35 0.83 49 1.16 61 1.44 57 1.34 70 1.65 60 1.42 68 1.60
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Outcome
Outcome at seven-days following GAS isolation was 
reported for 30 cases: 
· 27 were still alive 
· three patients died: GAS was the main or 
contributory cause of death for all three 
patients 
The seven-day case fatality rate (CFR) for iGAS disease 
was 10% in 2010, which is the same as in 2009.
In addition to the above, the overall outcome was 
stated for a further 10 cases:
· one patient (aged three months) was reported 
to have died but it was not stated if this was 
directly attributable to iGAS 
· seven patients were recovering
· two patients were still ill 
Of the nine STSS cases, two patients died resulting in 
a CFR of 25% (with outcome provided for eight of nine 
cases).
Antimicrobial susceptibility
Antimicrobial susceptibility data were reported on 64 
iGAS isolates (60 from blood, three from tissue and 
one from an unspecified fluid) by 16 laboratories in 
2010 (note: these were reported via the EARS-Net 
Antimicrobial Resistance Surveillance Network, of which 
55 were also notified to public health via CIDR). All 
isolates tested were susceptible to penicillin (n=60) and 
vancomycin (n=43).  Resistance to erythromycin was 
reported in seven (12%) of 58 isolates, to clindamycin 
in one (4%) of 24 isolates and to tetracycline in three 
(12.5%) of 26 isolates.
Conclusion
iGAS disease remains an uncommon but potentially 
severe disease in Ireland.  Ongoing surveillance is 
essential, specifically completion of the enhanced data 
questionnaire, to gain a greater understanding of iGAS, 
to enable early detection of clusters/outbreaks, to 
ensure prompt implementation of infection prevention 
and control precautions and appropriate management 
of contacts.  The incidence of iGAS has increased since 
it first became notifiable in 2004: from 0.8 per 100,000 
population in 2004 to 1.6 per 100,000 population in 
2010, which most likely reflects increased notifications 
rather than a true increase in incidence.   Antimicrobial 
susceptibility data confirm that iGAS remains 
susceptible to penicillin and that penicillin should 
continue to be the first line treatment where iGAS is 
suspected.  
HPSC would like to thank participating microbiology 
laboratories for their contribution to iGAS enhanced 
surveillance scheme. 
All microbiology laboratories are encouraged to return 
enhanced iGAS surveillance forms for all patients with 
iGAS and to submit antimicrobial susceptibility data 
on all iGAS cases along with their EARS-Net quarterly 
returns.
The enhanced surveillance form can be downloaded 
from the HPSC web site at:
http://www.hpsc.ie/hpsc/A-Z/Other/
GroupAStreptococcalDiseaseGAS/SurveillanceForms/
Further information on iGAS disease in Ireland, 
including factsheets for patients and contacts and 
national guidelines, is available at: http://www.ndsc.ie/
hpsc/A-Z/Other/GroupAStreptococcalDiseaseGAS/
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Diseases Reporting (CIDR) System on 2nd September 
2011. 
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In 2009, 479 cases of tuberculosis (TB) were notified 
in Ireland, corresponding to a crude notification rate 
of 11.3 per 100,000 population, which remains stable 
in comparison to 2008 (11.0/100,000 population) and 
2007 (11.3/100,000 population). A summary of the 
epidemiology of TB in Ireland during 2009 is shown in 
table 1 while the number of cases and crude incidence 
rates from 1991 to 2010* with three-year moving 
averages are shown in figure 1. 
The highest crude incidence rates were reported 
by HSE-E (15.7/100,000 population) and HSE-S 
(13.2/100,000 population) while the lowest rates were 
reported by HSE-W (5.1/100,000 population) and HSE-
SE (6.0/100,000 population). Rates reported in HSE-MW 
(7.5/100,000 population) and HSE-NE (6.9/100,000 
population) were also significantly lower than the 
national incidence rate. 
The highest age-specific rate in 2009 occurred among 
those aged 65 years and over (18.4/100,000) followed 
by those aged 25-34 years (17.6/100,000 population). 
The rate among males (14.1/100,000 population) 
was higher than that among females (8.3/100,000 
population). Rates among males were higher than 
females for all age groups except in the 0-14 year age 
group where the rate in males was lower (1.8 compared 
to 2.4/100,000 population). The highest rate among 
males (27.0/100,000 population) was in the group aged 
65 years and older while the highest rate in females 
(13.2/100,000 population) was in the 25-34 year age 
group. The female to male ratio (0.6:1.7) reported in 
2009 was consistent with the ratio reported in previous 
years. 
Geographic origin
During 2009, 43.0% (206 cases) of TB cases were born 
outside Ireland. This is similar to the proportion of 
foreign-born cases reported during 2008 (43.3%) and 
higher than those reported between 2003 and 2007 
(range: 22%-40%). The crude rate in the indigenous 
population at 7.6 per 100,000, was the same as 2008 
2.4 Tuberculosis, 2009
Summary
Number of cases, 2009: 479
Number of culture confirmed cases: 341
Crude incidence rate, 2009: 11.3/100,000
Number of TB deaths, 2009: 10
Number of cases, 2010*: 427 
Crude incidence rate, 2010*: 10.1
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Table 1. Summary of the epidemiology of TB in Ireland, 2009
Parameter Number % of Total 
cases
Total number of cases 479
Crude notification rate per 100,000 11.3
Cases in indigenous population† 270 56.4
Cases in foreign-born persons† 206 43.0
Culture positive cases 341 71.2
Pulmonary cases 314 65.6
Smear positive pulmonary cases 139 44.3
Multi-drug resistant cases 1 0.2
Mono-resistant to isoniazid 11 2.3
Deaths attributable to TB 10 2.1
Outcomes reported in cases 395 82.5
TB meningitis cases 8 1.7
*  Data for 2010 are provisional data which may change significantly following validation
†  Country of birth was unknown for 3 cases
(7.6/100,000 population). Similarly, the crude rate in the 
foreign-born population at 33.6 per 100,000 was similar 
to 2008 (33.0 per 100,000 population). There was a 
notable difference in age between those born in Ireland 
and those born outside Ireland, with a median age of 
53 years and 32 years respectively. In 2009, among 
countries in the EU and Western Europe who reported 
data to the European Centre for Disease Prevention and 
Control (ECDC), 23.6% of notifications were in foreign-
born cases. In Belgium, Slovakia and Slovenia, where 
crude incidence rates are similar to those reported in 
Ireland, the percentage of cases of foreign origin in 
2009 ranged from 1.4%-48.6%.1
Site of infection 
Pulmonary TB was reported in 314 (65.6%) cases, 164 
(34.3%) had exclusively extrapulmonary disease and 
diagnostic type was not reported in one case. Of the 
extrapulmonary cases reported in 2009, there were 
eight cases of TB meningitis corresponding to a rate of 
0.19/100,000 population (1.9/million population). 
Microbiology
Of the 479 cases reported in 2009, 71.2% (341 cases) 
were culture confirmed. Of the 341 culture confirmed 
cases, species identification showed M. tuberculosis in 
96.2% (328 cases), M. bovis in 2.3% (8 cases) and M. 
africanum in 0.3% (1 case) (organism was not reported 
for four culture confirmed cases). The number of M. 
bovis isolates detected in 2009 was less than that 
detected during 2008 (n=12) but slightly higher than 
the numbers previously reported (3-6 cases per annum 
between 2002-2007). Of the 314 cases with a pulmonary 
component, 243 (77.4%) were culture confirmed, and 
139 (44.3%) were smear positive.  
Drug sensitivity 
Information on antibiotic sensitivity testing was available 
for 323 (94.7%) of the 341 culture confirmed cases. Of 
these, resistance was documented in 26 (8.0%) cases, 
one (0.2% of total cases) of which was an MDR-TB case. 
Mono-resistance to isoniazid was recorded in 11 cases, 
to streptomycin in three, to pyrazinamide in two cases 
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Figure 2: TB outbreak summary by year
Figure 1: Notified cases of TB in Ireland with crude rates per 100,000 population, 1991 to 2010* 
and 3-year moving averages, 1992-2009
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*  Data for 2010 are provisional data which may change significantly following validation
and to ethambutol in one. For further details on the 
resistance profiles of TB cases reported 2009 will be 
available in the HPSC Report on the Epidemiology of TB 
in Ireland, 2009 (www.hpsc.ie).
Outcome
In 2009, information on treatment outcome was 
provided for 82.5% (395) of cases, a decrease compared 
to 88.7% in 2008. Treatment outcome was reported 
as completed for 307 (64.1%) cases, 34 (7.1%) cases 
died, 30 (6.3%) were lost to follow up, 19 were still on 
treatment (4.0%), four (0.8%) had treatment interrupted 
and one (0.2%) case transferred out. Ten (29.4%) of the 
34 deaths were attributable to TB. During 2009, the 
reported treatment success rate was 67.7% for new 
culture confirmed pulmonary TB cases and 72.6% for 
new smear-positive pulmonary TB cases. 
Outbreaks 
The introduction of the amendment to the Infectious 
Disease Regulations 1981 on January 1st 2004, made 
outbreaks, unusual clusters or changing patterns of 
illness statutorily notifiable by medical practitioners and 
clinical directors of laboratories to the medical officer of 
health. Standard reporting procedures for surveillance 
of TB outbreaks were formally agreed in 2007. 
During 2009, nine outbreaks of TB were reported to 
HSPC, with 28 cases of active TB, 53 with latent TB 
infection (LTBI), 16 hospitalisations and two deaths. 
Three outbreaks were reported by HSE-E, two by HSE-
SE, three by HSE-S and one by HSE-W. There were 
five general outbreaks, three of which occurred in 
community settings, one was in a residential institution 
and one was in a day care facility. There were also 
four family outbreaks, two of which occurred across 
extended families and two were in private houses. The 
number of outbreaks reported during 2009 remained 
stable in comparison to 2008, however the number of 
active TB cases decreased while the number of those 
with LTBI increased. Figure 2 shows a summary of TB 
outbreaks from 2004 to 2010 by year of outbreak, 
number of active TB cases and number of persons with 
LTBI.
Summary:
When compared to recent years, the crude notification 
rate of TB for 2009 has remained stable at 11.3 per 
100,000. Rates were higher in males for almost all age 
groups with the highest age specific rates reported 
in those aged 65 years and over.  Over 40% of all TB 
cases notified were foreign born which is comparable to 
other European countries with similar crude incidence 
rates to Ireland.  The rate in the indigenous population 
was 7.6 per 100,000 population.  Irish born cases were 
older than foreign born which is also reflected in other 
European countries.1 
Of the 314 cases with a pulmonary component 77.4% 
were culture confirmed, an increase from 72.7% in 
2008. The proportion of new culture confirmed cases 
with a pulmonary component, increased to 80.1%, an 
increase compared to 2008 (75.0%) which also reaches 
the EU monitoring framework target of ≥ 80% culture 
confirmation among new pulmonary TB cases.2 
 
Only one MDR TB case was reported for 2009 which 
is a decrease compared to recent years with two 
reported in 2008 and seven reported in 2007.  The 
proportion of new culture confirmed pulmonary cases 
with reported DST results reported declined from 
97.0% in 2008 to 94.7% in 2009. This falls below the 
EU monitoring framework action plan target of 100% 
of new culture confirmed pulmonary cases with DST 
results.2 Continuous vigilance is needed in relation to 
drug resistance especially with the global emergence of 
XDR-TB. 
There was a slight decline in the level of outcome data 
reported compared to 2008. The proportion of total 
cases where outcome was reported as completed 
(64.1%) also declined during 2009 compared to 
2008 (72.4%) and 2007 (69.2%). The proportion of 
new culture-confirmed pulmonary TB cases where 
outcome was reported as completed was 67.7%, 
falling short of EU monitoring framework action plan 
targets of successfully treating 85% or more of all new 
culture-confirmed pulmonary TB cases.2  It is of critical 
importance to TB control in Ireland that surveillance of 
TB and reporting of outcome data be maintained at a 
high level especially with the global threat of resistant 
strains.
As of January 1st 2011, the National TB Surveillance 
System moved to the Computerised Infectious Disease 
Reporting system (CIDR). This increased awareness 
of TB outbreak reporting and also facilitated the 
retrospective reporting of outbreaks not previously 
reported. Data on historic TB outbreaks are now more 
complete and timeliness has been improved for current 
outbreak reporting. 
Guidelines on the Prevention and Control of 
Tuberculosis in Ireland were published in April 2010.3 
The recommendations in these guidelines are based 
on a review of international literature, expert opinion 
and an extensive consultation process. They provide 
advice on the diagnosis and treatment of active TB 
and latent TB Infection (LTBI), outbreak management 
and contact tracing procedures and screening for 
TB in special situations e.g. healthcare settings, new 
entrants to Ireland, prison and homeless settings.  The 
guidelines aim to improve the prevention and control 
of the disease and to help Ireland meet World Health 
Organization (WHO) targets for the elimination of TB. 
Stop TB partnership aims to reduce the global incidence 
of TB to less than one case per million population by 
2050, which will eliminate the disease as a global health 
problem.4  The importance of good surveillance data 
cannot be underestimated in this context as they will 
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help guide where resources should be directed e.g. risk 
groups  in order to implement effective TB prevention 
and control strategies in Ireland and in order to reach 
the elimination target by 2050.
Provisional 2010 data
There were 427 cases of TB provisionally notified 
in 2010, corresponding to a crude rate of 10.1 per 
100,000 population. It is important to note that these 
data are provisional and may change significantly 
following validation. 
Of the 427 cases provisionally notified in 2010, 
•   Pulmonary TB was diagnosed in 250 cases (58.5%), 
extrapulmonary TB in 150 cases (35.1%) and 
pulmonary and extrapulmonary TB in 24 cases (5.6%). 
Diagnostic type was not reported for three cases.
•   Of the 274 cases with a pulmonary disease 
component, 193 (70.4%) were culture positive and 
113 (41.2%) were smear positive.
•   There were eight cases of TB meningitis provisionally 
notified corresponding to a rate of 0.19 per 100,000 
population (1.9/million population).
•   There were 243 (56.9%) cases born in Ireland and 171 
(40.0%) were foreign-born. Country of birth was not 
reported for 13 (3.0%) cases.
•   There were 162 cases (37.9%) notified in females, 263 
cases (61.6%) in males and sex was not reported for 
two cases (0.5%)
•   The mean age of cases was 41.4 years (range: 0 to 98 
years).
•   Resistance was reported in 18 cases, five of which 
were mono-resistant to isoniazid. Two cases of MDR-
TB were reported during 2010. Twelve (66.7%) of the 
18 resistant cases (including both MDR cases) were 
born outside Ireland.
•   There were seven TB outbreaks reported to HPSC 
during 2010, with 41 active TB cases, 60 cases of 
latent TB infection and 20 hospitalisations. No deaths 
were reported from these outbreaks. 
More detailed surveillance reports can be found under 
Topics A-Z at www.hpsc.ie
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Campylobacteriosis became a notifiable disease 
in Ireland in 2004 under the Infectious Diseases 
regulations. Prior to this, data on laboratory-confirmed 
cases of Campylobacter infection in humans were 
collected nationally as part of the EU Zoonoses 
Regulations (while some cases were included in the 
former category of “Food Poisoning
(bacterial other than salmonella)”). It is an acute 
zoonotic bacterial disease characterised by diarrhoea, 
abdominal pain, malaise, fever, nausea and vomiting. 
Symptoms generally last for only a few days.  
Campylobacteriosis is the commonest bacterial cause of 
gastroenteritis in Ireland and Europe.
During 2008, a European Union-wide baseline survey of 
Campylobacter in broiler batches and broiler carcasses 
was carried out by The European Food Safety Authority 
(EFSA). This survey found that 75.8% of broiler carcasses 
sampled were contaminated with Campylobacter while 
98% of Irish broiler carcasses sampled were positive 
for Campylobacter.1 EFSA currently estimates that 
handling, preparation and consumption of broiler meat 
may account for 20-30% of human campylobacteriosis 
while 50-80% of cases may be attributed to the broiler 
reservoir as a whole.2 The importance of poultry meat 
as a source of human campylobacter infection was 
supported by the  food-borne outbreak data reported 
to EFSA during 2009, where seven out of 12 verified 
food-borne outbreaks of campylobacteriosis (with a 
specified food item) were poultry related.3  In response 
to such evidence, the Food Safety Authority of Ireland 
(FSAI) published “Recommendations for a Practical 
Control Programme for Campylobacter in the Poultry 
Production and Slaughter Chain” during 2011.4
Findings of the first national case control study 
conducted in Ireland investigating risk factors 
for sporadic Campylobacter infections show that 
consuming chicken, lettuce and eating in takeaways 
were important risk factors for contracting the disease 
in Ireland. Contact with sheep, peptic ulcer, hiatus 
hernia lower bowel problems were also independently 
associated with infection. However mains water supply 
showed protective effect from contracting the illness.5
During 2010, 1,661 cases were notified in Ireland, 
corresponding to a crude incidence rate (CIR) of 39.2 
per 100,000 population. This is a decrease compared 
to the number of cases reported during 2009 (n=1,807, 
3.1 Campylobacter 
Summary
Number of cases: 1,661
Crude incidence rate: 39.2/100,000
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Figure 1. Campylobacteriosis crude incidence rates per 100,000 population (95% CI) by HSE 
area, 2009 & 2010.
Figure 1: National CIR of Campylobacter by Region, 2007 and 2008.
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CIR: 42.6). The European Centre for Communicable 
Disease Prevention and Control (ECDC) annual 
epidemiological report on communicable diseases in 
Europe reported a European crude incidence rate of 
44.1 per 100,000 population during 2008, a decrease of 
3% compared to 2007.6 
Geographical variation in CIR was observed within HSE 
areas. The highest CIR was observed in HSE-M at 50.1 
per 100,000 population, an increase from the 2009 CIR 
of 43.7 per 100,000 population. The lowest CIR was 
observed in HSE-NE at 26.9 per 100,000 population, a 
decrease compared to the 2009 CIR of 34.3 per 100,000 
population. Figure 1 illustrates the campylobacteriosis 
CIR by HSE area during 2010 and 2009, with 95% 
confidence intervals. 
Campylobacteriosis occurs in all age groups with the 
highest burden of illness experienced in the 0-4 year 
age group. During 2010, this age group accounted 
for 25.2% of cases and had the highest age specific 
incidence rate (ASIR) of 138.3 per 100,000 population. 
The second highest ASIR observed was in the 20-
24 year age group (43.8/100,000 population). The 
lowest ASIR was observed in the 15-19 year age group 
(21.0/100,000 population), the 10-14 year and 55-
64 year age groups (26.3/100,000 population). This 
preponderance in younger children is a well described 
characteristic of the disease and is also observed at 
European level. The highest European notification rate 
during 2008 was reported in males in the 0-4 year age 
group (117.3/100,000 population) and in females of the 
same age (96.2/100,000 population).6 
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Figure 2. Campylobacteriosis notifications and age specific incidence rate per 100,000 population by 
age group (years) and sex, 2010 (CIDR)
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Figure 3. Number of campylobacteriosis notifications by month, 2004-2010
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During 2010, 53.3% of all cases were male, 46.7% of 
cases were female and sex was not reported for 0.4% 
of cases. Further analysis of the age-sex distribution 
of campylobacteriosis cases shows a predominance of 
male cases in the 0-14 year age group and the 65 years 
age and older group while there was a predominance 
of female cases in the 35-44 year age group. Figure 2 
illustrates the number of campylobacteriosis cases and 
age specific incidence rates by age group (years) and 
sex during 2010.
Campylobacteriosis has a well documented seasonal 
distribution with a peak in early summer. During 2010, 
notifications of campylobacteriosis peaked during June 
(n=204) and July (n=175) with a smaller secondary peak 
observed in September (n=170). Figure 3 illustrates the 
seasonal distribution of campylobacteriosis notifications 
in Ireland from 2004 to 2010. 
Information on country of infection was recorded in 
12.0% of all cases, which is a slight decrease on the 
proportion of cases with this information provided in 
2009 (14.2%). Of the 200 cases where country of origin 
was specified, indigenous cases accounted for 77.0%. 
There were also 46 cases (23.0%) with a recent history 
of foreign travel. These travel associated cases had 
exposures in 24 different countries. The majority of 
campylobacteriosis cases (92%) in Europe reported to 
ECDC (where country of infection was known) during 
2008 were also indigenous.6
Of the cases notified in Ireland during 2010, 99.9% were 
laboratory confirmed. However, as there is currently 
no national reference facility for routine typing of 
Campylobacter isolates, information on Campylobacter 
species is strikingly incomplete. In 2010, 37.7% (n=626) 
of isolates were speciated.  Of the 626 speciated 
isolates, 89.9% of isolates were C. jejuni, 9.9% were 
C. coli and 0.2% were C. fetus. The remaining 62.3% 
(n=1,034) of Campylobacter isolates identified were 
not further speciated. This compares with 49% of 
Campylobacter isolates in Europe reported to ECDC 
during 2008 remaining unspeciated.6 
During 2010, there were two outbreaks of 
campylobacteriosis reported with 20 associated cases 
of illness, one of whom was hospitalised. One local 
general outbreak occurred in a hotel with mode of 
transmission reported as food-borne. The remaining 
outbreak occurred across an extended family with 
mode of transmission reported as person to person 
spread (Table 1).  During 2009, sixteen European 
countries reported 333 food-borne outbreaks of 
campylobacteriois to EFSA. These outbreaks comprised 
1,421 associated cases of illness, 97 hospitalisations 
and one death and accounted for 6% of the total food-
borne outbreaks reported to EFSA.3 
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Table 1. Campylobacteriosis outbreaks summary, 2010 (CIDR)
Mode of transmission Outbreak location Number outbreaks Number ill Number 
hospitalised
Number dead
Person-to-person Extended family 1 15 0 0
Foodborne Hotel 1 5 1 0
Total 2 20 1 0
Cryptosporidium is a protozoal parasite that causes a 
diarrhoeal illness in humans known as cryptosporidiosis. 
It is transmitted by the faecal-oral route, with both 
animals and humans serving as potential reservoirs. 
Human cryptosporidiosis became a notifiable disease 
in Ireland in 2004, and the case definition in use is 
published in the HPSC case definition booklet. 
In 2010, 294 cases of cryptosporidiosis were notified in 
Ireland, a crude incidence rate (CIR) of 6.9 per 100,000 
population, with 34% of notified cases reported as 
hospitalised for their illness. This was a 34% decrease on 
the number of cases notified in 2009 (Figure 1). In 2008 
(the most recent year for which data are available), the 
ECDC reported an incidence rate overall of 2.44 per 
100,000 population in the European Union, with Ireland 
reporting the highest rate among those countries 
reporting on this disease at the time. The second 
highest incidence rate among EU Member States was 
reported by the United Kingdom at 8.1 per 100,000.
Consistent with previous years, the highest reported 
incidence was in children under 5 years, with around 60 
cases per 100,000 population in this age group (Figure 
2). While there is likely to be a bias towards testing of 
diarrhoeal stool specimens from children (as opposed to 
adults) for Cryptosporidium, it is also possible that this 
distribution reflects to some extent a true difference in 
risk between adults and children, and may also reflect 
in part some immunity among a proportion of the adult 
population.
The crude incidence (CIR) rates by HSE area for 2010 
are reported in Figure 3. As in previous years, there 
was a strong urban-rural divide, with the HSE-E having 
a much lower reported incidence rate (1.2 per 100,000) 
than most other HSE areas. The HSE- W reported the 
highest crude incidence rate (16.66 per 100,000) –over 
twice the national rate. Compared to 2009, six areas 
reported decreased rates: in the HSE-W and the HSE-M, 
these decreases were statistically significant.
The highest number of cases was recorded in spring, 
albeit at lower levels than in previous years (Figure 4). 
Notably although only 17 (6%) notifications across the 
full year were specifically reported as being associated 
with foreign travel, seven of these were reported during 
the month of August (Figure 5). 
Speciation of Cryptosporidium specimens can 
provide valuable information on the epidemiology of 
this disease. C. hominis is a species primarily linked 
with humans, whereas both humans and animals, 
3.2 Cryptosporidiosis
Summary
Number of cases, 2010: 294
Number of cases, 2009: 445
Crude incidence rate, 2010: 6.9/100,000
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Figure 1. Annual number and crude incidence rate 
cryptosporidiosis, Ireland 2004-2010.
Figure 2. Age-specific incidence rate cryptosporidiosis, Ireland 
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in particular calves and lambs, can be sources of  
C parvum infections. Species that are less commonly 
reported in humans have been associated with other 
animal reservoirs. In 2010, less than 5% of positive 
human Cryptosporidium specimens were referred for 
speciation to the UK Cryptosporidium Reference Unit 
in Swansea by a small number of hospital laboratories. 
This is a decrease on the proportion of cases for which 
specimens were typed in 2009 (17%) and 2008 (35%), 
and may reflect the enhanced use of this service when 
outbreaks are occurring. As in 2008 and 2009, C. 
parvum was the most common species reported (12/14 
cases). There was one case each of C. hominis and C. 
meleagridis. 
There were no general outbreaks of cryptosporidiosis 
this year. Over the last couple of years, there has been a 
decrease in the number of general outbreaks reported, 
with one general outbreak in 2009, four in 2008 and six 
in 2007. 
All eight outbreaks of cryptosporidiosis reported in 
2010 were family outbreaks: all were small outbreaks, 
and between them accounted for only 15 cases. Table 
1 lists the reported transmission routes and locations 
for these outbreaks. Six were suspected to be due to 
person-to-person transmission, one was suspected to 
be due to animal contact and one travel-associated 
outbreak was suspected to be waterborne. The 
overwhelming majority of cases in 2010 were reported 
as sporadic cases.
The seasonal distribution of cases in Ireland suggests 
an important role for animal sources in human 
cryptosporidiosis: historically in the United Kingdom, 
spring peaks in incidence have been associated with 
transmission from sources such as calves and lambs. 
The species distribution reported here is consistent 
with this. The higher disease incidence in more rural 
versus more urban HSE-areas suggests that animal 
contact or waterborne routes of transmission may play 
a stronger role overall in transmission in Ireland than 
person-to-person spread, food or travel, as the latter 
would be expected to have a more even geographical 
distribution. 
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Figure 3. Regional crude incidence rates cryptosporidiosis, 
Ireland 2010 relative to 2009
Figure 4. Seasonal distribution of cryptosporidiosis cases 
2007-2010 
Figure 5. Seasonal distribution cryptosporidiosis cases by 
travel status, Ireland 2010
Table 1. Cryptosporidiosis outbreaks Ireland 2010 
Month HSE-area Outbreak type Transmission mode Location No. ill
Mar S Family Person-to-person Private house 2
Mar SE Family Person-to-person Private house 2
Apr S Family Person-to-person Extended family 2
May NW Family Person-to-person Private house 2
Jun S Family Animal contact Private house 2
Jun NW Family Person-to-person Private house 2
Oct M Family Waterborne Travel related 1
Oct NE Family Person-to-person Private house 2
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Introduction
Reported verotoxigenic E. coli (VTEC) incidence rates 
in Ireland have been rising steadily over the last five 
years, such that in 2008 and 2009, Ireland reported 
the highest VTEC incidence rate of any Member State 
in the European Union.1, 2 In Ireland, infection has 
historically been most commonly associated with VTEC 
serogroup O157, with smaller numbers of non-O157 
VTEC reported, although this may reflect diagnostic bias 
as the techniques for the detection of non-O157 VTEC 
are more complex than for VTEC O157, and different 
policies may exist in different laboratories for the 
routine examination of stool specimens. 
The dominant transmission routes for VTEC in Ireland 
appear to be person-to-person spread, especially in 
creches/childminding facilities and among families with 
young children, and waterborne transmission associated 
with exposure to water from untreated or poorly 
treated private wells. Other important transmission 
routes identified internationally include food (often 
minced beef products or fresh produce such as lettuce 
and spinach), and contact with infected animals or 
contaminated environments.
Data Source and Methods
Infection due to Enterohaemorrhagic E. coli (EHEC) 
is a notifiable disease (S.I. 707 of 2003) since 2004. 
This chapter focuses on cases that conform to the 
case definition used for VTEC enhanced surveillance 
(http://www.ndsc.ie/hpsc/A-Z/Gastroenteric/VTEC/
SurveillanceForms/). 
Incidence
In 2010, there were 199 confirmed and probable cases 
of VTEC notified, equating to a crude incidence rate 
(CIR) of 4.7 per 100,000 (Table 1). If only confirmed 
VTEC cases are considered, the 197 cases (CIR=4.7 
[4.0-5.3]) notified this year represent a 17% decrease 
overall on the number of confirmed cases notified in 
2009. Non-O157 VTEC made up 41% of cases in 2010, 
however, and this overall change in VTEC case numbers 
was made up of a 30% decrease in the number of VTEC 
O157 cases and an 11% increase in non-O157 VTEC 
cases reported compared to 2009 (Figure 1). 
Interesting in 2010 in Scotland, there was also a 
decrease in the VTEC O157 incidence rate to 4.1 per 
100,000 (11% decrease) and in England and Wales, 
VTEC O157 case numbers fell by 23%. 3, 4  The CIR 
for VTEC overall of 4.7 per 100,000 population in 
Ireland, however, remains high relative to Europe 1,2 
3.3 Verotoxigenic E. coli 
Summary
Number of cases, 2010: 199
Number of cases, 2009: 241
Crude incidence rate, 2010: 4.7/100,000
Number of VTEC-Associated HUS 2010: 19
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Table 1. Number and crude incidence rates confirmed and 
probable VTEC, Ireland 2004-2010
Year Confirmed 
cases 
Probable 
cases 
Total VTEC CIR VTECa 
(95% CI) 
2004 61 0 61 1.4 (1.1-1.8)
2005 125 0 125 3.0 (2.4-3.5)
2006 153 5 158 3.7 (3.2-4.3)
2007 115 52 167 3.9 (3.3-4.5)
2008 213 13 226 5.3 (4.6-6.0)
2009 238 3 241 5.7 (5.0-6.4)
2010 b 197 2 199 4.7 (4.0-5.4)
a Data from the 2006 census were used to calculate rates 
b Confirmed cases include 116 VTEC O157 cases, 67 VTEC O26 cases 
and 14 VTEC strains of other serogroups. Two probable cases were 
reported on the basis of being epidemiologically linked to laboratory 
confirmed cases (VTEC O157 in one instance and VTEC O121 in the 
second instance).
The reported VTEC incidence in 2009 at European 
community level was 0.7 VTEC cases per 100,000 
population, with Denmark (2.90/100,000), Sweden 
(2.46/100,000) and the United Kingdom (2.19 per 
100,000) reporting the next highest rates after Ireland.
Of 192 cases where information was available on 
symptoms, 147 (77%) were symptomatic, 75 (51%) of 
which developed bloody diarrhoea. Nineteen individuals 
(9.5%) developed HUS compared to 24 (10%) last year 
(21% decrease). And where reported, 42% of notified 
cases required hospitalisation (72/173). 
The reduction of 21% in the VTEC-associated HUS 
numbers suggests that the decrease in the overall 
reported incidence of VTEC in 2010 was a true 
decrease.
Seasonal distribution
Typically, VTEC cases are most commonly associated 
with late summer; overall this year, 48% of cases 
were reported in quarter 3. However, the seasonal 
distribution varied by serogroup, with VTEC O26 being 
more common in quarter 2 while VTEC O157 remained 
more common in quarter 3. It is possible that the overall 
seasonal distribution noted previously was biased by 
the dominance of VTEC O157 in the national dataset, 
and that these variations in seasonal distribution by 
serogroup may reflect a seasonal difference in sources 
or transmission routes for different serotypes. 
Regional distribution
Overall the highest VTEC incidence rates were reported 
in the HSE-MW and HSE-NW, where the rates were over 
twice the national crude rate (Table 2). As in previous 
years, the HSE-E reported the lowest overall crude 
incidence rate (Table 2), just over one quarter of the 
national rate this year. The crude incidence rate in the 
HSE-NE is also consistently low relative to other areas.
When the incidence by HSE-area is examined by 
serogroup, the incidence rate across HSE-areas for 
VTEC O157 is similar across six of the HSE-areas, with 
only HSE-E and HSE-NE showing lower incidence rates 
(Table 2 and Figure 3). The elevated overall incidence 
rates in the HSE-MW and HSE-NW were strongly 
influenced by their high reported incidence rates for 
non-O157 infections. Historically, the HSE-NW (and 
more recently the HSE-MW) have reported relatively 
high numbers of non-O157 VTEC infections. While it is 
possible that there is a true geographical difference in 
risk for different serogroups, it is likely that this regional 
variation in reported non-O157 VTEC incidence to 
some extent reflects regional differences in laboratory 
diagnostic practice for non-O157 infections.
Review of regional HUS incidence due to confirmed 
or probable VTEC infection gives a slightly different 
perspective on the relative importance of VTEC by 
region (Table 2 and Figure 3). The HSE-S reported the 
highest VTEC-associated HUS incidence rates in 2010, 
followed by HSE-M, HSE-MW and HSE-NW. The eastern 
part of Ireland including HSE-E, HSE-SE and HSE-NE 
displayed the lowest VTEC-associated HUS incidence 
rates. 
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Figure 1. Annual number of confirmed and probable VTEC 
cases by serogroup, Ireland 1999-2010
Figure 2. Seasonal distribution of VTEC cases by serogroup, 
Ireland 2010
Table 2. Number and crude incidence rate confirmed and probable VTEC by serogroup and HSE area, and number and crude 
incidence rate VTEC-associated HUS by HSE-area, Ireland 2010
HSE-area Number [CIR (95% CI)] 
VTEC O157
Number [CIR (95% CI)] 
non-O157 VTEC
Number [CIR (95% CI)] all 
VTEC
Number [CIR (95% CI)] 
VTEC-associated HUS
East 11 [0.7 (0.3-1.2)] 7 [0.5 (0.1-0.8)] 18 [1.2 (0.7-1.8)] 3 [0.2 (-0.0-0.4)]
Midlands 11 [4.4 (1.8-7.0)] 6 [2.4 (0.5-4.3)] 17 [6.8 (3.5-10.0)] 2 [0.8 (-0.3-1.9)]
Mid-West 13 [3.6 (1.6-5.6)] 26 [7.2 (4.4-10.0)] 39 [10.8 (7.4-14.2)] 3 [0.8 (-0.1-1.8)]
North-East 7 [1.8 (0.5-3.1)] 1 [0.3 (-0.2-0.8)] 8 [2.0 (0.6-3.4)] 1 [0.3 (-0.2-0.8)]
North-West 9 [3.8 (1.3-6.3)] 25 [10.5 (6.4-14.7)] 34 [14.3 (9.5-19.2)] 2 [0.8 (-0.3-2.0)]
South-East 17 [3.7 (1.9-5.4)] 0 [0.0 (0.0-0.0)] 17 [3.7 (1.9-5.4)] 0 [0.0 (0.0-0.0)]
South 30 [4.8 (3.1-6.6)] 10 [1.6 (0.6-2.6)] 40 [6.4 (4.4-8.4)] 6 [1.0 (0.2-1.7)]
West 19 [4.6 (2.5-6.7)] 7 [1.7 (0.4-2.9)] 26 [6.3 (3.9-8.7)] 2 [0.5 (-0.2-1.2)]
Ireland 117 [2.8 (2.3-3.3)] 82 [1.9(1.5-2.4)] 199 [4.7 (4.0-5.4)] 19 {0.5 (0.3-0.7)]
*Rates per 100,000 calculated using CSO census 2006 for denominator data
0
50
100
150
200
250
300
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
year
N
u
m
b
er
 o
f 
ca
se
s
Total
O157
non-O157
0
5
10
15
20
25
30
1 2 3 4 5 6 7 8 9 10 11 12
month number
nu
m
be
r 
of
 n
ot
if
ic
at
io
ns
VTEC O157
VTEC O26
Other VTEC
VTEC typing
In 2010, all isolates from the 197 confirmed VTEC cases 
were referred to the HSE PHL Dublin Mid Leinster, 
Cherry Orchard Hospital and their serotype and 
verotoxin profiles are displayed in Table 3. As usual 
among VTEC O157 in Ireland, isolates containing the 
genes for verotoxin 2 (vt2) were more common (86%) 
than isolates containing both vt1 and vt2. VTEC O26 
isolates containing only vt1 made up 55% of all VTEC 
O26 reported, with 36% of VTEC O26 containing the 
genes for both vt1 and vt2. 
HUS cases in 2010 were associated with VTEC O157 
isolates containing vt2 or both vt1 and vt2, and with 
VTEC O26 containing vt2 or both vt1 and vt2, but not 
with any of the VTEC O26 strains containing vt1 alone. 
In 2010, the DML-PHL at Cherry Orchard introduced a 
new more highly discriminatory typing service whereby 
all human VTEC isolates were routinely typed by pulsed 
field gel electrophoresis (PFGE) rather than referred to 
the Health Protection Agency laboratory in the United 
Kingdom for phage typing. This confirmed that no 
large undetected clusters/outbreaks occurred among 
laboratory confirmed VTEC cases in Ireland in 2010. On 
a small number of occasions, indistinguishable isolates 
were identified among pairs of cases reported as 
sporadic (and sometimes between a family cluster and 
another case reported as sporadic). On these occasions, 
the HSE PH departments were informed and review of 
case histories undertaken, however, no epidemiological 
evidence of links were uncovered on any of these 
occasions. 
Risk factors
Under enhanced surveillance for VTEC, risk factor 
information is routinely collected on VTEC notifications 
(Table 4).
Among VTEC cases in Ireland in 2010, exposure to 
farm animals or their faeces and exposure to private 
well water were common among cases; 52.4% and 
42.9% reported these exposures respectively. This is 
consistent with the low incidence of VTEC infection 
among residents in the largely urban HSE-E population 
and the higher incidence recorded in more rural parts of 
the country. 
Unlike salmonellosis, foreign travel plays only a minor 
role in VTEC infection in Ireland, with the majority of 
infections acquired indigenously. The countries where 
the small number of travel-associated Irish VTEC cases 
had travelled to during their potential incubation 
periods were Bulgaria, Cyprus, Sri Lanka and United 
Kingdom (n=2). 
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Table 3. Serotype and verotoxin (VT) profiles for VTEC isolates as determined at the PHL HSE Dublin Mid Leinster, Cherry 
Orchard Hospital in 2010 by HUS status as recorded on CIDR
Strain HUS a Non-HUS a Unknown Total
O157 VT1 + VT2 1 14 2 17
 VT2 11 86 3 100
O26 VT1 35 1 36
 VT1 + VT2 4 19 1 24
 VT2 2 4 6
Other –non O157 VTEC VT1 6 6
VT1 + VT2 6 6
VT2 2 2
Total 18 172 7 197
a One HUS and one non-HUS case in 2010 were reported on the basis of being epidemiologically linked to laboratory confirmed cases, and thus 
no isolates were available for inclusion in this table 
Table 4. Number of cases (and percentage where information received) for which specified risk factor was reported, Ireland 2010
Risk factor
Number ‘Yes’ and % 
where reported
Number ‘No’ and % 
where reported
Number where risk factor 
was unknown or not 
reported
Food suspected 19 (12.2%) 137 (87.8%) 43
Exposure to farm animals or their faeces 97 (52.4%) 88 (47.6%) 14
Exposure to private well watera 73 (42.9%) 97 (57.1%) 29
Foreign travel 6 (3.3%) 176 (96.7%) 17
aThis is a composite variable recoded from two different water supply exposure variables in CIDR
Figure 3: Crude incidence rate VTEC O157, non-O157, and 
VTEC-associated HUS by HSE-area, Ireland 2010
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For the 19 cases where food was suspected as the 
cause of illness, burgers and other minced beef 
products were listed as suspected for seven cases, 
sausages were listed for three cases, and other meat 
products and foods for five cases. Where tested, 
no foods were found positive for the VTEC strains 
implicated in the human cases, although one raw 
sausage product tested was found positive for an 
unrelated VTEC O8 strain.
Outbreak and environmental investigations
Forty-five VTEC outbreaks were notified in 2010, 
which included 103 of the 199 VTEC notifications. The 
majority of outbreaks (96%) were family outbreaks 
with only two general outbreaks notified. Both general 
outbreaks involved private households and childcare 
arrangements/creche facilities: five persons in total 
were reported ill between these two outbreaks. One 
general outbreak was reported as being due to person-
to-person spread while the transmission route for the 
second general outbreak was reported as unknown.
Twenty-four outbreaks (53%) were caused by VTEC 
O157, sixteen (36%) by VTEC O26, four (9%) by other 
non-O157 and one (2%) was caused by a mixture of 
VTEC strains. The suspected modes of transmission 
reported are listed in table 5. 
Person-to-person spread is an important mode of VTEC 
transmission particularly between young children, and 
was suspected to have played a role in 30 (67%) VTEC 
outbreaks in 2010 in which 65 persons were reported ill. 
Unusually, the second most common transmission 
route reported for VTEC outbreaks in 2010 was animal 
contact, which was reported to have contributed to four 
outbreaks (9%). 
Unlike previous years, when exposure to private well 
water was a commonly reported transmission route 
(Figure 4) , there was only one VTEC outbreak reported 
as waterborne in 2010 (Figure 4). This family outbreak 
was reported associated with an untreated private well. 
No VTEC organisms were identified in the suspected 
water supply.
Separately, a family outbreak of two VTEC cases 
was reported to the United Kingdoms’ outbreak 
reporting system comprising two UK residents who had 
returned home following a visit to Ireland. Follow-up 
investigation by the HSE-E showed the outbreak also to 
be waterborne.  A private well water sample taken from 
a premises at which they had stayed was found positive 
at the DML-PHL for a VTEC strain indistinguishable from 
one of their infections. 
Unlike previous years, no foodborne VTEC outbreaks 
were reported in 2010 (Figure 4). But for over one 
quarter (n=12) of VTEC outbreaks, the transmission 
route was reported as unknown.
In 2010, one sporadic VTEC case was reported in a 
laboratory worker who had exposure to VTEC during 
the course of their work. 
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Figure 4. Number of VTEC outbreaks by suspected 
transmission route and year, Ireland 2004-2010
Note: In this figure, reported transmission routes were grouped 
for simplicity. Any outbreak where food was suspected to have 
contributed was reported as foodborne, any outbreak where water 
was suspected to have contributed was reported as waterborne, any 
outbreak where animal contact was suspected to have contributed 
was reported as Animal contact. Person-to-person outbreaks include 
only those outbreaks reported as being due only to person-to-person 
transmission.
Table 5. VTEC outbreaks in Ireland 2010 by suspected mode 
of transmission
Suspected mode of 
transmission
Number 
of 
outbreaks
Number 
ill 
Number 
confirmed 
cases
Animal contact 2 3 4
Person-to-person & 
animal contact 2 3 4
Person-to-person 27 60 58
Person-to-person & 
airborne 1 2 2
Waterborne 1 1 2
Unknown/Not specified 12 30 33
Total 45 99 103
Hepatitis A virus causes an acute, usually self-limiting 
disease of the liver. It is primarily transmitted from 
person to person via the faecal-oral route and is 
associated with poor hygiene and sanitation. Common 
source outbreaks due to contaminated food or water 
also occur.
The incidence of hepatitis A in Ireland has been low in 
recent years and remained low in 2010, with 46 cases 
notified. This corresponds to a crude notification rate 
of 1.1/100,000 population and is similar to 2009 when 
50 cases were notified (figure 1). Case classification 
was reported for all cases. Forty cases were laboratory 
confirmed, three cases were classified as probable and 
three as possible.
Fifty two percent of cases were male (n=24) and 48% 
were female (n=22). All age groups were affected but 
the highest notification rates were in children, teenagers 
and young adults (figure 2). 
Fourteen cases were linked to travel outside of Ireland 
3.4 Hepatitis A
Summary
Number of cases, 2010: 46
Crude notification rate, 2010: 1.1/100,000
Number of cases, 2009: 50
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Figure 1. Number of hepatitis A notifications, 1995-2010
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis A, 2010
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and a further four cases had a history of recent travel 
outside of Ireland but could also have been infected in 
Ireland. Twenty two cases were infected in Ireland, but 
ten of these were contacts of an index case infected 
outside of Ireland. Country of infection was not known 
for the remaining six cases.
Three hepatitis A outbreaks were reported in 2010 and 
one case notified in 2010 was associated with a 2009 
outbreak. The 2009 outbreak involved 18 people and 
was associated with an index case who had travelled 
to India. The largest of the 2010 outbreaks was in the 
HSE-S and involved 7 adults and 4 children. The index 
case was a child adopted from an endemic country and 
most of the other cases were family or extended-family 
members. The other two outbreaks were in the HSE-E. 
One involved two children and one adult and the other 
involved two young adults. All were infected in Ireland.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 13th October 
2011. These figures may differ from those published 
previously due to ongoing updating of notification data 
on CIDR.
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Rotavirus is the commonest cause of paediatric 
gastrointestinal infection and causes sporadic, seasonal 
and occasionally severe gastroenteritis of infants and 
young children, characterised by vomiting, fever and 
watery diarrhoea. Transmission is usually person-to-
person, mainly via the faecal-oral route. Children 
less than two years of age are most susceptible to 
infection, although cases are often seen in elderly and 
immunocompromised adults, particularly in institutional 
settings. By the age of six years old, virtually all 
children will have had at least one episode of rotavirus 
infection. Symptoms usually last for only a few days but 
in severe cases hospitalisation may be required due to 
dehydration. In developed countries, mortality due to 
rotavirus is low; however, the morbidity and economic 
costs associated with infection are significant. Three 
primary serogroups of rotaviruses infect humans; A, B 
and C; A being the commonest infecting serogroup. 
Given the universal distribution of rotavirus, the 
numbers of notifications will always represent an 
underestimate of the true incidence and are likely to 
be more reflective of habits of presentation to medical 
practitioners and of styles of investigation, notification 
and testing.
Since 2004, rotavirus, although not specifically listed, 
has been a notifiable disease in Ireland under the Acute 
Infectious Gastroenteritis (AIG) disease category. Prior 
to 2004, rotavirus caress were notified in the former 
notification category of “Gastroenteritis in children 
under two years”. In April 2008 the case definition 
of AIG was amended specifying definitions for both 
rotavirus and the newly notifiable Clostridium difficile 
associated disease. On 4th May 2008 these amended 
definitions formally replaced the previous AIG case 
classification. 
3.5 Rotavirus
Summary
Number of cases: 2,501
Crude incidence rate: 59.0/100,000
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Figure 1. Rotavirus crude incidence rate by HSE area and year, 2004-2010 (CIDR).
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Rotavirus case definition:
A case of rotavirus infection is a patient with acute onset 
of vomiting followed by watery diarrhea with fever, 
which typically lasts between three and eight days, AND 
one of the following laboratory criteria for diagnosis:
• Detection of rotavirus by antigen assay
• Detection of rotavirus-specific RNA
• Detection of rotavirus by electron microscopy 
• Isolation of rotavirus
During 2010, there were 4,288 cases of AIG notified in 
Ireland, corresponding to a national crude incidence 
rate (CIR) of 101.2 per 100,000 population and 
representing a decrease of 1.5% compared to 2009. 
Of the 4,288 AIG notifications, 2,501 (58.3%) were 
rotavirus. This corresponds to a national CIR of 59.0 per 
100,000 population and represents an increase of 5.9% 
compared to 2009.  
Significant geographical variation was observed in 
regional rotavirus CIR. The highest regional CIR was 
observed in HSE-M at 136.7 per 100,000 population and 
in HSE-NW at 100.0 per 100,000 population. The lowest 
regional CIR was observed in HSE-E at 26.9 per 100,000 
and HSE-MW at 30.2 per 100,000 population. 
Rotavirus infection has a well documented seasonal 
pattern in Ireland with the number of cases peaking 
each year in early spring. During 2010, this pattern 
was evident with rotavirus notifications peaking during 
March (n=698) and April (n=643). Figure 2* illustrates 
the seasonal variation in rotavirus cases by month of 
notification from 2004 to 2010. 
Rotavirus is the most common cause of acute 
gastroenteritis in children worldwide with children 
generally affected in the first 2-3 years of life. In 2010, 
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Figure 2. Number of rotavirus notifications by month, 2004-2010 (CIDR).
Figure 3. Number of cases of rotavirus in children less than two years of age by year, 2001 to 2010
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*There is a ‘false’ second peak seen in 2005 during week 33, 2005 caused by bulk uploading of notifications for the HSE-W
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72.7% (n=1,817) of cases were aged two years or under. 
Data from 2004 to 2010 show that the peak incidence 
of clinical disease occurred in the 6-18 month age 
group, with 59.1% of notifications in this age group. 
Figure 3 presents the number of cases of rotavirus in 
children less than two years of age by year, 2001 to 
2010.
During 2010, 1,191 cases (47.6%) were female and 
1,306 (52.2%) were male. Sex was not reported for four 
(0.2%) cases.  This represented a ratio of females: males 
of 0.9:1.1, which was similar to the ratio observed in 
previous years.
There were seven outbreaks of rotavirus notified during 
2010 with 59 cases of associated illness and six cases 
were hospitalised. One outbreak was reported as a 
rotavirus and norovirus co-infection. Of the seven 
outbreaks, five were family outbreaks occurring in 
private homes or across extended families while 
two general outbreaks occurred in a crèche and in a 
restaurant/cafe. Mode of transmission was reported as 
person to person spread for all outbreaks. During 2010, 
43% of all rotavirus outbreaks occurred during March, 
coinciding with the peak in rotavirus notifications. The 
largest outbreaks with the highest numbers ill occurred 
during April, also coinciding with high levels of rotavirus 
activity. Table 1 summarises the number of rotavirus 
outbreaks by location and month during 2010.
Table 1: Summary of rotavirus outbreaks by location and month, 2010 
Month Location Number of 
outbreaks
Number ill Number 
hospitalised
Number dead
February Crèche 1 9 2 0
March Private house 3 6 2 0
April Restaurant / Cafe 1 35 2 0
May Private house 1 2 0 0
June Extended family 1 7 0 0
Total 7 59 6 0
Salmonellosis typically presents clinically as an acute 
enterocolitis, with sudden onset of, abdominal pain, 
diarrhoea, nausea, headache and occasionally vomiting. 
Fever is almost always present. Dehydration, especially 
amongst vulnerable populations such as infants, the 
immunocompromised and the elderly, may be severe. 
Invasive infection occurs in a proportion of cases. 
S. Typhi and S. Paratyphi can cause enteric fever, a 
severe systemic life threatening condition, but this is 
not common in Ireland and is almost invariably travel-
associated.
Notification data (CIDR)
There were 356 cases of salmonellosis in reported in 
2010. Of these, 349 were laboratory confirmed with 
an additional seven probable cases that were not 
laboratory confirmed. The national crude incidence 
rate (CIR) for salmonellosis in 2010 was 8.4 per 100,000 
population which was a slight increase compared 
to 2009 (7.9/100,000) as shown in figure 1. Figure 2 
illustrates the regional variation in CIR during 2010. 
The highest CIR occurred in HSE-M (18.3/100,000), 
representing an increase of 9.5 per 100,000 population 
compared to 2009. This was the only region to 
experience a significant increase in the regional CIR 
during 2010.  The lowest CIR occurred in HSE-S 
(6.4/100,000), which remains stable compared to 5.6 per 
100,000 population during 2009. The largest decrease 
in regional CIR during 2010 was observed in HSE-NW, 
with a decrease of 3.4 per 100,000 population. 
The female:male ratio for 2010 was 0.96:1.05. In 
terms of age distribution, 21.1% of cases occurred in 
children under five. This is likely to be, at least in part, 
a reflection of clinicians more readily seeking clinical 
samples in that age group. This is also reflected in the 
age specific incidence rate (ASIR) with the 0-4 age 
group having the highest ASIR nationally (22.3/100,000 
in females and 27.2/100,000 in males) in both sexes 
(figure 3). 
The seasonality of salmonellosis notifications in Ireland 
during 2010 is shown in figure 4, with the highest 
number of notifications occurring between May and 
October. A peak in indigenous notifications was 
observed during May due to an outbreak of S. Infantis 
3.6 Salmonella 
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while the peaks observed during August to October 
were largely due to travel associated salmonellosis 
notifications. These are anticipated seasonal increases 
that correlate with peak holiday periods and resultant 
increase of people travelling abroad. 
Of the 356 cases notified on CIDR during 2010, travel 
history was provided for 277 cases (77.8%). Of the 277 
cases where travel history was reported, 149 (53.8%) of 
salmonellosis cases were indigenous to Ireland and 128 
cases (46.2%) reported a recent history of travel. Where 
travel history was documented, the three countries with 
highest occurrence of recent travel and subsequent 
development of salmonellosis were; Spain (n=23), 
Thailand (n=13) and Turkey (n=8). When serotyping 
data are analysed by travel history, 30.5% of all travel 
associated cases are S. Enteritidis whereas 45.6% of 
cases indigenous to Ireland are S. Typhimurium (table 
1). 
NSSLRL data:
The National Salmonella, Shigella and Listeria 
Reference Laboratory (NSSLRL) based in Galway has 
been providing reference services nationally since 2000. 
In 2010, the NSSLRL analysed 363 human Salmonella 
isolates referred for further typing, identifying 62 
serotypes. Table 2 presents the most dominant 
serotypes detected during 2010.  S. Typhimurium* 
(n=132) was the most common serotype, followed by S. 
Enteritidis (n=70). 
The NSSLRL conducted phage typing analysis on all 
132 S. Typhimurium and all 70 S. Enteritidis isolates. 
Phage types DT8 (21.2%), DT104 (19.7%), DT193 
(13.6%), Untypable (11.4%) and DT104b (10.6%) were 
the commonest phage types observed among S. 
Typhimurium isolates while phage types PT14b (24.3%), 
PT1 (20.0%) and PT4 (12.9%) were the dominant types 
observed among S. Enteritidis isolates.
Figure 2. Salmonellosis notifications and crude incidence rate per 100,000 population by 
HSE area, 2010 (CIDR)
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Figure 3. Salmonellosis notifications and age specific incidence rate per 100,000 
population by age group (years) and sex, 2010 (CIDR)
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Of the 363 human isolates analysed by the NSSLRL, 
189 (52.1%) were fully susceptible to all antimicrobials 
tested. The remaining 174 isolates exhibited some 
degree of antimicrobial resistance. The three 
commonest resistance patterns§ seen were isolated 
resistance to nalidixic acid (Na, n=38, 10.5%), resistance 
to ampicillin, streptomycin, sulphadiazine and 
tetracycline (ASSuT, n=27, 7.4%) followed by ampicillin, 
chloramphenicol, streptomycin, sulphadiazine and 
tetracycline (ACSSuT, n=26, 7.2%). Over 96% of human 
isolates with a resistance profile of ACSSuT or ASSuT 
were S. Typhimurium while 73.7% of human isolates 
with a resistance profile of Na were S. Enteritidis. One 
isolate each of S. Concord and S. Worthington were 
resistant to nine antibiotics tested; three S. Concord 
and one isolate each of S. Infantis, S. Newport and S. 
Unnamed were resistant to eight antibiotics tested 
while four S. Typhimurium, and one isolate each of S. 
Enteritidis, S. Infantis and S. Kentucky were resistant to 
seven antibiotics tested. Please refer to the NSSLRL’s 
Annual Report 2010 for more detailed analysis of 
results1 . The pattern of antimicrobial resistance 
observed is broadly similar to previous years.   To date 
carbapenemase production in salmonella has not been 
detected in Ireland.
Outbreaks:
There were 16 outbreaks of Salmonella during 2010 
which remains stable compared to the number of 
salmonellosis outbreaks reported in 2009. These 
outbreaks resulted in 87 cases of illness, one death 
and an associated hospitalisation rate of 41.4% (n=36 
cases). Table 3 outlines the number of salmonellosis 
outbreaks and number ill by outbreak location and 
outbreak transmission mode during 2010.
There were 11 family outbreaks during 2010, six of 
which were in private houses, three occurred across 
extended families and two were travel associated. 
Of the two travel associated family outbreaks, one 
reported exposure in Spain and the other reported 
exposure in the Bahamas. Four family outbreaks were 
reported as food-borne transmission, four as person 
to person transmission and two as animal contact. 
Transmission was unknown for the remaining outbreak. 
Of the four food-borne outbreaks, suspected food 
items reported included raw milk2, imported eggs and 
a catered meal. Of the outbreaks linked with animal 
contact, both reported reptile contact. 
There were five general outbreaks during 2010, two of 
which were national outbreaks in community locations, 
one was a national travel related outbreak and the 
remaining two were local outbreaks occurring in a 
private house and a community location. 
Figure 4. Salmonellosis notifications by month of notification and travel history, 2010 (CIDR)
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Table 1. Percentage of Salmonellosis notifications by serotype and travel history, 2010 (CIDR)
Salmonella serotype Travel associated Indigenous Travel history 
unknown
Total
S. Enteritidis (%) 30.5 8.1 19.0 18.5
S. Typhimurium (%) 11.7 45.6 40.5 32.3
Other serotypes (%) 57.0 43.0 39.2 47.2
Serotype not specified (%) 0.8 3.4 1.3 2.0
All serotypes (n) 128 149 79 356
All serotypes (%) 36.0 41.9 22.2 100.0
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*  This includes 19 S. Typhimurium isolates with serotype 4,5,12:1
§ Where A= Ampicillin, C= Chloramphenicol, Na = Naladixic acid, S= Streptomycin, Su= Sulphonamide and T= Tetracycline
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One national general outbreak of S. Typhimurium 
DT8 was reported which was associated with duck 
egg exposure. Thirty-five people were reported ill in 
total, 18 (51%) of which were reported to have been 
admitted to hospital for their illness and one case died. 
Salmonellosis was not considered to be the cause of 
death in this case. The cases were dispersed across 
seven of the eight HSE-areas, with onset dates ranging 
from mid August 2009 to the end of February 2011. 
Descriptive and microbiological evidence pointed 
towards duck eggs as being the most likely source 
of these infections. Exposure to duck eggs explained 
72% of cases. Trace-back investigations identified S. 
Typhimurium from several egg-laying duck flocks which 
were indistinguishable or closely related on molecular 
typing to the strains producing human illness. Press 
releases were issued to the public, and point of sale 
notices were distributed to duck egg retailers, advising 
consumers to handle and cook duck eggs appropriately. 
A series of control measures were also taken by the 
Department of Agriculture including restriction of 
infected duck flocks, development of a code of practice 
for duck egg producers, and introduction of legislation 
(S.I. No. 565 of 2010), the ‘Diseases of Animals Act 
1966 (Control of Salmonella in Ducks) Order 2010’. This 
Order now sets down a legal basis for the control of 
salmonellosis in ducks and duck eggs.3,4
One national general outbreak of S. Java, consisting 
of four associated cases during a two week period, 
was detected by NSSLRL during 2010. No history of 
recent travel was reported by the cases and the route of 
transmission remains unknown for this outbreak.
One national general outbreak was caused by   
S. Typhimurium and resulted in four cases of illness, two 
of whom were hospitalised. All cases reported a history 
of recent travel to Spain. 
One local general outbreak in HSE-NE was caused by 
S. Montevideo with five confirmed cases, two of whom 
were hospitalised and two of whom died. The cause of 
death was not salmonellosis in one case and the cause 
of death for the other deceased case was not known. 
Mode of transmission was reported as unknown for this 
outbreak. 
Table 3. Number of salmonellosis outbreaks and number ill by outbreak location and outbreak transmission mode, 2010 (CIDR)
Animal contact Food-borne** Person-to-person †† Unknown Total
Location
No. 
outbreaks
No. 
ill
No. 
outbreaks
No. 
ill
No. 
outbreaks
No. 
ill
No. 
outbreaks
No. 
ill
No. 
outbreaks
No. ill
Community out-
break
0 0 1 33 0 0 2 7 3 40
Extended family 0 0 2 8 1 2 0 0 3 10
Private house 2 4 2 17 3 8 0 0 7 29
Travel related 0 0 1 2 0 0 2 6 3 8
Total 2 4 6 60 4 10 4 13 16 87
Table 2. Number and percentage of human Salmonella isolates 
by serotype, NSSLRL 2010 
Salmonella serotype Number of isolates % Isolates
Typhimurium† 132 36.4
Enteritidis 70 19.3
Infantis 17 4.7
Unnamed‡ 10 2.8
Newport 8 2.2
Typhi 8 2.2
Braenderup 7 1.9
Dublin 7 1.9
Java 7 1.9
Montevideo 7 1.9
Saintpaul 7 1.9
Other 83 22.9
Total 363 100.0
† This includes 19 (14.4%) S. Typhimurium isolates with serotype 4,5,12:1
‡   Unamed is not a serotype.  The term refers to a very diverse group of isolates where the complete antigenic formula cannot be determined 
and which therefore can not be formally designated as belonging to any specific serovar
**  Includes 1 outbreak reported as Person to Person and Foodborne
††  Includes 1 outbreak reported as Person to Person and Animal contact
One local general outbreak in HSE-M was caused by S. 
Infantis and resulted in 15 cases of illness, two of whom 
were hospitalised. This outbreak was reported as food-
borne transmission associated with a catered party in a 
private house.
Typhoid/Paratyphoid:
The number of S. Typhi and S. Paratyphi cases 
diagnosed in Ireland remains elevated when compared 
to previous years. In 2010 there were eight cases of S. 
Typhi reported and five cases of S. Paratyphi. Four of 
the S. Typhi had known recent travel history to India, 
two to Bangladesh and one each to Nepal and Guinea. 
In the five S. Paratyphi cases one had known recent 
travel history to Bangladesh, one to Pakistan and one 
to the US. One further case reported travel in Asia. 
The remaining paratyphoid case’s travel history was 
unknown.
References: 
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Listeriosis 
Ten cases of human listeriosis were notified in 2010, 
the same number as in 2009. This equates to a crude 
incidence rate of 0.24 (95% CI 0.09-0.38) per 100,000, 
below the EU average of 0.36 per 100,000 in 2009.  
Among these, there were three pregnancy-related and 
one neonatal case reported. This is an increase on the 
number of pregnancy-associated cases reported relative 
to 2009 (Figure 1). 
There were also six adult cases. Five were female and 
one male, and ages ranged from 42 to 81 years of age. 
Three cases were reported as elderly (>65 years); and all 
six were reported as suffering from an underlying illness 
that predisposed them to listeriosis. 
There were no reported deaths due to listeriosis this 
year. 
Since 2007, the National Salmonella Reference 
Laboratory (now the National Salmonella, Shigella and 
Listeria Reference Laboratory) in Galway has offered a 
national service for typing of Listeria strains. Between 
2007 and 2009, isolates for 77% of the notified listeriosis 
cases were referred. In 2010, isolates from only four of 
the ten notified cases were referred. The serotypes for 
these four cases are listed in table 1 below. 
Listeriosis in Ireland remains a hazard for the elderly, 
persons with underlying illness, and other vulnerable 
groups such as pregnant women and neonates.
3.7  Less common gastroenteric 
 infections
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Table 1. Listeriosis Notifications by Case Type and Serotype, Ireland 2010 -typing data provided courtesy of Prof Martin 
Cormican and staff at the NSSLRL
Type Serotype 1/2 Serotype 4b Not referred for sero-
typing
Total
Adult or juvenile 0 2 4 6
Pregnancy-related 1 0 2 3
Neonatal 1 0 0 1
Total 2 2 6 10
Figure 1. Number Listeriosis Notifications by Case Type, Ireland 2006-2010
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Giardiasis
In 2010, there were 57 cases of giardiasis notified, a 
slight decrease on the number notified in 2009 (n=61) 
and in 2008 (n=71). This equates to a crude incidence 
rate of 1.34 (95% CI 1.00-1.69) per 100,000. 
Cases ranged in age from 0-84 years (median age=31 
years) with only 12 paediatric cases reported. Similar 
numbers of males (n=26) and females (n=31) were 
affected. Hospitalization rates were low with four cases 
admitted out of 48 (8%) for which this information was 
available. 
The number of cases for which travel status was 
reported has increased markedly over the last five years 
from 11% of cases in 2006 to 53% of cases this year 
(Figure 2). Twenty-three cases (40%) were reported as 
being associated with foreign travel: the countries of 
infection reported were India (n=7), Ethiopia (n=5), 
Spain (n=3), and there was one case each reported 
associated with travel to Egypt, South Africa, Uganda, 
Bangladesh, Pakistan, Cuba, Haiti and Peru. Seven cases 
were reported as being acquired in Ireland, and for the 
remaining 27 cases, country of infection was unknown or 
not specified. 
In 2010, there was one small family outbreak with two 
persons ill reported associated with foreign travel. 
Giardiasis in Ireland appears to be largely an adult 
disease. And if the travel histories of those with known 
Country of infection are representative of all reported 
giardiasis cases in Ireland, then as many as three-
quarters may be related to foreign travel. Among these 
cases, Asia and Africa figure most prominently as travel 
destinations. 
Yersiniosis 
In 2010, there were three cases of yersiniosis, the 
same as in 2009 and 2008. All were adult males. Two 
cases were reported as Y. enterocolitica and one as 
Yersinia pseudotuberculosis. The reported incidence of 
yersiniosis in Ireland is low relative to the EU as a whole, 
and to Northern Europe in particular. 
Yersiniosis is commonly associated with consumption of 
pork products however, in Spring 2011, an outbreak was 
reported in Norway associated with salad leaves. 1
1 E MacDonald et al. 2011. Yersinia enterocolitica O:9 infections 
associated with bagged salad mix in Norway, February to April 2011. 
Eurosurveillance, Volume 16, Issue 19, 12 May 2011
Foodborne intoxications 
Notifications of foodborne intoxications in Ireland are 
uncommon. In 2010, there were no cases or outbreaks 
of Clostridium perfringens (type A) food-borne disease, 
staphylococcal food poisoning, Bacillus cereus food-
borne infection/intoxication or botulism notified. 
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Figure 2. Number Giardiasis Notifications by Travel Status, Ireland 2006-2010
Note: Travel status is inferred from Country of Infection variable on CIDR
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In the last decade, the number of cases of shigellosis in 
Ireland has been low in comparison to the number of 
cases notified in the early 1990s (Figure 1). Shigellosis, 
however, remains a common cause of gastrointestinal 
illness in developing countries, and many cases notified 
in Ireland are now identified as being travel-associated.  
While person-to-person spread is an important 
transmission route between children, risks also remain 
from food, with at least four general outbreaks having 
been reported in Scandinavia in 2009 associated with 
imported fresh produce.1-5  Transmission between men 
who had sex with men (MSM) has been reported in 
Canada.6
Sixty cases of shigellosis were notified in Ireland in 2010 
(CIR 1.42 per 100,000), all of which were laboratory 
confirmed. This compares to 70 cases in 2009 and 75 
in 2008 (Figure 1). Of 45 cases where hospitalisation 
status was recorded, 12 (27%) were reported as hospital 
in-patients.
Cases ranged in age from 8 months to 76 years 
(median age=32 years). Like 2009, more males (n=35) 
than females (n=25) were notified. This differs to the 
previous three years when there were more females 
than males reported each year. The increase in male 
cases was particularly notable in the 15-44 year age 
group (Figure 2).
Information on travel history is very valuable when 
3.8 Shigellosis
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Figure 1. Annual number of notifications shigellosis, Ireland 1991-2010
Table 1. Number of notifications shigellosis by species and country of infection, Ireland 2010
Ireland Africa Asia Other Not known/ not 
reported
Total
S. boydii 2 0 0 0 0 2
S. dysenteriae 0 0 0 0 0 0
S. flexneri 9 0 3 2 7 21
S. sonnei 9 4 8 4 7 32
Species not specified/not known 0 2 2 0 1 5
Total 20 (33%) 6 (10%) 13 (22%) 6 (10%) 15 (25%) 60
(Data source: CIDR)
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reviewing surveillance data for possible indigenous 
clusters, and data on country of infection in the national 
dataset is improving being available this year for 
75% of shigellosis notifications. 25 cases (42%) were 
reported associated with foreign travel (Table 1). The 
countries of infection reported were India (n=7), Spain 
(n=4), Egypt (n=3), with one case associated each with 
travel to Cameroon, Nigeria, Zambia, Bangladesh, 
Indonesia, Jordan, Kazakhstan, Nepal, Pakistan, 
Costa Rica and Haiti.  Twenty infections (33%) were 
reported as being acquired in Ireland, while no country 
of infection information was provided for 15 (25%) 
cases. Unsurprisingly, travel-associated cases were 
more common in summer and later in the year, while 
indigenous case numbers remained similar year round 
(Figure 3).
Shigella sonnei was the most common species reported 
(53%), followed by S. flexneri (35%). There were also 
two S. boydii (3%), and five confirmed cases (8%) 
for which the species was not reported. The species 
distribution of cases by country of infection is reported 
in Table 1. 
More detailed typing of Shigella isolates can provide 
useful information on the relatedness of strains 
which can be used by public health personnel to 
outrule/provide evidence for links between cases 
during investigations of case clusters. The National 
Salmonella, Shigella and Listeria Reference Laboratory 
(NSSLRL) in University College Hospital, Galway can 
provide laboratory services for speciation, serotyping, 
antimicrobial resistance profiling, and where 
appropriate, Pulsed Field Gel Electrophoresis (PFGE) of 
Shigella isolates.
In 2010, 40 human Shigella isolates were referred to the 
NSSLRL, two-thirds of the isolates from all confirmed 
cases. The species/serotype distribution of these 
isolates is reported in Table 2. 
There were three shigellosis outbreaks notified in 2010, 
details of which are provided in Table 3. 
Although foreign travel is a major risk factor for 
shigellosis among Irish residents, indigenous risks are 
likely to be through person-to-person spread (in some 
instances from persons who have contracted shigellosis 
Table 2. Species/serotypes of Shigella isolates referred to 
NSSLRL in 2010 (Data courtesy of Prof. Martin Cormican and 
staff at NSSLRL)
Strain Number of isolates
Shigella boydii 3
Shigella flexneri 1a 1
Shigella flexneri 1b 3
Shigella flexneri 1c 1
Shigella flexneri 2a 2
Shigella flexneri 3a 3
Shigella flexneri 3b 2
Shigella flexneri 4c 3
Shigella flexneri 6 3
Shigella sonnei 17
Shigella unidentifiable 1
(blank) 1
Total 40
[Data source: NSSLRL]
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Figure 2. Age-sex distribution shigellosis notifications, Ireland 2010 relative to 2006-2009
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abroad), and from food as demonstrated by the 
Scandinavian outbreaks associated with imported foods 
in recent years. 
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Table 3. Shigellosis outbreaks, Ireland 2010
Month HSE-area Transmission Route Location Type Number ill
Apr E Person-to-person Community General 6
Aug MW Waterborne Private house Family 3
Sep S Unknown Private house Family 4
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Note: For the purposes of this figure, shigellosis notifications 
were categorised as indigenous if the country of infection was 
reported on CIDR as Ireland, whereas notifications where a country 
of infection other than Ireland was reported were categorised as 
travel-associated.
Figure 3. Number shigellosis notifications by travel and 
quarter of notification, Ireland 2010
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Toxoplasmosis
During 2010, 37 cases of toxoplasmosis were notified 
compared to 37 in 2009 and 49 in 2008.  
One congenital case was reported. The remaining 36 
cases ranged in age from 15 years to 58 years (median, 
33 years).  As in previous years, female cases dominated 
(65%). The high number of cases reported among 
women of child-bearing age may reflect enhanced 
testing during pregnancy (Table 1). 
Q Fever
Nine cases of Q fever were notified during 2010, two of 
which were reported to have been hospitalized (22%). 
This is a decrease compared to 17 notifications in 2009 
and 13 notifications in 2008. 
Three cases occurred in males and six in females (Table 
2). The cases ranged in age from 19 to 75 years (median 
age, 44 years). All cases were classified as confirmed.
Seven cases were reported from HSE-S and two from 
HSE-MW. This distribution may reflect a regional 
difference in risk or variation in diagnostic policy/
practice in different parts of the country. 
The disease is commonly acquired through occupational 
exposure to infected sheep and other small ruminants, 
e.g. by farmers, veterinarians, and abattoir workers. 
Over the last number of years, the south of the 
Netherlands has been experiencing large community 
outbreaks of Q fever during the summer months. Some 
clusters have been linked with Q fever outbreaks on 
goat farms. 1
1. Schwimmer et al, B. 2009. Sustained intensive transmission of 
Q fever in the South of the Netherlands, 2009. http://www.
eurosurveillance.org/images/dynamic/EE/V14N19/art19210.pdf
4.1 Other Non-IID Zoonotic Diseases
-71-HPSC Annual Report 2010 4 Vectorborne and Zoonotic Diseases
Table 1. Toxoplasmosis notifications by age and sex, Ireland 
2010
Age group Male Female Total
<1 yr 1 0 1
1-4 yrs 0 0 0
5-14 yrs 0 0 0
15-24 yrs 3 3 6
25-44 yrs 6 19 25
45-64 yrs 3 2 5
65+ yrs 0 0 0
Total 13 24 37
Table 2. Q fever notifications by age and sex, Ireland 2010
Age group Male Female Total
<5 yr 0 0 0
5-14 yrs 0 0 0
15-24 yrs 0 1 1
25-44 yrs 0 4 4
45-64 yrs 2 0 2
65+ yrs 1 1 2
Total 3 6 9
Brucellosis
During 2010, two cases of brucellosis were notified 
compared to zero in 2009 and 3 notifications in 2008. 
Both cases were adult males. One was reported as 
chronic. 
The age and sex distribution for brucellosis in recent 
years in Ireland suggests that occupational exposure is 
likely to be the main transmission route for this disease. 
The case definition permits inclusion of acute and 
chronic cases. In previous years, many cases were 
reported as chronic cases with only small numbers of 
acute cases reported.  
Echinococcosis
In 2010, there was one notification of echinococcosis 
in an adult. This is the fourth case of echinococcosis 
notified in Ireland since the disease became notifiable 
in 2004; in 2008, two adult cases were notified, and in 
2009, one adult case was notified. 
Because of the long incubation period for this disease, it 
is possible that infection occurred many years ago. 
Trichinosis
No cases of trichinosis were notified in Ireland in 2010.
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Among EU Member States reporting malaria data to 
the European Centre for Disease Control, Ireland had 
the third highest incidence rate for imported malaria 
in 2008, third only to France and the United Kingdom.1  
Compared to the number of cases of malaria notified 
prior to 2006 (Figure 1), malaria notifications in Ireland 
in 2010 remained at elevated levels with 82 cases 
notified. Moreover, one Irish resident died as a result of 
their illness, a woman of African origin who was resident 
in Ireland for several years but who was exposed on a 
return visit to Africa.
The group most affected in Ireland continued to be 
African immigrants and their families who were exposed 
while returning to their countries of origin to visit family 
and friends. This almost certainly reflects the greater 
frequency with which this group travels to malarious 
areas, and reflects also Ireland’s increasing importance 
as a destination for those emigrating from English 
speaking West Africa. Seventy per cent of cases with a 
known reason for travel in 2010 cited ‘visiting family in 
country of origin’, with at least 83% of these being of 
African origin (Table 1). 
Unusually, the second most common reason for travel 
this year was being an ‘Irish citizen living abroad’ (10 
cases -15% of cases with known reason for travel). This 
compares with a total of 6 cases listing this as their 
reason for ‘travel’ over the previous four years. At least 
six of these ten cases had been living in an endemic 
country for one year or more. There were only two 
4.2 Malaria 
Summary
Number of cases, 2010: 82
Number of cases, 2009: 90
Crude incidence rate, 2010: 1.9/100,000
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Figure 1. Annual number of notifications malaria, Ireland 1991-2010
Table 1. Number of cases malaria by reason for travel and country of birth, Ireland 2010
Reason for travel
Country of birth
Nigeria Other Africa Asia Ireland Other Not specified Total
Visit family country origin 28 10 0 5 2 1 46
Irish Citizen Living Abroad 0 0 1 7 1 1 10
Holiday travel 0 1 0 1 0 0 2
Other 1 0 0 2 2 3 8
Not specified 2 0 0 0 0 14 16
Total 31 11 1 15 5 19 82
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cases associated with holiday travel in 2010, down from 
between five and thirteen annually reported in the 
period 2006-2009.
Other reasons for travel includes: business/professional 
travel (n=2), new entrants (n=2), aid/volunteer workers 
(n=3), and foreign visitors ill while in Ireland (n=1)
Nigeria remained the country most frequently visited 
-50% of cases (Table 2). Ghana was reported as 
the country of infection for eight cases (10%). The 
remaining cases reporting travel to other parts of Sub-
Saharan Africa or to Asia. And as in previous years, P. 
falciparum was responsible for the majority of malaria 
cases reported in Ireland in 2010 (Table 2), most likely 
because P. falciparum is the most common form of 
malaria acquired in Africa and the majority of Irish cases 
are acquired there. 
In recent years in Ireland, there has been concern 
about the reported number of paediatric malaria cases. 
In 2010, 11 paediatric malaria cases were notified 
compared to between 16 and 26 cases annually in the 
previous four years. Eight of these reported ‘visiting 
family in country of origin as their reason for travel, 
while one was a new entrant. 
The small decline in case numbers in 2010 (9% decrease 
compared to 2009) in particular among children is 
welcome, however, efforts should continue in the 
education of the travelling public about the steps 
that can be taken to minimise their risk of contracting 
malaria while overseas.
References
 European Centre for Disease Prevention and Control. Annual 
Epidemiological Report on Communicable Diseases in Europe 2010.
Stockholm: ECDC; 2010. ISBN 978-92-9193-222-1 http://www.ecdc.
europa.eu/en/publications/Publications/Forms/ECDC_DispForm.
aspx?ID=578 
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Table 2. Number of cases malaria by infecting species and country of infection, Ireland 2010.
Species
Country of infection
Nigeria Ghana
Other 
Africa
Asia
Not 
specified
Total
P. falciparum 34 7 13 3 10 67
P. falciparum/ P. vivax 2 0 0 0 0 2
P. ovale 2 1 1 0 2 6
P. vivax 0 0 0 1 1 2
P. malariae 0 0 0 0 0 0
Not Specified 3 0 1 0 1 5
Total 41 8 15 4 14 82
Seventeen cases of leptospirosis were notified in
Ireland in 2010, a 29% reduction compared to the 24 
cases notified in 2009 (Figure 1). This equates to a 
crude incidence rate of 0.40 per 100,000 (95% CI 0.21-
0.59). The last year for which data is available across 
the European Union is 2008. Among the 25 countries 
that reported on leptospirosis incidence at that time, 
Ireland reported the second highest incidence rate. The 
incidence in the EU as a whole was 0.15 per 100,000. 
The leptospirosis notification dataset is typically 
dominated by adult males, and this year is no exception 
(Table 1). Sixteen cases (94%) were male and the age 
range was 19-82 (mean age =41 years, median age=37 
years). This is consistent with the exposures most 
commonly associated with leptospirosis in temperate 
regions, e.g. occupational contact with farm animals and 
watersports.
Among the 16 cases for which hospital admission status 
was reported, 15 (94%) required hospitalization. No 
deaths were reported. 
Six cases (35%) were believed to have acquired 
their illness occupationally –all were either farmers 
or reported contact with farm environments. Five 
(29%) cases were reported as being associated with 
recreational activities: two with travel to a tropical 
destination, and one each with kayaking, diving and 
fishing. No risk factor information was available for the 
remaining six (35%) cases. 
While a number of regional hospital laboratories offer 
a diagnostic service for leptospirosis, annually around 
two thirds of cases are diagnosed by the National Virus 
Reference Laboratory. Positive specimens are generally 
referred to the UK Leptospirosis Reference Unit for 
confirmation and for typing where possible. Species 
information was available on CIDR for only two cases 
in 2010–one each Leptospira interrogans hardjo and 
Leptospira interrogans icterohaemorrhagiae.  Both were 
reported as occupationally acquired. Species was not 
reported for the remaining 15 cases. 
Activities that continue to be associated with 
leptospirosis risk in Ireland include farming and 
recreational activities such as water sports. In the last 
few years, travel to Asia and other tropical destinations 
has emerged as a risk factor for leptospirosis. In general 
the incidence of leptospirosis is much higher in tropical 
climates than in temperate areas like Ireland.
4.3 Leptospirosis           
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Figure 1. Annual number of leptospirosis notifications, Ireland 1991-2010
(data source: CIDR)
Table 1. Leptopirosis notifications by age and sex, Ireland 2010
Age group Male Female Total
<5 yr 0 0 0
5-14 yrs 0 0 0
15-24 yrs 5 0 5
25-44 yrs 4 1 5
45-64 yrs 5 0 5
65+ yrs 2 0 2
Total 16 1 17
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Summary
Number of cases, 2010: 17
Number of cases, 2009: 24
Crude incidence rate, 2010: 0.4/100,000
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Blood-borne and 
Sexually Transmitted Infections
Hepatitis B is a vaccine preventable disease caused 
by the hepatitis B virus. It is transmitted through 
percutaneous or mucocutaneous contact with the blood 
or body fluids of an infected person. Over 90% of 
people infected in late childhood and adulthood clear 
the virus within a year of infection, but there is a high 
probability of developing chronic infection if hepatitis 
B is acquired in infancy (approx. 90%) or when aged 
under five years (approx. 30%).1 Between 15 and 40% 
of people with chronic infection ultimately develop 
cirrhosis, liver failure or hepatocellular carcinoma (liver 
cancer).2
The prevalence of hepatitis B in the general population 
in Ireland is low (less than 1%) and most cases fall 
into defined risk groups such as people with multiple 
sexual partners, household or sexual contacts of known 
cases, injecting drug users and people who were born 
in countries with intermediate (2-7%) or high ( >8%) 
hepatitis B endemicity.
The number of hepatitis B cases reported in 
Ireland decreased by 20% in 2010, with 645 cases 
(15.2/100,000 population) notified compared to 
803 in 2009 (figure 1). Sixty four percent (n=412) of 
notifications were from the HSE-E, corresponding to a 
notification rate of 27.5/100,000 population.
All cases were laboratory confirmed and 93% contained 
information on acute/chronic status. Where status was 
known, 8% of cases were acute (n=49) and 92% were 
chronic (n=554).
Acute cases (recent infections)
Of the 49 acute cases notified in 2010, 90% (n=44) 
were male and 10% (n=5) were female. The highest 
notification rates were in young to middle aged adults, 
and 71% (n=35) of acute cases were aged between 
20 and 44 years when notified (figure 2). Female cases 
were younger than males overall, with a median age of 
27 years compared to 36.5 years for males.
5.1 Hepatitis B
Summary
Number of cases, 2010: 645
Crude notification rate, 2010: 15.2/100,000 
Number of cases, 2009: 803
HPSC Annual Report 2008  
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Figure 1. Number of hepatitis B notifications by acute/chronic status, 1996-2010
Information on risk factor was available for 84% (n=41) 
of acute cases. Of these, 66% (n=27) were likely to have 
been sexually acquired. Fourteen were men who have 
sex with men, eleven were heterosexual and sexual 
orientation was not known for two cases. No risk factors 
were identified for twelve cases (29%) despite follow up 
being carried out.
Country of birth was known for 92% (n=45) of acute 
cases.  Seventy three percent (n=33) were born in 
Ireland and 16% (n=7) were born in Eastern or Central 
European countries. Where country of infection was 
known, 80% (n=24) of acute cases were infected in 
Ireland. Information on reason for testing was available 
for 47 acute cases. Most were identified because they 
were symptomatic (75%, n=35) or through STI screening 
(17%, n=8).
The number of acute cases of hepatitis B notified in 
Ireland is generally relatively low and decreased by 37% 
in 2010 (n=49) compared to 2009 (n=78). The decrease 
is mostly attributable to decreases in sexually acquired 
cases of acute hepatitis B in both men who have sex 
with men and heterosexuals. 
Chronic cases (long-term infections)
Of the 554 chronic cases notified in 2010, 50% (n=276) 
were male, 49% (n=272) were female and sex was not 
known for 1% (n=6). Eighty five percent (n=468) of 
chronic cases were aged between 20 and 44 years when 
notified (figure 2). The median age at notification for 
female cases was 28 years and the median age for males 
was 33 years. 
Some data on risk factor, country of birth or asylum 
seeker status were available for 47% (n=261) of the 
chronic cases notified in 2010. Of these, 66% (n=172) 
were born in hepatitis B endemic countries or were 
identified as asylum seekers. Data on country of birth 
was available for 42% (n=233). The most common 
regions of birth were Eastern or Central Europe (31%, 
n=73), Sub-Saharan Africa (30%, n=69) and Asia (29%, 
n=67). Other risk factors included sexual acquisition 
(14%, n=37), vertical acquisition (5%, n=13), household 
contact with a known case (4%, n=10) and being a 
resident of an intellectual disability institution (3%, n=8).
Reason for testing was known for 64% (n=357) of 
chronic cases. Thirty six percent (n=130) were identified 
through antenatal screening programmes, 15% (n=54) 
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Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis B by acute/chronic status, 2010
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were identified through asylum seeker screening 
programmes, 10% (n=36) were tested in STI settings, 
9% (n=32) were cases that were previously diagnosed 
but not notified and 9% (n=31) were diagnosed as a 
result of routine health screens.
The dramatic increases in hepatitis B notifications 
between 1998 and 2008 were mostly attributable to 
large numbers of people immigrating to Ireland from 
hepatitis B endemic countries. Between 2000 and 2010, 
95% of asylum applicants, and 73% of new work permit 
recipients, were from countries with intermediate or 
high hepatitis B endemicity. Immigration to Ireland 
has decreased in recent years and this is likely to have 
contributed to the 19% decrease in chronic hepatitis B 
notifications in 2010. (Data on work permits and asylum 
applications received via personal communications from 
Department of Enterprise, Trade and Innovation and the 
Office of the Refugee Applications Commissioner).
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 13th October 2011. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
References
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Hepatitis C is a major cause of liver disease worldwide. 
The hepatitis C virus is primarily transmitted through 
sharing contaminated equipment when injecting 
drugs or through receipt of unscreened blood or 
blood products. Sexual, occupational and perinatal 
transmission can also occur but are less common. 
Infection is initially asymptomatic in most cases, but 
approximately 75% of those infected fail to clear 
the virus and develop chronic infection. Between 5 
and 20% of chronically infected individuals develop 
cirrhosis of the liver after 20 years of infection. Of 
those with cirrhosis, 1.5 to 2.5% will go on to develop 
hepatocellular carcinoma (liver cancer) each year.1 
Effective treatment, which eradicates the virus in over 
50% of cases, is available for hepatitis C.2 
The overall prevalence of chronic hepatitis C in Ireland is 
comparable to other Northern European countries and is 
estimated to be between 0.5 and 1.2%. The prevalence 
in the general population is low and most cases fall into 
defined risk groups such as injecting drug users, people 
who received unscreened blood or blood products in the 
past and people who were born in hepatitis C endemic 
countries.3
The number of cases of hepatitis C reported in 2010 was 
very similar to 2009, with 1,239 notifications (29/100,000 
population) compared to 1,241 in 2009 (figure 1). There 
was a strong predominance of males:  67% (n=833) 
of cases were male, 32% (n=396) were female and 
sex was not known for 10 cases (figure 1). The highest 
notification rates were in young to middle aged adults. 
Seventy two percent (n=896) of cases were aged 
between 25 and 44 years (figure 2). The median age for 
females was younger (33 years) than that for males (36 
years). 
The geographic distribution of cases was skewed, 
with the HSE-E reporting 76% of all cases notified in 
2010. The highest notification rates were in the HSE-E 
5.2 Hepatitis C
Summary
Number of cases, 2010: 1,239
Crude notification rate, 2010: 29/100,000
Number of cases, 2009: 1,241
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Figure 1. Number of hepatitis C notifications, 2004-2010
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(63/100,000 population, n=940) and the HSE-M 
(28/100,000 population, n=71) (figure 3).
Data on most likely risk factor were available for 59% of 
cases (n=728). The most common risk factors reported 
were injecting drug use (76%, n=550), being an asylum 
seeker/born in an endemic country (9%, n=63), sexual 
exposure (5%, n=38) and receipt of blood or blood 
products (3%, n=19).
Of the nineteen cases acquired through blood or blood 
products, seven were infected in Ireland, five were 
infected outside Ireland and country of infection was 
not known for seven. All cases acquired in Ireland were 
infected many years in the past, but were notified for 
the first time in 2010. 
The number of cases of hepatitis C notified in 2010 
remained high and, where risk factor data were 
available, injecting drug use was the predominant mode 
of transmission. Although information on risk factor was 
not available for 41% of cases, the age and sex profile 
of these cases did not differ significantly from those for 
whom information was available.
Data on country of birth and country of infection were 
too incomplete to allow for reporting. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 13th October 2011. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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Figure 3. Notification rates/100,000 population for hepatitis C by HSE area, 2007-2010
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis C, 2010
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A total of 331 new HIV diagnoses (240 men and 89 
women) were reported to HSPC during 2010. This 
compares to 395 in 2009 and represents a 16.2% 
decrease. The rate of newly diagnosed HIV infection in 
Ireland in 2010 was 7.8 per 100,000 population (11.3 
per 100,000 men and 4.2 per 100,000 women).
Completed surveillance forms were received for 290 
(87.6%) of the newly diagnosed cases. 
There were 54 new AIDS diagnoses reported to HPSC 
during 2010. There were 10 deaths among AIDS cases 
reported during 2010. It is important to note that there 
is both under-reporting and late reporting of both AIDS 
cases and deaths among AIDS cases. 
Figure 1 shows the number of HIV cases diagnosed 
annually in Ireland from 2000 to 2010, in males and 
females.  
Figure 2 shows probable route of transmission for newly 
diagnosed cases among the three major risk groups; 
heterosexual contact, men who have sex with men 
(MSM) and injecting drug users (IDUs) between 1994 
and 2010. 
Men who have sex with men (MSM)
•  The highest proportion of new HIV diagnoses in 2010 
was among MSM (40.5%).
•  The number of new cases among MSM (134) is very 
similar to 2009 (138). Between 2005 and 2009, the 
annual number of new diagnoses in MSM have more 
than doubled from 60 to 138. 
•  The median age of new cases among MSM in 2010 
was 34.0 years (range 20-62 years).
•  67.9% (91) were born in Ireland, 11.2% (15) were 
born in Latin America, 6.7% (9) were born in Western 
Europe and 6.0% (8) were born in Central and Eastern 
Europe.  
•  Of the new cases among MSM at the time of HIV 
diagnosis, 100 were asymptomatic, 11 were diagnosed 
with AIDS and four had acute HIV infection. 
Heterosexual transmission
•  37.2% of new diagnoses were attributed to 
heterosexual transmission. 
•  The number of cases attributed to heterosexual 
transmission decreased from 160 in 2009 to 123 in 
2010. 
•  Since 2002 when the number of heterosexual cases 
peaked at 232, there has been a general trend 
downwards among this group. 
•  Of the 123 heterosexual cases in 2010, 52.0% (64) 
were from a country with a generalised HIV epidemic, 
5.3 HIV and AIDS
Summary
Number of HIV cases: 331
Crude HIV incidence rate: 7.8/100,000 population
Number of AIDS cases: 54
Number of deaths in AIDS cases: 10
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Figure 1. New HIV and AIDS diagnoses by year of diagnosis (1990 to 2010) 
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
N
um
be
r o
f c
as
es
 
Year of HIV diagnosis 
Females Males Total 
7.3% (9) had a sexual partner from a country with a 
generalised HIV epidemic and 4.0% (5) had a high risk 
sexual partner.  No further information was available 
for the remaining 45 cases. 
•  69 of the new heterosexual cases were female and 54 
were male.
•  The median age among heterosexual cases was 34.0 
years (range 18-62 years), 32.0 in females (range 18-
53) and 37.0 in males (range 22-62).
•  50.4% (36 female and 26 male) were born in sub-
Saharan Africa and 25.2% (13 female and 18 male) 
were born in Ireland. 
•  Of the new heterosexual cases at the time of HIV 
diagnosis, 83 were asymptomatic, 11 had AIDS and 
five had acute HIV infection. 
Injecting Drug Users (IDUs)
•  6.6% of new infections were among IDUs.
•  The annual number of new cases among IDUs has 
decreased every year since 2004 (72 cases).
•  18 of the new cases were male and four were female.
•  The median age among IDUs was 32.5 years (range 
19-50 years).
•  36.4% (8 cases) were born in Ireland and 36.4% (8 
cases) were born in Central and Eastern Europe. 
•  Of the new cases in IDUs at the time of HIV diagnosis, 
11 were asymptomatic, two had AIDS and two had 
acute HIV infection. 
Mother to Child Transmission (MTCT) 
•  There were nine new diagnoses of HIV infection in 
children (younger than 16 years). The probable route 
of transmission was mother to child transmission 
(MTCT) for eight of the nine cases and was unknown 
for one.  There were a further two cases among adults 
where the probable route of transmission was MTCT 
giving a total of 10 MTCT cases in 2010. Of the ten 
MTCT cases, six were born in sub-Saharan Africa, two 
in Central Europe and two in Ireland. The mothers of 
the two Irish born cases were from sub-Saharan Africa. 
•  In addition, there were 107 babies born to HIV 
positive mothers in Ireland during 2010. Based on 
serial HIV PCR testing; 73 are not infected, 34 remain 
of indeterminate status (i.e. do not meet the criteria 
for HIV infection and are <18 months at time of test) 
and none are infected.  
Discussion
HIV infection is of major public health importance with 
evidence of continuing transmission in Ireland and 
Europe. In 2010, a total of 331 individuals were newly 
diagnosed, corresponding to a crude rate of 7.8 per 
100,000 population. This compares to a rate of 6.7 in 
the WHO European West region. In addition, there were 
54 cases of AIDS and 10 deaths among AIDS cases also 
reported to the HPSC during 2010. 
The total number of HIV diagnoses in 2010 represents a 
16.2% decrease compared to 2009 and is largely due to 
fewer diagnoses among people infected heterosexually 
(from 160 in 2009 to 123 in 2010). Of the 123 new cases 
among heterosexuals, 64 were diagnosed in individuals 
originating from countries with generalised HIV 
epidemics compared to 94 cases in 2009. 
While the number of new diagnoses among people 
infected heterosexually has declined, new diagnoses 
among MSM remain high and sex between men is 
now the predominant mode of transmission in Ireland.  
Increasing number of HIV infections among MSM 
has been observed in many other Western European 
countries and sex between men is now the predominant 
mode of transmission in the EU/EEA (European Union/
European Economic Area). A recent report from ECDC 
recommended that interventions to control HIV among 
MSM should be the cornerstone of HIV prevention 
strategies in countries in Western Europe1. 
 
The number of cases among IDUs has declined in recent 
years and in 2010 represented less than 7% of the newly 
diagnosed cases. 
During 2010, 29 cases presented with an AIDS defining 
illness at the time of their HIV diagnosis. It has been 
estimated that 30% of individuals infected with HIV 
in Europe are unaware of their infection are at risk 
of severe complications and possibly death, as they 
cannot benefit from treatment.1 In order to decrease the 
number of late presenters, and to ensure early diagnosis 
and access to treatment and counselling for all, ECDC 
recommended in a recent report that HIV testing and 
counselling should be promoted.  In addition, they 
recommended equal access to HIV treatment and care 
for all population groups. 
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Figure 2. New HIV diagnoses in Ireland by probable route of transmission 
(1994 to 2010)
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Background
A HIV infected mother can transmit the virus to her 
baby during pregnancy, delivery, or breastfeeding.  It 
has been clearly shown that the risk of mother-to-child 
transmission (MTCT) of the virus can be dramatically 
reduced by treatment of the mother, management 
of the delivery and avoidance of breastfeeding.  The 
combined effect of these interventions is reported in 
some studies to reduce the transmission risk from 15-
30% to 2% or less.1, 2, 3 However, measures to prevent 
transmission of HIV from mother to child can only be 
offered if HIV infection is diagnosed prior to delivery.  
In April 1999, the Department of Health and Children 
(DoHC), on the advice of the National AIDS Strategy 
Committee (NASC), introduced a policy of voluntary 
antenatal HIV testing in Ireland.  As part of this 
programme, it is recommended that antenatal screening 
for HIV be offered routinely to all pregnant women. 
Antenatal HIV testing commenced in all health boards 
during 1999, with the exception of the North Western 
Health Board where it commenced in 2000. On a 
recommendation from NASC, as outlined in the AIDS 
Strategy 2000 report,4 a system for monitoring and 
evaluating the routine antenatal testing programme was 
established by the Health Protection Surveillance Centre 
(HPSC) in July 2001. The voluntary testing replaced an 
anonymous unlinked testing scheme. 
Methods
HPSC collect aggregate data on a quarterly basis from 
20 maternity hospitals. Forms are completed on paper 
or electronically, usually by a clinic midwife, and are 
then posted, faxed or emailed to HPSC. In the HSE-
5.4  Voluntary antenatal HIV testing in 
Ireland: 2009 & 2010
Key Points
	 19 of 20 maternity hospitals provided data on 
HIV antenatal screening for 2009 and 2010
	 Uptake of antenatal screening among the 
participating hospitals was 99.0% in 2009 and 
2010
	 The number of HIV positive cases diagnosed at 
antenatal screening was 140 in 2009 and 118 in 
2010. This is a decrease from a peak of 157 in 
2002. 
	 Between 2002 and 2010, 1,133 antenatal HIV 
screening tests were positive. Of the 1,133 
women identified as HIV positive, 446 were not 
previously known to be HIV positive and were 
first diagnosed at antenatal screening. 
	 The number of newly diagnosed HIV cases (i.e. 
not previously known) has decreased by 81% 
from 112 in 2002 to 21 in 2010.
Parameter 2002 2003 2004 2005 2006 2007 2008 2009 2010
Number of hospitals participating 20/22 21/22 20/22 21/22 19/21 19/20 18/20 19/20 19/20
Number of live births per year (from CSO) 60,503 61,529 61,972 61,372 65,425 71,389 75,065 74,728 na
Number of women booked 51,777 45,259 40,171 44,874 52,434 60,111 66,558 68,378 70,024
Number offered test 51,777 45,259 40,171 44,874 52,434 60,052 66,558 68,026 69,615
Number tested 48,922 43,815 39,049 44,292 51,649 59,522 66,210 67,694 69,292
Uptake of HIV antenatal test (%) 94.5 96.8 97.2 98.7 98.5 99.0 99.5 99.0 99.0
Number HIV positive 157 144 103 118 113 117 123 140 118
Number new HIV positive (not previously diagnosed) 112 93 39 43 34 38 34 32 21
HIV prevalence among pregnant women (%) 0.32 0.33 0.26 0.27 0.22 0.20 0.19 0.21 0.17
HIV prevalence - East (%) 0.43 0.43 0.51 0.46 0.33 0.31 0.25 0.34 0.23
HIV prevalence - non East (%) 0.20 0.24 0.13 0.12 0.09 0.09 0.14 0.10 0.12
Table 1. Results of the antenatal screening programme, 2002 to 2010
Northwest and HSE-Southeast, data are collated at 
regional level prior to sending on to HPSC. 
Results
Nineteen maternity hospitals (of twenty) were able to 
provide data on their antenatal screening program 
in 2009 and 2010. No data were available from Sligo 
General Hospital for 2009 or 2010. Some hospitals are 
unable to provide data for their private patients. Table 
1 describes the data collected from maternity hospitals 
between 2002 and 2010. 
Discussion
HIV antenatal screening is vital to identify pregnant 
women who are HIV positive and to ensure they can 
avail of appropriate treatment and care, to decrease the 
risk of mother to child transmission and to help prevent 
transmission of HIV to sexual partners of pregnant 
women. In 2009 and 2010, the uptake of antenatal 
screening among the participating hospitals was 99.0%. 
Between 2002 and 2010, 1,133 antenatal HIV screening 
tests were positive. Of the 1,133 women identified 
as HIV positive, 446 were not previously known to be 
HIV positive and were first diagnosed at antenatal 
screening. 
The number of cases newly diagnosed through 
antenatal screening decreased from 112 in 2002 to 
21 in 2010. Data from the national HIV case based 
reporting system shows that there were reports of 25 
new diagnoses in pregnant women in 2010.5 
The prevalence rate in 2010 (0.17%), is the lowest 
prevalence rate since the screening program began. 
Prevalence of HIV infection among pregnant women 
varies among different hospitals ranging from 0.00% 
to 0.36% in 2010. Throughout Europe, pockets of 
higher prevalence among pregnant women have been 
reported in major urban areas.6
Limitations of the current surveillance system
Data are incomplete as one hospital was unable to 
provide data and other hospitals were unable to 
provide data on private patients. In addition, it is not 
possible to validate the data provided and currently 
there is no standardised systematic way of collecting 
the data at local or regional level.
Some of the maternity hospitals have difficulty 
accurately completing and returning data, in particular 
data on the number of women booked, number offered 
HIV screening and the number who accept. Particularly 
in hospitals without a computerised information system, 
the process can be tedious and time consuming and 
some hospitals can only provide estimates or proxy 
measures (see technical notes).  
Differences between the number of women reported 
through the HIV case based reporting system and 
through the HIV antenatal surveillance system are not 
unexpected and highlight the fact that they are stand 
alone surveillance systems. 
Every year, a number of women refuse the antenatal 
HIV screening test. The current surveillance system does 
not capture information on the reasons for declining 
screening or on the profile of women who refuse 
screening. 
References:
1. European Collaborative Study. Mother-to-child transmission of 
HIV infection in the era of highly active antiretroviral therapy. CID 
2005: 40
2. Sharland M, Gibb DM, Tudor-Williams G. Advances in the 
prevention and treatment of paediatric HIV infection in the 
United Kingdom. Sex Transm Infect 2003; 79 (1)
3. Duong T, Ades AE, Gibb DM, Tookey PA, Masters J. Vertical 
transmission rates for HIV in the British Isles: estimates based on 
surveillance data. BMJ 1999; 319
4. Department of Health and Children. AIDS Strategy 2000, Report 
of the National AIDS Strategy Committee (NASC). 
5.  HIV & AIDS in Ireland 2010. HPSC. Available at  http://www.
hpsc.ie/hpsc/A-Z/HepatitisHIVAIDSandSTIs/HIVandAIDS/
SurveillanceReports/File,12651,en.pdf
6. Giraudon I, Forde J, Maguire H, Permalloo N. Antenatal 
screening and prevalence of infection: Surveillance in London, 
2000-2007. Eurosurveillance 2009; 14 (9)
Technical notes:
1. Uptake was calculated as the number of women tested divided 
by the number of women booked. 
2. Prevalence of HIV infection was calculated as the number of 
women testing positive divided by the number of women tested. 
3. For one hospital. the number of rubella screens was used as 
a proxy for the number of women booked for antenatal care 
and the number of women tested for Rubella and HIV are not 
exclusively antenatal patients.
4. For one hospital, estimates were provided for 2008 and 2009. 
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Clinicians and laboratories notify their respective 
Medical Officer of Health probable and confirmed 
cases of sexually transmitted infections (STIs). These 
notifications are then reported to HPSC on a quarterly 
basis. STI notification data should be interpreted with 
caution: quarterly and annual data are not reported 
in a complete or timely manner; data are reported in 
an aggregate format which makes detailed analysis 
of the epidemiological trends difficult. This report 
focuses on STIs notified to HPSC in 2009. Regarding 
notification data for ano-genital warts, it is important 
to note that additional efforts were made improve 
data completeness of the 2009 notification data. 
These data will be used as baseline data in assessing 
the effectiveness of the HPV vaccination programme 
introduced in 2010.
In 2009, 10,834 STIs were reported in Ireland, a 
decrease of 4.1% compared to 2008 when 11,294 
STIs were reported (table 1). Between 2008 and 2009, 
notifications of syphilis, herpes simplex, trichomoniasis 
and ano-genital warts increased, while there was a 
reduction in notifications of infectious hepatitis B, 
non-specific urethritis, C. trachomatis infection and 
gonorrhoea (table 1). Two infectious diseases accounted 
for almost three-quarters (74.5%) of all STI notifications 
in 2009: ano-genital warts and Chlamydia trachomatis.
Males accounted for 51.7% of all notifications and 
females for 47.1% (table 2).  The number of notifications 
was greater among men than women for non-specific 
urethritis (94.4%), gonorrhoea (78.6%), syphilis (71.0%) 
and hepatitis B (66.7%). However, trichomoniasis, herpes 
simplex and  C. trachomatis infection were reported 
more frequently among women than men (96.2%, 62.9% 
and 58.6% respectively).
Almost two-thirds (61.4%) of notifications were among 
those aged 20 to 29 years (table 2). This age group 
accounted for the majority of notifications for each 
STI, except syphilis and trichomoniasis. The proportion 
of notifications among those aged less than 20 years 
increased to 12.7% of all STI notifications compared 
5.5  Sexually Transmitted Infections  
 (STIs), 2009
Summary
Total number of STI notifications in 2009: 10,834
Three most common STIs reported in 2009:
1.  Chlamydia trachomatis infection: 5,781 cases 
(136.3/100,000)
2. Ano-genital warts: 2,283 cases (53.8/100,000)
3. Non-specific urethritis: 1,209 cases (28.5/100,000)
-86-HPSC Annual Report 2010 5 Blood-borne and Sexually Transmitted Infections
Table 1. Notifications of sexually transmitted infections in Ireland, 2000 -2009 
Sexually Transmitted Infection 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Ano-genital warts 3735 3993 3932 3981 4174 3456 3494 3283 2134 2283
Chancroid 16 1 1 0 1 0 1 1 0 0
Chlamydia trachomatis infection 1343 1649 1922 2258 2803 3353 3144 5023 6290 5781
Gonorrhoea 290 349 214 186 270 342 431 417 444 434
Granuloma inguinale 0 0 0 0 1 0 0 0 0 0
Herpes simplex (genital) 269 331 358 375 411 441 455 988 394 469
Infectious hepaitis B 15 39 57 112 85 80 20 25 14 9
Lymphogranuloma venereum 0 0 1 0 0 1 0 2 0 0
Non-specific urethritis 1726 1634 2025 2332 2746 2106 2161 1870 1636 1209
Syphilis 46 279 303 235 144 282 134 212 312 570
Trichomoniasis 78 64 73 59 60 83 52 94 70 79
Total 7518 8339 8886 9538 10695 10144 9892 11915 11294 10834
with 10.3% in 2008 and 10.0% in 2007. Most notably, 
the proportion of notifications of gonorrhoea among 
those less than 20 years old more than doubled to 
16.1% in 2009 (table 2) compared with 7.0% in 2008 and 
6.7% in 2007.
During 2009, the crude incidence rate (CIR) for all 
STI notifications was 255.5 per 100,000 population. 
The rates in the HSE East (389.9/100,000), South East 
(326.1/100,000) and North West (260.2/100,000) were 
all greater than the national rate (table 3). However, 
this is likely to be a reflection of the areas in which STIs 
services are located as well as differences in reporting 
practices by clinics, clinicians and laboratories from one 
area to another.
Summary Statistics on Selected STIs, 2009
Ano-genital warts
The small increase (+7.0%, table 1) in notifications of 
ano-genital warts in 2009 (53.8/100,000) is most likely 
attributable to the additional efforts made to identify 
cases.  However, since this is a clinical diagnosis and 
notifications are outstanding for two large STI clinics, 
the figures presented here are probably an under 
estimation of the true number of cases. There were 
slightly more notifications among men (n=1,236, 54.1%) 
than women (n=1,029, 45.1%), and almost three-
quarters of notifications (n=1,685, 73.8%, table 2) were 
among people aged less than 30 years. 
Chlamydia trachomatis infection (genital)
Chlamydia was the most commonly reported STI 
in Ireland in 2009, with a CIR of 136.3 per 100,000 
population. It was reported more frequently among 
women (n=3,388, 58.6%) and those aged 20-29 years 
(n=3,869, 66.9%; table 2). 
Gonorrhoea
There was a small decrease (-2.3%, table 1) in the 
number of notifications of gonorrhoea in 2009 
(10.2/100,000). However, the proportion of notifications 
of gonorrhoea among those aged less than 20 years 
more than doubled to 16.1% in 2009 (table 2). There 
were also slightly more notifications among women 
in 2009 (n=88, 20.3%, table 2) compared with 2008 
(16.4%). Just over seventy-one percent (n=309, 71.2%, 
table 2), of notifications were among people aged less 
than 30 years. 
Hepatitis B
The data presented here for hepatitis B reflects only 
those cases notified through STI services.  Only 9 cases, 
from two HSE areas, were reported in total.  This is 
unlikely to represent the true incidence of sexually-
acquired hepatitis B in the population.  Of the nine 
cases reported, six were in men and 5 were aged 20-29 
years (table 2). Further information on the epidemiology 
can be found in the hepatitis B chapter of this report.
Herpes simplex (genital)
The increase in notifications of herpes simplex (19.0%, 
table 1) resulted in a higher crude incidence rate of 11.1 
per 100,000 population, compared with 9.3/100,000 in 
2008. There were more cases among women (n=295, 
62.9%) and almost half of cases (n=232, 49.5%) were in 
the age group 20-29 years (table 2).
Non-specific urethritis
The crude incidence rate of non-specific urethritis (NSU) 
dropped to 28.5 per 100,000 population compared 
to 38.6/100,000 in 2008. This decrease is probably 
explained by the outstanding data from two large STI 
clinics, as this is a clinical diagnosis. While the case 
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Table 2. Notifications of sexually transmitted infections by gender and age group, 2009 
Sexually Transmitted Infection Male Female
Gender 
Unknown
0-19 
yrs
20-29 
yrs
30-39 
yrs
40+ 
yrs
Age 
Unknown
Total
Ano-genital warts 1236 1029 18 287 1398 410 168 20 2283
Chancroid 0 0 0 0 0 0 0 0 0
Chlamydia trachomatis infection 2303 3388 90 862 3869 845 186 19 5781
Gonorrhoea 341 88 5 70 239 81 44 0 434
Granuloma inguinale 0 0 0 0 0 0 0 0 0
Herpes simplex (genital) 171 295 3 56 232 110 70 1 469
Infectious Hepatitis B 6 3 0 1 5 0 3 0 9
Lymphogranuloma venereum 0 0 0 0 0 0 0 0 0
Non-specific urethritis 1142 65 2 87 735 269 115 3 1209
Syphilis 405 156 9 9 158 218 184 1 570
Trichomoniasis 1 76 2 8 20 34 17 0 79
Total 5605 5100 129 1380 6656 1967 787 44 10834
% of Total STIs 51.7 47.1 1.2 12.7 61.4 18.2 7.3 0.4 -
definition for NSU specifies a “clinically compatible 
case in a male”, NSU continues to be reported among 
women (n=65, 5.4%, table 2).
Syphilis
Case-based information on the epidemiology of syphilis 
can be found in the syphilis chapter of this report.
Further information on STIs in Ireland in 2009, including 
trends in STI notifications from 1995, is available from 
http://www.hpsc.ie/hpsc/A-Z/HepatitisHIVAIDSandSTIs/
SexuallyTransmittedInfections/Publications/
STIAnnualandQuarterlyReports/2009/.
Note: Crude incidence rates calculated for 2008 and 
2009 based on Census 2006 denominator data.
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Table 3. Notifications and crude incidence rate of sexually transmitted infections by HSE area, 2009
Sexually Transmitted Infection East Midlands
Mid 
West
North 
East
North 
West
South 
East
South West Ireland
Ano-genital warts 847 37 0 4 322 563 506 4 2283
Chancroid 0 0 0 0 0 0 0 0 0
Chlamydia thrachomatis infection 3260 163 577 178 143 691 344 425 5781
Gonorrhoea 235 8 42 18 10 69 27 25 434
Granuloma inguinale 0 0 0 0 0 0 0 0 0
Herpes simplex (genital) 323 3 0 0 10 47 52 34 469
Infectious Hepatitis B 0 0 0 0 3 0 6 0 9
Lymphogranuloma venereum 0 0 0 0 0 0 0 0 0
Non-specific urethritis 735 0 0 0 125 83 266 0 1209
Syphilis 409 10 36 5 3 36 16 55 570
Trichomoniasis 38 3 5 11 1 14 7 0 79
Total 5847 224 660 216 617 1503 1224 543 10834
Crude incidence rate per 100,000 
population
389.9 89.0 182.8 54.8 260.2 326.1 197.1 131.1 255.5
Syphilis 
Case-based syphilis records are collated nationally 
since 2000. Case based surveillance is a subset of 
aggregate syphilis notifications. Forms are completed 
by Departments of Public Health in conjunction with 
the clinician and are then forwarded to HPSC. The 
data presented in this chapter relate to case-based 
reports received on syphilis which are held on a national 
database at HPSC. The syphilis figures presented are 
not comparable with the aggregate counts of syphilis 
notifications provided by HSE areas as part of the 
routine quarterly reporting of sexually transmitted 
infections (570 aggregate syphilis cases reported in 
2009; see STI chapter for more details). 
The first section of this report focuses on 2009 data and 
the second part on the main syphilis trends between 
2000 and 2009.
Syphilis case reports, 2009
In 2009, case-based reports were received on 283 
syphilis notifications, an increase of 27.5% compared 
with 2008 (n=222). One-hundred-and-sixty-five 
(3.9/100,000 population) cases were diagnosed with 
early, infectious syphilis (i.e. primary, secondary and 
early latent stages) and 98 cases were latent, late latent 
or tertiary, syphilis. The stage of infection was not 
recorded for 20 cases.
The 165 cases of early syphilis were analysed in more 
detail since the disease is infectious at this stage and 
therefore has the greatest public health implications. 
Cases ranged in age from 18 to 64 years of age (median 
33 years). The majority of cases were diagnosed in 
the HSE-E (91.5%, n=151/165) and the majority of the 
cases were also resident in HSE-E (80.6%, n=133/165). 
Ireland was recorded as the country of birth for 72.7% 
of early cases (n=120/165), while 82.4% of early cases 
(n=136/165) were acquired in Ireland.
Eighty-three percent of early syphilis cases (n=137/165) 
were men who had sex with men (MSM). These cases 
ranged in age between 19 and 64 years (median 
34 years), with the 25-29 years age group having 
the highest number of cases (n=27). Among MSM 
diagnosed with early syphilis, almost two thirds (62.7%) 
were primary syphilis or secondary while the remainder 
(n=51) were early latent. 
Just over fifty percent (51.1%, n=70/137) of early 
syphilis MSM cases had between 1 and 9 sexual 
5.6 Syphilis, 2009
Summary
Number of case-based syphilis reports, 2009: 283
Number of early syphilis cases, 2009: 165
Crude incidence rate of early syphilis, 2009: 3.9 per 
100,000
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Figure 1. Number of early syphilis cases diagnosed in Ireland by sexual 
orientation, 2000-2009, based on completed case-based surveillance forms  
 MSM  Other   Unknown  
0
50
100
150
200
250
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
N
um
be
r o
f e
ar
ly
 s
yp
hi
lis
 c
as
es
contacts in the 12 months prior to diagnosis; 18.2% 
(n=25) had 10-19 sexual contacts; 19.7% (n=27) had 20 
or more sexual contacts, while the number of contacts 
was not recorded for 10.9% (n=15) of cases. Oral sex 
was reported as the mode of transmission in 42.3% of 
early syphilis MSM cases (n=58).
Syphilis case reporting trends, 2000-2009
Between 2000 and 2009, a total of 2,282 case-based 
reports were received on syphilis. Most cases were 
reported among males (73.8%; n=1,684) while females 
accounted for 25.5% of cases (n=581); gender was 
not recorded for 17 cases (0.7%). Cases ranged in age 
from 0 to 95 years, with a median age of 33 years. The 
majority of cases occurred in the 25-29 year old and 30-
34 year old age groups: 450 and 462 cases respectively. 
Just over fifty percent (50.7%, n=1,158) were classified 
as early, infectious syphilis. The other stages reported 
were: congenital (n=4), late (n=438) and unknown 
(n=682). 
Surveillance forms were completed for 70.1% 
(n=1,599/2,282) of individual case-based reports and 
1,060 (66.3%) of these 1,599 cases were reported as 
early syphilis. Where surveillance forms were completed 
(n=1,599), the majority of cases were male (80.3%; 
n=1,284). Most male cases occurred in the 30-34 
years age group (20.9%, n=268/1,284) while most of 
the cases among females were in the 25-29 years age 
group (30.1%, n=92/306). 
Self-referral was the most frequent reason for attending 
(30.9%, n=494/1,599), followed by GP referral 
(13.0%, n=208/1,599) and contact referral (10.9%, 
n=174/1,599). While self-referral was also the most 
frequent reason for attending among MSM cases 
(39.4%, n=390/989), the next most frequent reason 
was contact referral (11.0%, n=109/989), followed by 
GP referral (10.2%, n=101/989).  Antenatal referrals 
accounted for 25.4% (n=148/582) of all other cases. The 
other most frequently reported reasons for attending 
among this group were GP referral (17.5%, n=107/610) 
and self referral (17.0%, n=104/610).
Early syphilis is common among MSM (figure 1, table 
1). Between 2000 and 2009, 989 cases of syphilis were 
reported among MSM, of these 82.9% (n=820) were 
staged as early syphilis cases. Among MSM, almost 13% 
(n=103/820) of early syphilis cases were re-infections. 
In contrast, only 3.3% (n=8/240) of all other cases were 
reported as re-infections. 
A significant proportion of early syphilis cases were 
found to be co-infected with HIV, particularly among 
MSM (20.6% compared with 8.3% among all other 
cases). There was no difference between these groups 
in relation to concurrent STIs, which were relatively 
common among all early syphilis cases, with 18.7% of 
cases (n=198/1,060) having an STI other than HIV.  A 
history of STIs was more frequent among early syphilis 
MSM cases (40.6%, n=333/820) than among all other 
early syphilis cases (18.8%, n=45/240).
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Table 1. A breakdown of early syphilis cases by sexual orientation in Ireland, 2000-2009, 
based on completed surveillance forms.
Diagnosis Heterosexual MSM Unknown Total
 Male Female* Unknown Male** Male  
Primary 48 21 2 305 6 382
Secondary 37 34 1 289 2 363
Early latent 37 43 0 215 5 300
Other 0 2 0 11 2 15
Total 122 100 3 820 15 1060
*Includes one bisexual female
**Includes 69 male bisexual cases
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Other infections
Encephalitis due to viruses not otherwise specified 
in the Irish Infectious Disease (Amendment) (No. 3) 
Regulations 2003 (SI No. 707 of 203) are notifiable 
under the disease viral encephalitis.  Clinicians and 
laboratories (the latter since 2004) are legally obliged to 
notify all cases of viral encephalitis.
In 2010, 22 cases of viral encephalitis were notified 
in Ireland (0.5/100.000 population).  This was the 
highest annual number of cases to be notified since 
2006 when 16 cases (0.4/100,000) were reported 
(figure 1).  Compared with 2008 or 2009 (5 cases each, 
0.1/100,000) there was over a four-fold increase in viral 
encephalitis notifications in 2010.  
Varicella zoster virus and herpes simplex virus tend to 
be the two main causative agents of viral encephalitis 
notifications in Ireland.  Notifications due to both 
of these pathogens increased in 2010, 11 cases of 
varicella zoster virus and 10 of herpes simplex virus 
were notified, accounting for 50% and 45% of the cases, 
respectively.  Of the 10 herpes simplex virus (HSV) 
encephalitis cases notified, seven were reported as HSV 
type 1, for the remaining three cases HSV type was not 
reported.
In 2010, all eight HSE areas notified cases of viral 
encephalitis (range 1-5 cases per area), indicating that 
cases were geographically distributed.   More viral 
encephalitis cases occurred in females (n=13) than 
males (n=9), giving a male to female ratio of 1.0:1.4.  
Cases ranged in age from 1 week to 86 years. The 
majority of the notifications occurred in the elderly aged 
65 years and over (41%; n=9) followed by the 45-64 
years age group (27%; n=6) (table 1).  However, the 
highest age specific incidence rate was in infants < 1 
year of age (3.3 cases per 100,000 population) where 
two cases due to herpes simplex virus were notified. 
No viral encephalitis deaths relating to 2010 
notifications were reported via the notification system.  
However, since this system does not have a process in 
place to actively follow up on the outcome of all viral 
encephalitis notifications, the true mortality rate due 
6.1 Viral Encephalitis
Summary
Number of cases, 2010: 22
Number of cases, 2009 5
Number of cases, 2008: 5
Crude incidence rate, 2010: 0.5/100,000
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Table 1.  Number, age-specific incidence rates and proportion of viral 
encephalitis notifications by age group, 2010
Age group 
(years)
Number by causative pathogen
ASIR
Proportion
(%)Herpes 
simplex
Varicella 
zoster
Unknown Total
<1 2 0 0 2 3.3 9.1
1-4 0 0 0 0 - -
5-14 0 1 0 1 0.2 4.5
15-24 0 0 0 0 - -
25-44 1 3 0 4 0.3 18.2
45-64 4 1 1 6 0.6 27.3
65+ 3 6 0 9 1.9 40.9
All ages 10 11 1 22 0.5 100
ASIR, age specific incidence rate per 100,000 population of total cases
to this disease cannot be determined from notification 
data.
In summary there was an increase in viral encephalitis 
notifications in Ireland in 2010.  Improved and more 
consistent reporting by the laboratories are considered 
to be the main contributory factors for this increase.
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 30th August 2010.  These 
figures may differ from those published previously due 
to ongoing updating of notification data in CIDR.
0 
5 
10 
15 
20 
25 
2004 2005 2006 2007 2008 2009 2010 
N
um
be
r o
f c
as
es
 
Year 
Unknown Varicella zoster virus Herpes simplex virus 
Figure 1.  Annual number of viral encephalitis notifications by causative pathogen, 
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Meningitis due to viruses not otherwise specified 
in the Irish Infectious Disease (Amendment) (No. 3) 
Regulations 2003 (SI No. 707 of 203) are notifiable 
under the disease viral meningitis.  Clinicians and 
laboratories (the latter since 2004) are legally obliged to 
notify all cases of viral meningitis.
In 2010, 169 cases of viral meningitis were notified 
in Ireland (4.0/100,000).  This was a 16% increase 
compared with 2009 when 142 cases were notified 
(3.3/100,000).  As in previous years there was a seasonal 
peak in 2010 with notifications at their highest during 
July and August.  However, the distinct seasonal peak 
seen particularly in 2006 and also in 2008 and 2009 
was not as pronounced in 2010; instead the summer 
upsurge of cases was more prolonged, spanning a four-
month period (figure 1).  
Of the 169 cases notified, 149 were classified as 
confirmed (88.2%), eight as probable (4.7%), 11 as 
possible (6.5%) and for one the case classification was 
not reported (0.6%). A similar number of cases occurred 
in males (n=82) and as in females (n=87), giving a male 
to female ratio of 1.0:1.06.  Cases ranged in age from 2 
weeks to 81 years with both an average and a median 
age of 16 years.  Unlike viral encephalitis where the 
highest proportion of cases occurred in those aged 
45 years of age and older (see previous chapter), the 
majority of viral meningitis cases occurred in children 
and young adults. Over two-thirds (67%) of the cases 
occurred in those 25 years of age and younger (table 
1).  The highest age specific incidence rate was by 
far in infants <1 year of age at 86.8 per 100,000 total 
population.  For all other age groups the age specific 
incidence rates ranged between 0.2 and 5.2 per 
100,000 population (table 1). 
In 2010, enterovirus was the most common pathogen 
associated with viral meningitis, accounting for 64% 
(n=108) of the notifications.  Herpes simplex virus (HSV) 
was the causative pathogen for 11% of the notifications 
(n=19), with HSV type 6 accounting for 12 of these 19 
notifications (table 1).
In 2010, the incidence of viral meningitis in HSE areas 
ranged between 1.2 per 100,000 population in HSE-M 
and 9.7 per 100,000 population in HSE-NW.  Incidence 
in HSE-NW (9.7/100,000; 95% CI 5.7-13.6/100,000) was 
significantly higher than the national rate (4.0/100,000; 
6.2 Viral Meningitis
Summary
Number of cases, 2010: 169
Number of cases, 2009 142
Number of cases, 2008: 97
Crude incidence rate, 2010: 4.0/100,000
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Table 1. Number, age-specific incidence rates and proportion of viral meningitis notifications by age group, 2010
Age group 
(years)
Number by causative pathogen
ASIR
Proportion
(%)Enterovirus Herpes 
simplex
Parechiovirus Varicella 
zoster
Unknown Total
<1 39 9 1 0 4 53 86.8 31.4
1-4 3 3 0 0 2 8 3.3 4.7
5-14 15 1 0 1 2 19 3.4 11.2
15-24 15 2 0 6 10 33 5.2 19.5
25-44 35 2 0 4 10 51 3.8 30.2
45-64 1 1 0 1 1 4 0.4 2.4
65+ 0 1 0 0 0 1 0.2 0.6
All ages 108 19 1 12 29 169 4.0 100
% of total 
cases
63.9 11.2 0.6 7.1 17.2 100
ASIR, age specific incidence rate per 100,000 population of total cases
95% CI 3.4-4.6/100,000), while in HSE-M (1.2/100,000; 
95% CI -0.16-2.5/100,000) it was significantly lower than 
the national rate (figure 2).   For all other HSE areas the 
incidence rate was not considered statistically different 
from the national rate.
Two viral meningitis deaths relating to 2010 notifications 
were reported through the notification system. One 
was in an adult with HSV and the other in an infant with 
enterovirus. However, information is not available as to 
whether viral meningitis was the primary cause of death 
or not in these two cases.
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 30th August 2010.  These 
figures may differ from those published previously due 
to ongoing updating of notification data in CIDR.
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Figure 1. Three-month moving average of the number of viral meningitis 
notifications, 2006-2010
Figure 2. Crude incidence rates per 100,000 population with 95% confidence intervals for viral 
meningitis notifications by HSE area, 2010
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Three cases of Creutzfeldt-Jakob disease (CJD) were 
notified in 2010 compared to five cases in 2009.  All 
cases in 2010 were aged greater than 50 years and were 
sporadic CJD cases.  Two cases were male and one was 
female.
In total, 51 cases of CJD were notified since CJD was 
first specified as a notifiable disease in December 1996.  
Figure 1 shows the 51 CJD notifications by age group.  
The majority (n=43, 84%) of the cases were aged great-
er than 54 years.  Of the 51 cases, 29 were male and 22 
were female.  Forty-eight cases were sporadic CJD, two 
were familial CJD and one was iatrogenic CJD.
Variant CJD (vCJD) is specified as a separate notifiable 
disease.  No cases of vCJD were notified in 2010.  Four 
cases of vCJD were notified since vCJD became notifi-
able in December 1996.  A summary of these four cases 
was provided in the 2006 HPSC annual report. 
Data presented in this summary are based on notifi-
cations from HSE Areas and from the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit.  Annual 
figures published here are based on the year the no-
tification was entered on the Computerised Infectious 
Disease Reporting (CIDR) system and consequently may 
differ from annual figures published by the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit.
6.3 Creutzfeldt-Jakob disease  
Summary
Number of cases, 2010: 3
Number of cases, 2009: 5
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Figure 1. Number of CJD notifications (n=51) from December 1996 
to 2010 by age group
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Infectious Disease Outbreaks
During 2010, 369 outbreaks of infectious diseases 
were reported with 5,222 associated cases of illness, 
including 1,054 (20.2%) cases hospitalised and eight 
deaths. Regional variation in outbreaks was observed 
between HSE areas with the highest rate observed 
in HSE-NW at 16.9 per 100,000 population while the 
lowest rate was observed in HSE-NE at 4.3 per 100,000 
population. Table 1 details the regional distribution 
of all outbreaks of infectious disease, outbreaks of 
infectious intestinal disease (IID) and outbreaks of non-
IID.
General outbreaks accounted for 69.1% (n= 255) of 
all outbreaks notified during 2010. The remaining 
outbreaks (30.9%, n= 114) were reported as family/
household outbreaks. Similar to previous years, 
person-to-person spread* was reported as the mode 
of transmission for the majority of outbreaks in 2010 
(81.8%, n=2,302). Most of these outbreaks were due to 
norovirus, AIG and measles. 
Private houses were the most frequently reported 
outbreak location in 2010, accounting for 24.7% (n=91) 
of all outbreaks while residential institutions were the 
second most common outbreak location, accounting 
for 20.9% (n=77) of all outbreaks. The highest numbers 
ill were reported from outbreaks in hospitals (n=2,133), 
residential institutions (n=1,210) and community 
hospital/long stay units (n=857). Table 2 details the 
number of IID and non-IID outbreaks and numbers ill by 
outbreak location for outbreaks reported during 2010.
Infectious intestinal disease (IID) outbreaks:
IID outbreaks accounted for 77.5% (n=286) of all 
outbreaks reported during 2010. This was a 7% increase 
compared to the number of IID outbreaks reported 
during 2009 (n=266).Table 3 details the regional 
distribution of outbreaks of infectious intestinal disease 
(IID) 
Norovirus/ suspect viral outbreaks, accounted for 67.5% 
of all IID outbreaks reported in 2010. Figure 1 compares 
norovirus/suspect viral outbreaks with non-norovirus IID 
outbreaks by year from 2001 to 2010. Norovirus was 
also responsible for the 10 largest outbreaks during 
2010, all of which occurred in hospitals. Numbers ill 
ranged from 461 cases to 75 cases. 
7. Outbreaks
Summary
Number of outbreaks: 369
Number of IID outbreaks: 286
Number of non-IID outbreaks: 83
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HSE area Number of 
outbreaks
Outbreak rate 
per 100,000
Number ill Number 
hospitalised
Number of 
deaths
Number of IID 
outbreaks
Number of 
Non-IID 
outbreaks
HSE-E 106 7.1 2,274 580 4 69 37
HSE-M 27 10.7 269 10 0 23 4
HSE-MW 25 6.9 216 131 0 22 3
HSE-NE 17 4.3 87 17 1 17 0
HSE-NW 40 16.9 404 81 0 36 4
HSE-SE 37 8.0 673 6 0 34 3
HSE-S 68 10.9 690 50 2 45 23
HSE-W 46 11.1 568 158 1 37 9
HPSC 3 - 41 21 0 3 0
Total 369 8.7 5,222 1,054 8 286 83
Table 1. Number of outbreaks by HSE area, 2010
*  Including 70 outbreaks reported as person to person and airborne transmission
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Table 2. Number of IID and non-IID outbreaks and number ill by outbreak location, 2010
Outbreak location
IID              Non-IID Total outbreaks
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill Number of outbreaks Number ill
Private house 62 152 29 83 91 235
Residential institution 73 1160 4 50 77 1210
Hospital 55 2085 6 48 61 2133
Comm. Hosp/Long-stay unit 53 857 0 0 53 857
School 0 0 17 183 17 183
Extended family 11 44 5 27 16 71
Other 9 76 3 20 12 96
Creche 4 44 7 48 11 92
Community outbreak 4 46 7 97 11 143
Hotel 6 123 1 2 7 125
Travel related 5 11 1 3 6 14
Restaurant / Cafe 3 45 0 0 3 45
University/College 0 0 1 3 1 3
Workplace 0 0 1 2 1 2
Coach tour 1 11 0 0 1 11
Not Specified 0 0 1 2 1 2
Total 286 4654 83 568 369 5222
  ‡ Includes all norovirus outbreaks and AIG outbreaks where organism was suspected norovirus, suspected viral or not specified
Table 3. IID outbreak summary by HSE area 2010
HSE area Number of outbreaks Outbreak rate per 
100,000
Number ill Number hospitalised Number of deaths
HSE-E 69 4.6 2,096 551 4
HSE-M 23 9.1 261 8 0
HSE-MW 22 6.1 205 129 0
HSE-NE 17 4.3 87 17 1
HSE-NW 36 15.2 329 78 0
HSE-SE 34 7.4 618 6 0
HSE-S 45 7.2 530 21 2
HSE-W 37 8.9 487 146 1
HPSC 3 - 41 21 0
Total 286 6.7 4,654 977 8
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Figure 1. Number of norovirus/suspect viral outbreaks  and number of non-norovirus IID outbreaks‡ by 
year, 2001-2010
Table 4. Number of general and family IID outbreaks by disease, 2010
Outbreak disease/pathogen
Family outbreak General outbreak Total IID outbreaks
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Acute infectious gastroenteritis 7 26 67 846 74 872
Campylobacteriosis 1 15 1 5 2 20
Cryptosporidiosis 8 15 0 0 8 15
Enterohaemorrhagic E. coli 45 97 3 10 48 107
Giardiasis 1 2 0 0 1 2
Hepatitis A (acute) 1 3 2 13 3 16
Noroviral infection 1 36 129 3484 130 3520
Salmonellosis 11 28 5 59 16 87
Shigellosis 2 7 1 6 3 13
Typhoid 1 2 0 0 1 2
Total 78 231 208 4423 286 4654
Table 5. Non-IID outbreak summary by HSE area, 2010)
HSE area Number of 
outbreaks
Outbreak rate per 
100,000
Number ill Number hospitalised Number of deaths
HSE-E 37 2.5 178 29 0
HSE-M 4 1.6 8 2 0
HSE-MW 3 0.8 11 2 0
HSE-NE 0 0.0 0 0 0
HSE-NW 4 1.7 75 3 0
HSE-SE 3 0.7 55 0 0
HSE-S 23 3.7 160 29 0
HSE-W 9 2.2 81 12 0
Total 83 2.0 568 77 0
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After norovirus (n=130), the next most commonly 
reported IID outbreaks during 2010 were acute 
infectious gastroenteritis (n=74), EHEC (n=48), 
salmonellosis (n=16) and cryptosporidiosis (n=8). The 
number of general and family outbreaks of IID and 
numbers ill, are outlined in Table 4.  
The most frequently reported locations for IID 
outbreaks were residential institutions (n=73), 
private houses (n=62) and hospitals (n=55). The most 
commonly reported outbreaks in residential institutions 
were of norovirus (n=43) and AIG (n=30). In private 
homes the most commonly reported outbreaks were 
of Enterohaemorrhagic E. coli (n=40), salmonellosis 
(n=7) and cryptosporidiosis (n=6). In hospitals the most 
commonly reported outbreaks were norovirus (n=46) 
and AIG (n=9).
Person-to-person (P-P) spread† was the most frequently 
reported mode of transmission implicated in IID 
outbreaks during 2010 (80.4%, n=230). 
The number of IID outbreaks peaked during the first 
three months of 2010. This peak is due to high numbers 
of norovirus outbreaks, with 40 norovirus outbreaks 
reported during January, 39 during February and 
24 during March. This seasonal variation has been 
observed in previous years. Figure 2 illustrates the 
number of IID and non-IID outbreaks by month of 
notification during 2010.
Non-IID outbreaks:
During 2010, 83 outbreaks of non-IID diseases were 
reported, representing 22.5% of all outbreaks notified 
nationally. The most common non-IID outbreak disease 
was measles accounting for 48.2% (n=40) of all non-
IID outbreaks reported. After mumps, the next most 
commonly reported non-IID outbreaks during 2010 
were tuberculosis (n=7) and chicken pox/suspected 
chicken pox (n=6). Table 5 details the regional 
distribution of non-IID outbreaks while the number of 
general and family outbreaks of non-IID disease and 
numbers ill are outlined in Table 6.  
The number of non-IID outbreaks also peaked during 
the first three months of 2010. This peak was due to 
high numbers of measles outbreaks, with 13 measles 
outbreaks reported during January, seven during 
February and 10 during March (figure 2). 
The most frequently reported locations for non-IID 
outbreaks were private houses (n=29), schools (n=17), 
crèches (n=7) and community settings (n=6), as shown 
in table 2. Non-IID outbreaks in these locations were 
most frequently caused by measles. 
Person-to-person (P-P) spread§ was the most frequently 
reported mode of transmission implicated in non-IID 
outbreaks during 2010 (86.7%, n=72). 
†Including 46 IID outbreaks reported as person to person and airborne transmission
§  Including 24 non-IID outbreaks reported as person to person and airborne transmission
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Table 6. Number of family and general non–IID outbreaks by disease, 2010
Outbreak disease/pathogen Family outbreak General outbreak Total Non-IID outbreaks
Number 
outbreaks
Number ill Number 
outbreaks
Number ill Number 
outbreaks
Number ill
Measles 24 73 16 76 40 149
Tuberculosis 2 17 5 24 7 41
Varicella /suspected varicella 1 2 5 51 6 53
Mumps 3 11 2 6 5 17
Pertussis 3 7 1 65 4 72
Influenza-like illness 0 0 4 74 4 74
Influenza 0 0 3 63 3 63
Scabies /suspected scabies 0 0 3 55 3 55
Hepatitis B 1 2 1 2 2 4
MRSA 0 0 2 10 2 10
Legionellosis 0 0 1 2 1 2
Malaria 1 3 0 0 1 3
Meningococcal disease 1 2 0 0 1 2
Impetigo 0 0 1 9 1 9
Respiratory Illness 0 0 1 5 1 5
Hand, foot & mouth disease 0 0 1 6 1 6
Parvovirus B19 0 0 1 3 1 3
Total 36 117 47 451 83 568
The information gathered from outbreaks reported 
is used to inform public health professionals on the 
causes and factors contributing to outbreaks, to target 
prevention strategies and to monitor the effectiveness 
of prevention programmes.
For further information on disease specific outbreaks, 
please refer to the individual disease chapter.
Health Protection Surveillance Centre   Annual Report 201008
Immunisation Uptake
Immunisation Uptake
In 2010, the HSE Areas provided HPSC with quarterly 
immunisation uptake data for their Area and for 
each of the Local Health Offices (LHOs) in their Area.  
HPSC collated these data and quarterly reports were 
produced which are available on the HPSC website.  
The annual immunisation uptake rates presented 
here represent the collation of the 2010 quarterly 
data.  The proportion of children who completed 
the recommended childhood immunisation schedule 
by 12 months (born between 01/01/2009 and 
31/12/2009) and 24 months (born between 01/01/2008 
and 31/12/2008) of age in 2010 are reported.  This 
report refers to children vaccinated under the two 
recommended immunisation schedules described 
below.
The Irish childhood immunisation schedule 
recommended that babies born from January to June 
2008 should receive one dose of vaccine against 
tuberculosis (BCG vaccine) at birth or by one month 
of age and three doses of vaccines against diphtheria 
(D3), tetanus (T3), pertussis (P3), Haemophilus influenzae 
type b (Hib3), polio (Polio3) and meningococcal group 
C (MenC3) with one dose of each given at two, four 
and six months of age.  Between 12 and 15 months 
of age these children were recommended to receive 
the first dose of the measles-mumps-rubella vaccine 
(MMR1) and a dose of Hib (Hibb).  Children born 
between September 2nd 2006 and June 30th 2008 were 
recommended pneumococcal conjugate vaccine (PCV) 
as part of a catchup campaign carried out between 
September 2008 and July 2009.  
Since September 1st 2008 the new primary childhood 
immunisation schedule has been implemented for 
children born on or after July 1st 2008 (table 1).  These 
children should receive one dose of vaccine against 
tuberculosis (BCG vaccine) at birth or by one month 
of age; three doses of vaccines against diphtheria, 
tetanus, pertussis,  Haemophilus influenzae type b, 
polio and Hepatitis B (HepB3) with one dose of each 
given at two, four and six months of age; three doses 
of pneumococcal conjugate vaccine (PCV3) given at 
two, six and 12 months of age and three doses of 
meningococcal group C (MenC3) vaccine given at 
four, six and 13 months of age.  At 12 months of age 
MMR1 is recommended and at 13 months Hibb is 
recommended.
Further vaccinations are recommended for older 
children; please see www.immunisation.ie for complete 
information on the Irish childhood immunisation 
schedule.
In children who reached 12 months of age in 2010 (born 
between 01/01/2009 and 31/12/2009) uptake of BCG, 
D3, T3, P3, Hib3, Polio3, HepB3 and two doses of PCV 
(PCV2) and MenC (MenC2) were measured.  In children 
who reached 24 months of age in 2010 (born between 
01/01/2008 and 31/12/2008) uptake of D3, T3, P3, Hib3, 
Polio3, MenC3, MMR1 and Hibb were measured.  As 
8. Immunisation Uptake
Summary
At 12 months (based on available data) uptake of:
D3, T3, P3, Hib3, Polio3, HepB3, MenC2 and PCV2 was 
89% 
At 24 months (based on available data) uptake of:
D3, T3, P3, Hib3 and Polio3 was 94%
HepB3 (Quarters 3 and 4 data only) was 94% 
MMR1 was 90%
PCV3 (Quarters 3 and 4 data only) was 88%
MenC3 was 86%  
Hibb was 85%
Compared to previous quarters, there was a large 
decline in MenC3 and a decline in Hibb uptake at 
24 months in Quarters 3 and 4 2010.  This decline 
coincided with the introduction of the new childhood 
immunisation schedule. Under the new immunisation 
schedule there is a change in timing of the MenC 
and Hibb vaccines (table 1).  A collaborative study 
was carried out by the HSE (HSE Areas, NIO and 
HPSC) to identify reasons for the decline in uptake so 
that targeted remedial actions could be undertaken.  
A key finding of this study was that most parents 
did not know their children were incompletely 
vaccinated and were unaware of the need for their 
child to visit the GP at 13 months for MenC and Hibb 
vaccinations.  The study findings have been used to 
inform communication to GPs and practice nurses 
as well as the development of new information 
materials for parents which highlight the importance 
of completing five GP visits to ensure children are 
fully vaccinated.
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the new primary childhood immunisation schedule was 
implemented for children born on or after July 1st  2008, 
uptake of HepB3 and PCV3 were measured in those who 
reached 24 months of age in Quarters 3 and 4 2010 
(born between 01/07/2008 and 31/12/2008).
The immunisation uptake rates are reported here by 
HSE Area and LHO.  While there are 32 LHOs the 
immunisation uptake rates for the LHOs of North Lee 
and South Lee are reported as a combined figure.
Caveats to data
As a new childhood immunisation schedule was 
introduced in 2008, for those born on or after July 1st 
2008, the 2010 HepB3 and PCV3 data at 24 months 
are for those born between July 1st and December 
31st 2008 (i.e. Quarters 3 and 4 2010 data) only.  As 
not all HSE Areas were able to provide data for each 
quarter a number of figures presented in this report are 
incomplete.  For both these reasons some figures for 
2010 may reflect data from less than four quarters and 
in some cases reflect data from one quarter only.  
The 2010 data for those at 12 months are incomplete 
as the following were unavailable: the Quarter 1 2010 
HSE-M and HSE-S data and the HSE-MW MenC2 data; 
the Quarter 2 2010 HSE-M data and HSE-S data and; 
the Quarter 4 2010 HSE-NE data.  The available 2010 
national 12 month D3, T3, P3, Hib3, HepB3, Polio3 and 
PCV2 cohort data may be around 87% (this figure is an 
estimate only) of the 2010 national birth cohort and the 
available MenC2 cohort may be around 85% (this figure 
is an estimate only) of the 2010 national birth cohort.  
BCG uptake data were available for the HSE-MW, HSE-
NW, and HSE-SE Areas in Quarters 1-4 2010, for the 
HSE-M Area in Quarters 3 and 4 2010 and the HSE-SA 
Area in Quarter 4 2010.  The available 2010 national 
BCG cohort data may be around 31% (this figure is an 
estimate only) of the national birth cohort.  
The 2010 data for those at 24 months are incomplete 
as the following were unavailable: the Quarter 1 2010 
HSE-M and HSE-S data and the HSE-E Dublin North 
Hibb data; the Quarter 2 2010 HSE-M data and; the 
Quarter 4 2010 HSE-NE data.  The available 2010 
national 24 month cohort data may be around 89-90% 
(this figure is an estimate only) of the 2010 national birth 
cohort. 
Data in 2010 are compared here to data in 2009.  The 
2009 data (at 12 and 24 months) were incomplete; the 
caveats were detailed in the 2009 annual report.  The 
available 2009 national 12 month D3, T3, P3, Hib3 and 
Polio3 cohort data may be around 88% (this figure is 
an estimate only) of the 2009 national birth cohort and 
HepB3, MenC2 and PCV2 data may be around 76%, 54% 
and 58% (these figures are estimates only), respectively, 
of the (combined Quarters 3 and 4) national birth 
cohort.  The available 2009 national BCG cohort data 
may be around 27% (this figure is an estimate only) of 
the national birth cohort.  The available 2009 national 
24 month D3, T3, P3, Hib3, Polio3, MenC3 and MMR1 birth 
cohort data may be around 98% of the national birth 
cohort and the available Hibb data may be around 95% 
of the national birth cohort (these figures are estimates 
only).  
Immunisation uptake rates at 12 months
National immunisation uptake rates (based on available 
data), in children 12 months of age in 2010, were 89% for 
D3, P3, T3, Hib3, HepB3, Polio3, MenC2 and PCV2 and 95% 
for BCG (table 2).  Compared with 2009, the uptake rates 
were unchanged.
Among the HSE Areas, uptake rates for D3, P3, T3, Hib3, 
HepB3 and Polio3 ranged from 87% to 93% (table 2).  
Among the LHOs, uptake rates for D3, P3, T3, Hib3, Polio3, 
MenC2 and PCV2 ranged from 78% to 96% and HepB3 
ranged from 78% to 95% (appendix 2.1).  The target 
uptake of 95% was reached or exceeded in Roscommon 
for D3, P3, T3, Hib3, Polio3, HepB3, MenC2 and PCV2 and 
reached in Cavan/Monaghan (combined Quarters 1-3 
data only) for D3, P3, T3, Hib3 and Polio3 (appendix 2.1).  
The target uptake of 95% was reached or exceeded for 
BCG in nine LHOs reporting data (appendix 2.1).
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Age Children born before 01/07/2008 Children born on or after 01/07/2008
Birth BCG BCG
2 months DTaP/Hib/IPV + MenC DTaP/Hib/IPV/HepB + PCV
4 months DTaP/Hib/IPV + MenC DTaP/Hib/IPV/HepB + MenC
6 months DTaP/Hib/IPV + MenC DTaP/Hib/IPV/HepB + PCV + MenC
12 months MMR + Hib MMR + PCV
13 months - MenC + Hib
Please see www.immunisation.ie for complete information on the Irish childhood immunisation schedule
BCG         Bacille Calmette Guerin vaccine 
DTaP Diphtheria, Tetanus and acellular Pertussis vaccine
Hib Haemophilus influenzae type b vaccine
IPV Inactivated Polio Virus vaccine
MenC  Meningococcal group C vaccine
HepB Hepatitis B vaccine
PCV Pneumococcal Conjugate Vaccine
MMR Measles, Mumps and Rubella vaccine
Table 1. Change in primary childhood immunisation schedule (introduced on September 1st 2008)
Immunisation uptake rates at 24 months
National immunisation uptake rates (based on available 
data), in children 24 months of age in 2010, were 94% 
for D3, T3, P3, Hib3, Polio3 and HepB3, 88% for PCV3, 
86% for MenC3 and 85% for Hibb (table 2).  Compared 
with 2009, the uptake rates for MenC3 declined by 
seven percent, Hibb declined by two percent, D3, T3, P3 
and Polio3 were unchanged and Hib3 increased by one 
percent (figure 1).  
MenC3 uptake was 93% in Quarter 1 2010 but declined 
to 80% in Quarter 3 2010 and was 82% in Quarter 4 
2010.  Hibb was 87% in Quarters 1 and 2 2010 but 
declined to 84% in Quarters 3 and 4 2010 (figure 2).  
There was also low uptake of PCV3 (88% combined 
Quarters 3 and 4 data).  Since September 1st 2008 
the new primary childhood immunisation schedule has 
been implemented for children born on or after July 
1st 2008 (table 1); children who were 24 months of age 
in Quarters 3 and 4 2010 were born between July 1st 
and December 31st 2008 and were the first children 
recommended the new immunisation schedule.  Under 
the new immunisation schedule children are now 
recommended HepB vaccine and PCV.  In addition, 
there is a change in timing of the MenC and Hibb 
vaccines (table 1). The changes to the schedule mean 
that three injections (6 in 1, PCV and MenC vaccines) 
are now recommended at six months of age and two 
GP visits are required after 12 months; the first dose of 
MMR and the third dose of PCV should be given at 12 
months of age and at 13 months of age the third dose 
of MenC vaccine and Hibb should be given (table 1).  
These quarterly uptake data indicated children were 
not receiving their MenC, PCV and Hibb vaccinations as 
recommended.    
Among the HSE Areas, uptake rates for 2010 for D3, 
P3, T3 and Polio3 ranged from 93% to 96%, Hib3 ranged 
from 93% to 95%, HepB3 ranged from 92% to 95%, PCV3 
ranged from 85% to 92%, MenC3 ranged from 82% to 
92% and Hibb ranged from 80-93% (table 2).  The target 
uptake of 95% was reached or exceeded during 2010 
in the HSE-MW for HepB3, in the HSE-NE for D3, T3, 
P3, Hib3, Polio3 (combined Quarters 1-3 data only) and 
HepB3 (Quarter 3 2010 data only) data and for D3, T3, P3, 
Hib3, Polio3 and HepB3 in the HSE-NW (table 2).
D3, Hibb and MenC3 uptake rates are mapped by LHO 
in figure 3.  Among the LHOs the uptake rates ranged 
from 88% to 99% for D3, T3, P3 and Polio3, 89% to 98% for 
Hib3, 87% to 98% for HepB3, 75% to 96% for PCV3, 74% 
to 96% for MenC3 and 71% to 95% for Hibb (appendix 
2.2).  Uptake rates of ≥90% were reported in 30 LHOs 
for D3, T3, P3, Hib3, Polio3 and HepB3, 15 LHOs for PCV3, 
11 LHOs for Hibb and in five LHOs for MenC3 (figure 3, 
appendix 2.2).
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Figure 1. National annual immunisation uptake rates (based on available data) at 24 months, 1999-2010
Since T3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented.
The 2005 MMR1 uptake figure is incomplete as the HSE-E was unable to provide MMR data for Quarter-4 2005, due to technical problems with 
extraction of MMR1 data from the HSE-E database.  The 2006 MMR1 figure includes the Quarter-1 2006 HSE-E figure, which is an estimate only 
due to technical problems with extraction of MMR1 data from the HSE-E database.  The 2007 national Hibb figure is incomplete, as the HSE-W 
data for Quarter 1 2007 and the HSE-NW data for Quarter 3 2007 were not available.  The 2007 national Hibb figure also includes the HSE-SE 
data which are an underestimate due to data extraction methods.  The 2008 Hibb figure is incomplete as the HSE-SE data for Q2 2008 and the 
HSE-MW data for Quarter 3 2008 were not available.  The 2008 national MenC3 figure is incomplete as the HSE-E and HSE-MW MenC3 data 
for Quarter 3 2008 were not available. The 2009 data are incomplete as the following were unavailable: the Quarter 1 2009 HSE-E D3, T3, P3 
and Polio3 data for those born on the 31/03/2007; the Quarter 2 2009 HSE-E Dublin North Hibb uptake data and; the Quarter 4 2009 HSE-MW 
data, HSE-E Dublin North Hibb data and HSE-SE Hibb data for those given a Hib dose as part of the five in one or six in one vaccine after 12 
months of age.  The 2010 data are incomplete, please see text for details of caveats.
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The target uptake of 95% was reached or exceeded in 
15 LHOs for D3 (figure 3a), T3, P3, Hib3, Polio3 and HepB3 
and in one LHO (Roscommon) for Hibb (figure 3b), 
MenC3 (figure 3c) and PCV3 (appendix 2.2). 
During 2010 MMR1 uptake was 90% nationally; 
unchanged when compared to 2009 (figure 1).  Among 
the HSE Areas, uptake rates for MMR1 ranged from 
88% to 93%, with five HSE Areas reporting uptake of 
≥90% (table 2).  Uptake rates for MMR1 ranged from 
79% to 96% among the LHOs, with 20 LHOs reporting 
uptake of ≥90% and one LHO (Roscommon) reaching 
and exceeding the target uptake of 95% (figure 3d, 
appendix 2.2).  
There was a large decline in MenC3 and a decline in 
Hibb uptake at 24 months in Quarters 3 and 4 2010 
i.e. children who were born between July 1st and 
December 31st 2008 and were the first recommended 
the new immunisation schedule.  There is a change 
in timing of the MenC and Hibb vaccines under the 
new immunisation schedule (table 1).  MenC and Hib 
are serious, potentially life threatening illnesses. The 
majority of illnesses caused by these infections can be 
prevented by vaccination but for maximum protection 
requires that all children receive their recommended 
doses of vaccines, at the recommended ages.  The 
National Immunisation Advisory Committee has 
recommended certain vaccines be given at specific 
ages to make sure babies are protected from serious 
diseases at the age when they are most vulnerable.  A 
collaborative study was carried out in four of the HSE 
Areas to determine whether the local immunisation 
databases accurately reflected immunisation uptake 
Table 2. Annual immunisation uptake rates (based on available data) by HSE Area for children 12 and 24 months of age in 2010
% Uptake at 12 months
Cohort born 01/01/2009 - 31/12/2009
% Uptake at 24 months
Cohort born 01/01/2008 - 31/12/2008*
D3 Hib3 MenC2 PCV2 BCG D3 Hib3 Hibb HepB3 MenC3 PCV3 MMR1
HSE-E 87 87 87 87 na 93 93 83 94 85 87 89
HSE-M 89 89 89 89 93 93 93 84 93 82 89 90
HSE-MW 92 92 92 92 97 94 94 89 95 88 91 92
HSE-NE 93 93 91 91 na 95 95 92 95 92 92 93
HSE-NW 93 93 93 93 95 96 95 90 95 88 88 92
HSE-SE 90 90 90 90 96 94 94 93 94 88 90 93
HSE-S 87 88 86 86 88 93 94 80 92 83 87 89
HSE-W 88 88 88 89 na 93 93 80 93 85 85 88
Ireland 89 89 89 89 95 94 94 85 94 86 88 90
na=not available
The 2010 data are incomplete, please see text for details of caveats
* HepB3 and PCV3 uptake data presented here for those at 24 months  are only for those born between 01/07/2008 and 31/12/2008 
At 12 months, since T3, P3, Polio3 and HepB3 uptake identical to D3 uptake only D3 uptake figures presented
At 24 months, since T3, P3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented
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Figure 2. National quarterly immunisation uptake rates at 24 months
Note scale ranges from 60-95%
The Q4-2005 MMR1 figure is based on data from seven of the eight HSE-Areas.  The Q1-2006 MMR1 figure includes the HSE-E figure that is an 
estimate only.  The Q1-2007, Q3-2007, Q2-2008 and Q3-2008 Hibb figures are based on data from seven of the eight HSE Areas.  In Q1-2008 
the HSE-SE changed their Hibb data extraction method compared to previous quarters; in Q1-2008 the uptake of Hibb in the HSE-SE was 83% 
compared to 53% in Q4-2007.  The Q3-2008 MenC3 figure is based on data from six of the eight HSE Areas.  The Q1-2009 HSE-E D3, P3, T3, Polio3 
and MMR1 uptake figures exclude those born on the 31/03/2007.  The Q2-2009 HSE-E Hibb uptake figures exclude uptake figures from Dublin 
North.  The Q4-2009 figures are based on data from seven of the eight HSE Areas.  The Q4-2009 Hibb figures also exclude uptake figures from 
Dublin North.  The Q1-2010 figures are based on data from six of the eight HSE Areas.  The Q1-2010 Hibb figures also exclude uptake figures 
from Dublin North.  The Q2-2010 and Q4-2010 figures are based on data from seven of the eight HSE Areas.  
for the group of children who were 24 months of age in 
Quarter 3 2010 as well as to identify potential reasons 
for missing those vaccines so that more targeted 
remedial actions could be undertaken.1  A key finding 
of this study was that most parents did not know 
their children were incompletely vaccinated and were 
unaware of the need for their child to visit  the GP at 
13 months for the MenC and Hibb vaccination. The 
findings have been used to inform communication to 
GPs and practice nurses as well as the development of 
new information materials for parents which highlight 
the importance of completing five GP visits to ensure 
children are fully vaccinated.
In 2010, national uptake rates at 24 months for all 
vaccines were below the target rate of 95%.  However, 
among the HSE Areas (based on available data) the 
target uptake of 95% was reached or exceeded for 
those at 24 months during 2010 in two HSE Areas for D3, 
T3, P3, Hib3 and Polio3 and in three HSE Areas for HepB3.  
Among the LHOs (based on available data), the target 
uptake of 95% was reached or exceeded for those 
at 24 months during 2010 for D3, T3, P3, Hib3, Polio3 
and HepB3 in 15 LHOs and for all vaccines in one LHO 
(Roscommon).  Roscommon reached or exceeded the 
target of 95% and had the highest uptake for D3, T3, P3, 
Hib3, Polio3, HepB3, MenC2 and PCV2 at 12 months and 
for all vaccines at 24 months.  
The 2010 immunisation uptake rates for each LHO are 
presented in appendix 2.  The immunisation reports for 
Quarters 1 to 4 2010 are available on the HPSC website 
in Topics A-Z under the heading vaccination. 
1.  Rebolledo J, Cotter S, Gee S, Corcoran B (on behalf of the HSE 
MenC3 decline investigation team). Study examines decline in 
MenC3 and Hib booster vaccination uptake.  Epi-Insight 2011; 
12(10).  Available on-line: http://ndsc.newsweaver.ie/epiinsight/1vgn
wz0l64n1cyivlh5r33?a=1&p=17742945&t=17517774 
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Figure 3. D3 (A), Hibb (B), MenC3 (C) and MMR1 (D) immunisation uptake rates (%) in those 24 months of age in 2010 by Local 
Health Office (LHO)
2010 data are incomplete, please see text for details
LHOs in Dublin are highlighted separately for ease of viewing
North Lee and South Lee are separate LHOs, however, their combined (labelled NSL on the map) immunisation uptake rate is reported here
Please see appendix 2.3 to translate LHO codes
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9.1.1 Clostridium difficile-associated Disease 
New cases of C. difficile-associated disease
New cases of C. difficile-associated disease (CDAD) 
in persons two years or older have been notifiable in 
Ireland under the disease category “acute infectious 
gastroenteritis” (AIG) since May 2008. Recurrent CDAD 
cases are not currently notifiable.  
There were 4,290 notifications of acute infectious 
gastroenteritis (AIG) in 2010, of which 1,696 (39.5%) 
were new CDAD cases.  All cases were laboratory 
confirmed. This represents a national crude incidence 
rate (CIR) of 40.0 new CDAD cases per 100,000 
population, a decrease of 10.5% from 44.7 cases per 
100,000 population reported in 2009 (Table 1). Regional 
variation was observed in the incidence of CDAD 
(Table 1). However, this most likely reflects differences 
in laboratory diagnosis and reporting rather than true 
variation in disease incidence. Identification of seasonal 
patterns in the CIDR data is hindered by late and batch 
notifications from laboratories.
As in 2009, the majority of new cases were in female 
patients (59%) and in older age groups.  The mean age 
of cases was 69 years (range 2-103 years) (Figure 1) with 
1,191 cases (70%) reported in patients over 65 years.  
Of note, the 75-84 year age group had the highest 
number of cases (n=479), representing 40% of the over 
65 year age group. 
The majority of CDAD cases (67%) were notified by 
healthcare facilities. Patients classified as ‘hospital 
inpatient’ accounted for 73% of all such cases notified, 
12% were classified as general practice patients, 3% as 
hospital outpatients or day patients, 3% as Emergency 
Department patients, 2% as ‘other’ and 7% as either 
‘not specified’ or ‘unknown’. However, this data does 
not provide information on the origin or onset of 
CDAD, rather it represents the location of the patient at 
the time of CDAD diagnosis.  Information on the origin 
and onset of CDAD cases is collected as part of the 
enhanced surveillance system. 
C. difficile outbreaks
In 2010, five C. difficile outbreaks, all healthcare-
associated and involving 31 patients, were notified 
(Table 2). One was linked to a hospital, three to nursing 
homes and one to a long-term care facility.
9.1.0  Healthcare-associated infections 
(HCAI)
Key Points
•  In 2010, 1,696 new cases of Clostridium difficile-
associated disease (CDAD) were notified.  This 
represents a national crude incidence rate of 40.0 
new cases per 100,000 population, a decrease of 
10.6% from 2009
•  Of the 1,696 new CDAD cases, 1,191 (70%) were 
reported from patients aged over 65 years
•  In the voluntary enhanced surveillance scheme, 
1,185 CDAD cases [1,094 (92%) new and 91 (8%) 
recurrent] were reported from 33 hospitals. The 
national CDAD incidence rate was 2.8 cases per 
10,000 bed days used.  Twenty percent of all 
CDAD cases were associated with the community, 
an increase from 13% in 2009. As in 2009, 10% of 
CDAD cases were associated with nursing homes. 
While the majority of patients experienced onset 
of symptoms in healthcare facilities, 27% had 
onset of symptoms in the community, an increase 
from 23% in 2009
•  Of the 49 specimens for which ribotyping data 
were available (from five hospitals), the most 
common ribotypes reported were; 078 (n=8, 
16%) followed by 013, 014, 015, 027 and 106 
(n=4, 8% each) 
C. difficile enhanced surveillance
Although the notifiable CDAD data provides important 
preliminary information on the burden of new cases 
of CDAD in Ireland, it represents an underestimate of 
the true burden of CDAD, as recurrent CDAD cases 
are not captured and it does not capture information 
on the origin or onset of CDAD. National collation of 
C. difficile enhanced surveillance commenced on a 
voluntary basis on 1st August 2009. Information on case 
type, origin, onset and severity of CDAD is collected 
using European Centre for Disease Control (ECDC) 
case definitions. By the end of 2010, 33 hospitals 
participated in the voluntary enhanced surveillance 
scheme, comprising 30 acute public hospitals (seven 
tertiary, 21 general, two specialist hospitals) and three 
private hospitals. 
In 2010, 1,185 cases of CDAD were reported to the 
enhanced surveillance scheme. Of these, 1,094 (92%) 
were classified new CDAD cases (representing 65% of 
all the new CDAD cases reported through the notifiable 
AIG category) and 91 (8%) recurrent. Sixty percent 
(n=711 cases) originated within the reporting healthcare 
facility which corresponds to an overall national CDAD 
incidence rate of 2.8 cases per 10,000 bed days used. 
This rate is based only on the number of cases that 
originated in the participating healthcare facility and 
is calculated using data from the Business Intelligence 
Unit, Corporate Planning and Corporate Performance 
(CPCP) at the Health Services Executive for acute public 
hospitals and directly from acute private hospitals. 
There was a wide range in the incidence of CDAD 
among participating hospitals (range, 0 – 9.1 cases per 
10,000 bed days used; median, 2.3). Tertiary hospitals 
showed a higher median incidence rate (CDAD rate = 
2.8, n=7) compared to general hospitals (CDAD rate 
= 1.7, n=26). These differences may reflect differences 
in patient case mix, C. difficile ribotypes, laboratory 
testing protocols, antimicrobial policies and surveillance 
resources between hospitals. No obvious seasonal 
trend is distinguishable at present.
Severe CDAD
As for notifiable CDAD, most cases reported through 
the enhanced surveillance scheme were female (56%) 
and in the over 65 age group (72.5%). Seventeen (1.6%) 
severe cases were reported: four patients requiring 
surgery and intensive care unit (ICU) admission, one 
requiring surgery only and 12 requiring ICU admission 
without surgery. Forty-nine deaths were reported, of 
which three were directly attributed to CDAD and 33 
were not directly attributed to CDAD. The cause of 
death for the remainder was either unknown or not 
specified.
Onset & origin of CDAD
Onset: Patient location when symptoms of CDAD 
commenced
Seventy-three percent (n=862) had onset of CDAD 
symptoms in a healthcare facility – healthcare onset 
(HCO), with 82% (n=707) of these occurring in the 
reporting hospital, 5% (n=46) in another hospital and 
10% (n=85) in a nursing home. The remainder (n=22) 
had onset in another unspecified healthcare facility or 
unknown. However, 27% (n=321) of all CDAD cases had 
onset of symptoms in the community, an increase from 
23% in 2009.  
Origin
The majority of cases, 77% (n=911), were healthcare-
associated:
•  90% (n=824) of these patients experienced onset 
of CDAD symptoms at least 48 hours following 
admission to a healthcare facility (healthcare-onset, 
healthcare-associated)
•  9% (n=86) patients experienced symptom onset in 
the community within four weeks of discharge from 
a healthcare facility (community-onset, healthcare-
associated)
Of the 911 healthcare-associated CDAD cases, 80% 
(n=725) CDAD originated in the reporting hospital, 
7% (n=66) in other hospitals and 10% (n=91) in 
nursing homes, with the remainder (n=29) in another 
unspecified healthcare facility or unknown.
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Figure 1. Age and Sex distribution of CDAD in Ireland, 2010 
(Source, CIDR)
*Rates calculated using 2006 census data  
Figure 2. Origin and Onset of CDAD Cases, 2010 
(Source, C. difficile Enhanced Surveillance System)
(HCA: Healthcare-Associated, CA: Community-Associated)
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Origin of CDAD by case type 
Healthcare-onset Community-onset 
Of the 20% (n=234) CDAD cases classified as 
community-associated:
•  89% (n=208) patients experienced onset of CDAD 
symptoms while outside a healthcare facility and 
without a history of discharge from a healthcare facility 
within the previous 12 weeks
•  11% (n=26) patients experienced symptom onset 
within 48 hours of admission to a healthcare facility, 
without residence in a healthcare facility within the 
previous 12 weeks 
The origin of 3% (n=40) of cases was unknown, where 
onset of symptoms occurred within 4-12 weeks of a 
patient being discharged from a healthcare facility.
C. difficile PCR ribotyping
Of the 49 samples (from five hospitals) for which 
ribotyping data were available, the most common 
ribotypes reported were: 078 (n=8, 16%) and 013, 014, 
015, 027 and 106 (n=4, 8% each).  In one hospital, all 
isolates of healthcare-associated CDAD from Q2 to Q4 
2010 were typed. The most common ribotypes were 
078 (n=5), 013 and 014 (n=4 each), and 015 (n=3).
In March 2009, national C .difficile ribotype data was 
collected for the first time as part of a one month pilot 
study.  In addition to highlighting the burden of CDAD 
outside acute care facilities, this study demonstrated the 
overall predominance of ribotype 027 at this time (with 
over 40% of these originating from one hospital).
Conclusion
The collation of national data on C. difficile through 
notification of new CDAD and the enhanced CDAD 
surveillance system of both new and recurrent case has 
provided a valuable insight into the burden of CDAD in 
Ireland. There was decline in the number of new CDAD 
cases reported in 2010 compared to 2009.
In 2010, 8% of all CDAD cases reported through the 
enhanced surveillance scheme were recurrent infections 
compared with 14% in 2009. This may represent an 
improvement in infection prevention and control 
strategies and management of patients with CDAD.  
However, it may also reflect changes in laboratory 
testing protocols. Recurrent CDAD is difficult to manage 
clinically and can result in severe infection, places a 
burden on limited isolation resources and results in 
significant patient morbidity. Therefore, knowledge of 
the burden of recurrent CDAD in Ireland is essential to 
help guide preventative strategies.
During 2010, 20% of all CDAD cases were associated 
with the community, an increase from 13% in 2009 
(70 of 522 cases) and 8% were associated with 
nursing homes, which is the same as in 2009 (42 of 
522 cases). Moreover, 27% of all cases had onset of 
symptoms in the community compared with 23% in 
2009. This indicates that C. difficile is not confined to 
hospitals and is increasingly common in community 
and nursing home settings.  It is essential that CDAD is 
considered in the differential diagnosis of all patients 
presenting with diarrhoea and that specimens are sent 
in a timely fashion for laboratory diagnosis.  Patients 
with CDAD in healthcare facilities must be isolated 
with contact precautions as outlined in national 
guidelines: http://www.hpsc.ie/hpsc/A-Z/Gastroenteric/
Clostridiumdifficile/Publications/File,2936,en.pdf.  
All healthcare professionals must promote practices 
known to reduce the incidence of CDAD including; 
compliance with infection prevention and control 
measures, awareness of local CDAD surveillance 
data and prudent use of antimicrobials. The national 
guidelines for antimicrobial stewardship in hospitals 
in Ireland are available at: http://www. hpsc.ie/
hpsc/A-Z/MicrobiologyAntimicrobialResistance/
gyforthecontrolofAntimicrobialResistanceinIrelandSARI/
AntimicrobialStewardship/Publications/
Table 1.  Number of notified cases, crude incidence rate of 
CDAD in Ireland by HSE area, 2010, and total number with 
crude incidence rate for 2009 (Source, CIDR)
* Rates calculated using 2006 census data 
Table 2. C. difficile outbreaks reported in Ireland in 2010 by 
HSE area (Source, CIDR)
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HSE Area No. of cases *CIR incl. 95% C.I.
East 681 45.4 (42.1-48.9)
Midlands 47 18.7 (13.4-24.0)
Mid West 95 26.3 (21.0-31.6)
North East 50 12.7 (9.2-16.2)
North West 90 38 (30.5-46.3)
South East 252 54.7 (48.1-61.7)
South  269 43.3 (38.1-48.5)
West 212 51.2 (44.5-58.3)
Total 2010 1696 40.0 (38.1-41.9)
Total 2009 1895 44.7 (42.8-46.8)
HSE Area Outbreak location Total number ill
East Residential Home 11
Midlands Residential Home 2
South Residential Home 6
South Hospital 2
North West Community Hospital/ Long 
Stay Unit
10
9.1.2 HCAI Surveillance 
9.1.2.1 National Pilot Study on Catheter-Related 
Infection in Irish Critical Care Units 
Ongoing surveillance of catheter-related infection 
(CRI) has been carried out in many countries, such 
as the United States for several years. Interventions 
such as use of central venous catheter (CVC) insertion 
checklists, CVC maintenance care bundles and 
ongoing promotion of strict adherence to Standard 
Precautions, including hand hygiene compliance, have 
been implemented and shown to impact positively on 
reduction of CRI. There is currently no national CRI 
surveillance programme in Ireland. 
A multidisciplinary steering group convened in 2010 
to plan a three-month pilot study of CRI in critical 
care units in Ireland. This was a collaborative study 
between the Intensive Care Society of Ireland (ICSI), 
Health Protection Surveillance Centre, the Irish 
Critical Care Trials Group (ICCTG) and the Health 
Service Executive Critical Care Programme (HSE-
CCP). Funding was provided by HSE for a 0.5 whole 
time equivalent local CRI audit nurse to collect data 
in each participating unit, and jointly by the ICSI and 
MSD Pharmaceuticals for a national data manager 
to collate the study results. Following completion 
of the study, all participating critical care units were 
issued with a local unit report and a national report 
was also prepared. The complete national report is 
available on the HPSC website: http://www.hpsc.
ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/
InfectionControlandHAI/Surveillance/20102011National
Catheter-RelatedInfectionPilotStudy/File,12711,en.pdf
In 2010, the Strategy for the Control of Antimicrobial 
Resistance in Ireland (SARI) published national guide-
lines for prevention of intravascular catheter-related 
infection in Ireland. These are available at http://www.
hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/
InfectionControlandHAI/IntravascularIVlines/Publica-
tions/File,4115,en.pdf
Ongoing surveillance of CRI is a key recommendation of 
the Irish national guidelines.
Key Points
•  This three-month pilot study took place between 
November 1st 2010 and January 31st 2011 with 
nine participating hospitals incorporating 11 
critical care units
•  Valid surveillance forms were received for 614 
patients incorporating 1209 temporary CVCs
•  The percentage of patients who had a CVC 
inserted varied greatly between the units (49% - 
96%) with a national CVC utilisation figure of 71%
•  The median age of patients was 66 years with a 
male predominance (60%)
•  The majority of CVCs were inserted in the ICU 
(63%), followed by the operating theatre (22%) 
and other location (15%)
•  The most common anatomical site of CVC 
insertion was the internal jugular vein (72%), 
followed by the femoral (17%) and subclavian 
(11%) veins
•  84% of CVCs were inserted electively compared 
with 13% of CVCs which were inserted under 
emergency circumstances
•  Nationally, there were seventeen CRIs identified 
in the 1209 CVCs, denoting a national CRI rate of 
2.2 infections per 1000 CVC days (95% CI: 1.3 - 
3.5). CRI rates for individual units ranged from 0.0 
to 8.1 CRIs per 1000 CVC days
•  The most common causative pathogen of CRI 
was coagulase-negative staphylococci, which 
was associated with six CRIs (35%), followed by 
Candida albicans which was associated with four 
CRIs (24%)
•  Development of a CRI was associated with a 
longer ICU stay and patients who developed a 
CRI had more CVCs inserted and more CVC days 
than the patients without a documented CRI
•  The CRI rate for CVCs inserted in emergency 
circumstances was 3.9 per 1000 CVC days 
compared to a rate of 2.0 for CVCs that were 
inserted electively
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Key Points
•  In 2010, 33 ICUs participated in the study
•  Level 2/3 ICUs (n = 19) having both ICU and high 
dependency unit patients or a variable combination of 
these groups
•  Level 3 ICUs (n=14) having ICU patients only
•  ICU bed occupancy and isolation room occupancy 
rates were high in both the level 2/3 (87% and 84%, 
respectively) and level 3 ICU groups (90% and 87%, 
respectively)
•  Large differences were reported in single room 
resources; four of the ICUs did not have any single 
rooms and 36% fell below the recommendation of 
one single room to every four ICU beds as set out in 
the 2005 national MRSA guidelines. While all single 
rooms were equipped with hand wash basins, only 
45% had anterooms
•  Only four of the ICUs (12%) could successfully isolate 
all of their MRSA patients when surveyed. Level 2/3 
ICUs could isolate on average 61% of MRSA patients 
surveyed while level 3 ICUs could isolate 82%
•  All participating ICUs screened patients for MRSA 
colonisation on admission
•  The prevalence of MRSA in level 2/3 ICUs was 8.2% 
(range = 1.9% – 22.4%, median = 10.2%) and in level 
3 ICUSs was 9.3% (range = 1.8% - 18%, median = 
10.1%). The prevalence of MRSA was significantly 
higher in level 3 ICUs compared to the level 2/3 group 
in 2008 and 2009 but no significant difference was 
reported in 2010 
•  Due to difference in patient case-mix, level 3 ICUs 
tend to care for a more complex patient population 
with a higher risk of acquiring MRSA prior to ICU 
admission and post admission through increased 
intensity of care.  The weekly proportion of MRSA 
that were ICU-acquired was 0.7% in level 2/3 ICUs in 
2010 (range = 0 - 3.9%, median = 0.64%) and 0.7% in 
level 3 ICUs (range = 0 – 1.4%, median = 0.9%).  The 
majority of ICUs (88%) reported a proportion of MRSA 
acquisition of <1.5%, therefore figures on MRSA 
acquisition were low in the majority of ICUs 
9.1.2.2 MRSA in Intensive Care Units Prevalence 
Study
The meticillin-resistant Staphylococcus aureus (MRSA) 
in intensive care unit (ICU) prevalence study began 
in April 2008. The primary objective of the study has 
been to provide a weekly snapshot of MRSA in the 
critical care setting using methodology requiring 
minimal additional resources. Participants complete 
and return a weekly questionnaire to capture data 
on MRSA prevalence, transmission, bed occupancy 
and isolation capabilities, with quarterly feedback of 
results to participants. Participating ICUs were stratified 
according to ICU type. The complete national report 
is available on the HPSC website:  http://www.hpsc.
ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/
peanAntimicrobialResistanceSurveillanceSystemEARSS/
ReferenceandEducationalResourceMaterial/
SaureusMRSA/MRSAinICUPrevalenceStudy/Reports/
File,12638,en.pdf
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Key Points
•  In 2010 the median rate of AHR consumption 
decreased to 20.3 litres per 1,000 bed-days used, 
from 22.1 in 2009. This represents an 8% drop in 
national consumption since 2009 but is still a 94% 
overall rise in consumption since surveillance began in 
2006 (Table 1)
•  The increase between 2006 and 2009 could be 
explained in part by the increased importance 
placed on hand hygiene since the publication of the 
national hand hygiene guidelines by the Strategy for 
the Control of Antimicrobial Resistance in Ireland 
(SARI) Infection Control Subcommittee in 2005, 
local hospital initiatives (including participation in 
the WHO ‘Clean Hands Save Lives’ campaign), and 
national information campaigns aimed at the public 
and healthcare workers. The overall level of AHR 
consumption is comparable to other successful hand 
hygiene campaigns internationally
•  In 2010, 42 hospitals submitted data, a decrease 
from 49 in 2009 (Table 1) which may be a factor in the 
decrease in consumption. However, the reason for 
the decrease in consumption seen in 2010 is unclear. 
Ongoing surveillance is required to see if this trend 
continues
•  The wide variation in levels of AHR consumption 
between hospitals (7.6 - 36.4 litres per 1,000 bed-days 
used)) may, in part, be explained by differences in 
methodologies for collecting and reporting the data, 
and difference in types and range of hand hygiene 
agents used. The main limitation of this surveillance 
system is that the data refer to the use of AHR only, 
and do not take account of other hand hygiene 
agents (e.g. medicated liquid soap) that may also 
be in use in hospitals. In addition, the data do not 
give an indication of the frequency with which hand 
decontamination is carried out at a given hospital nor 
distinguish between who has used the AHR (visitor, 
patient or healthcare worker)
•  There is clearly a need for better standardisation of 
data collection and reporting. However, even with 
better standardisation, the volume of AHR consumed 
remains a crude measure of hand hygiene activity 
and additional process and outcome measures are 
required
•  With this in mind, HPSC in conjunction with the 
Infection Prevention Society, developed and piloted 
a national hand hygiene observation audit tool 
and standard operating procedure for use in acute 
hospitals in 2010.  This is due to be adapted and 
rolled out in 2011 with a programme of hospital 
hand hygiene auditor training in advance of national 
collation of hand hygiene compliance in hospitals
9.1.2.3 Alcohol Hand Rub Surveillance
Hand hygiene is one of the most important ways 
to prevent HCAI.  Alcohol hand rubs (AHR) are an 
effective and rapid method of hand hygiene, and 
recommended as the primary means of hand hygiene 
in national and international guidelines. Measurement 
of hospital-level consumption of AHR, expressed as 
volume used per 1,000 bed-days, has been shown to 
correlate with overall hand hygiene activity in hospitals. 
It is a recommended process measure of hand hygiene 
activity by both the World Health Organisation (WHO) 
and the US Centers for Disease Control & Prevention 
(CDC). 
HPSC has collated data on AHR consumption in 
acute public hospitals in Ireland since 2006. The data 
collected represent the total volume of AHR delivered 
or dispensed to wards, clinics and other hospital areas 
per quarter, excluding that used for pre-operative 
surgical hand hygiene. The rate of usage per hospital 
is calculated as the total volume of AHR consumed in 
litres per 1,000 bed-days used (Table 1). 
Further information may be found at: http://www.hpsc.
ie/hpsc/A-Z/Gastroenteric/Handwashing
Table 1. National data on AHR consumption in acute public 
hospitals in Ireland by year, 2006 – 2010.
 2006 2007 2008 2009 2010
Number of 
participating 
hospitals
52 50 50 49 42
National 
consumption rate*
10.5 15 18.7 22.1 20.3
Range for 
participating 
hospitals in litres 
per 1,000 bed-days 
used
0.5 - 
29.0
5.2 - 
47.1
5.9 - 
52.5
7.8 - 
48.0
7.6 - 
36.4
* The consumption rate is the total volume of AHR consumed in the defined 
time period in litres per 1,000 bed-days used. The national rate represents the 
median of the national sample for each time period
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9.1.2.4 Healthcare-Associated Infections in European 
Long Term Care Facilities
The European Centre for Disease Prevention and 
Control (ECDC) coordinated a point prevalence 
survey on healthcare-associated infection (HCAI) and 
antimicrobial use in European long term care facilities 
(LTCFs) in summer 2010 (HALT survey).  The HPSC 
was the national coordinating centre for Ireland.  
Seven hundred and twenty-two LTCFs in 25 European 
countries participated. Participating LTCFs were 
asked to survey residents on one day only, thereby 
providing a snapshot of HCAI and antimicrobial use 
on that particular day. ECDC provided the information 
technology tool that enabled participating LTCFs to 
receive immediate feedback of their own results so 
that they could commence evaluating them and plan 
further preventive programmes.  In September 2010, 
HPSC circulated a summary report to participants. 
The national report for the Republic of Ireland was 
published in November 2010. 
http://www.hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobial 
Resistance/InfectionControlandHAI/Surveillance/
HCAIinlongtermcarefacilities/HALTproject2010/Results/
File,4723,en.pdf
Summary
 Key Points
•  In 2010, the total number of LTCFs in Ireland was 598 
(453 (75%) private and 145 (25%) public) (Source: HSE 
and Nursing Homes Ireland).  Therefore, 11.3% of all 
Irish LTCFs (42% public, 1.7% private) participated
•  In Ireland 4,170 residents in 69 LTCF (61 in public and 
eight in private ownership) participated in HALT (Table 
2). Thirty-nine percent (n=27) were classified as general 
nursing homes, 10% (n=7) as catering for intellectually 
disabled clients and the remaining 51% (n=35) provided 
a mix of care, including residential, psychiatric, 
physically disabled, rehabilitation, palliative, sanatorium 
or other
•  The mean number of beds per LTCF was 67 with a 
range of 10 to 382 beds and a median of 47.  Only 27% 
of the beds were in single rooms
•  A third of residents (34.3%) were aged over 85 years 
and over half were disorientated (50.6%) with impaired 
mobility (50.4%)
•  Ninety-nine residents had 102 infections (HCAI 
prevalence of 2.4%, range 0% - 14.8%, median 1.7%) 
as defined by the McGeer definitions. When physician 
diagnosis was included as a criterion in each category 
of infection (adapted McGeer), 149 residents were 
categorised with 156 infections (HCAI prevalence of 
3.7%, range 0% - 22.2%, median 2.7%). Seven patients 
had more than one HCAI type present 
•  The three most common infection types were urinary 
(62 residents, 40% of HCAI), respiratory (43 residents, 
28%), and skin infections (31 residents, 20%) as shown 
in Table 3
•  Antimicrobials were prescribed for 426 (10.2%) 
residents. Antimicrobials were prescribed for the 
treatment of infection in 245 residents, (57.8%), for 
prophylaxis in 179 residents, (40.2%), and for an 
unspecified reason in nine residents (2%)
•  The most frequently prescribed antimicrobials 
were trimethoprim (21.6%), co-amoxiclav (19%), 
nitrofurantoin (13.2%), flucloxacillin (7.7%) and 
ciprofloxacin (4.6%). For 245 residents (5.9%) on 
therapeutic antimicrobials, the most common 
indications included respiratory infection (92), urinary 
infection (84)) and skin infection (57). Of the 179 (4.3%) 
residents on prophylactic antimicrobials, the majority 
were for the prevention of UTI (89% of all prophylactic 
antimicrobials prescribed). Indeed, of all antimicrobials 
prescriptions for the urinary tract, 65.9% were for 
prophylactic use. Trimethoprim was the most frequently 
prescribed prophylactic antimicrobial. Seventeen 
residents (10.5%) on UTI prophylaxis had a urinary 
catheter in situ
•  The study provides an important baseline on HCAI 
and antimicrobial consumption in Irish LTCFs to inform 
future preventative strategies. The prevalence of 
HCAI risk factors in the population surveyed reflects 
a high dependency level in Irish LTCFs. The low rate 
of pressure sores (2.9%) and urinary catheter use 
(5.6%) despite a high proportion of incontinent and/
or immobile residents reflects high quality nursing and 
medical care provided within in the facilities 
•  The antimicrobial use reported in this study (10.2%), 
corresponds with the 2009 Irish ESAC results (overall 
prevalence 10.9%) which is higher than the European 
overall prevalence of 5.9%
•  The proportion of antimicrobials that were prescribed 
for prophylactic use (42%) is of concern, specifically 
prophylaxis of UTI in catheterised patients highlighting 
the need for national antimicrobial stewardship 
guidelines for LCTFs and education of prescribers
•  Participation in this study was the first opportunity 
for Irish LTCFs to undertake HCAI surveillance using a 
standardised protocol. The level of participation and 
enthusiasm demonstrated by staff in all participating 
LTCFs reflects their commitment to evaluating and 
improving the care delivered to their residents
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Table 2. Breakdown of LTCFs by region and ownership
Category Count of LTCF-s
Total residence 
surveyed
Median residents 
surveyed/LTCF 
(range)
Median single 
rooms/100 beds 
(range)
Median bed 
occupancy 
By Ownership
Public 61 3706 38 (9 - 359) 16 (0 - 80) 93
Private 8 464 54 (42 - 112) 61 (30 - 87) 93
By HSE Region
Dublin North 
East 7 520 51 (10 - 159) 17 (9 - 41) 87
Dublin Mid-
Leinster 18 1555 60 (12 - 359) 15 (0 -77) 94
South 9 717 60 (19 - 157) 13 (1 - 60) 90
West 35 1378 29 (9 - 148) 19 (0 - 87) 93
National 69 4170 42 (9 - 359) 17 (0 - 87) 93
Table 3. HCAI prevalence by infection type using the Adapted McGeer 
definition
HCAI Type
Number of 
infections
Percent
HCAI 
Prevalence*
Urinary Tract Infection 62 39.7 1.5
Respiratory Tract Infection 44 28.2 1
Cold 15 9.6 0.4
Flu 0 0 0
Pneumonia 6 3.8 0.1
Other 23 14.7 0.6
Eye, Ear, Nose, Mouth 11 7.1 0.3
Eye 6 3.8 0.1
Ear 2 1.3 0
Nose 0 0 0
Mouth 3 1.9 0.1
Skin 31 19.9 0.7
Cellulitis 29 18.6 0.7
Fungal 2 1.3 0
Herpes 0 0 0
Scabies 0 0 0
Gastrointestinal Infection 8 5.1 0.2
Systemic 0 0 0
Primary Bloodstream 
Infection 0 0 0
Unexplained febrile episode 0 0 0
Total 156 100 3.6
The HCAI prevalence of infection is calculated as the number of infected 
residents per total eligible residents. Please note that seven residents had 
more than one infection.
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Ireland participates in the European Surveillance of 
Antimicrobial Consumption (ESAC) project which 
aims to collect systemic antimicrobial usage data from 
the outpatient (ambulatory, community or primary 
care) setting and from the hospital (inpatient) setting. 
Consumption is measured in Defined Daily Dose (DDD), 
which is the assumed average maintenance dose per 
day for a drug used for its main indication in adults. 
Rates are calculated in DDD per 1000 inhabitants per 
day (DID) for outpatients and DDD per 100 bed-days 
used (DBD) for inpatients. 
Outpatient Antimicrobial Consumption
The overall outpatient antimicrobial consumption for 
Ireland in 2010 was 20.3 DID, a 2% decrease from 
the previous year’s rate of 20.8 DID. In the latest 
ESAC annual yearbook (2009), the reported range of 
outpatient antimicrobial usage was 10.2 DID (Romania) 
to 38.6 DID (Greece). The median for all 32 European 
countries with reliable data was 19.0 DID and the 
interquartile range was 15.2 to 23.1 DID. 
Since outpatient antimicrobial usage in Ireland has 
been 18.0 – 22.6 DID for the last ten years, the overall 
rate in Ireland is mid-to-high in Europe.  The peak 
use was in 2007 and the rate has now declined to a 
level similar to 2004. There is still marked seasonal 
fluctuation in use, with the higher levels corresponding 
to increased influenza activity. January of 2010 had the 
lowest monthly use since July 2001, most likely due to 
unusually cold weather leading to limited distribution 
and demand of drug products in community care. 
Consumption for the rest of the year was in line with 
expected use, as modelled on previous years’ trends 
and seasonality (Figure 1).
In Ireland in 2010, outpatient consumption of 
penicillins accounted for the largest class used (52% 
of total at 10.7 DID), followed by macrolides (18%, 
3.7 DID), tetracyclines (13%, 2.6 DID), cephalosporins 
(6%, 1.2 DID), sulphonamides (6%, 1.1 DID) and 
fluoroquinolones (5%, 0.9 DID). Other antimicrobial 
classes accounted for less than 1% of total use.
Penicillin in combination with beta-lactamase 
inhibitor (such as co-amoxiclav) accounted for the 
largest proportion of penicillins (52%). There was a 
dramatic increase in the consumption of this group of 
antimicrobials between 2000 (3.2 DID) and 2008 (5.6 
DID). However, the rate has declined slightly since 
then (5.5 DID in 2010 and 2009 from 5.6 DID in 2008). 
Broad-spectrum penicillin (such as amoxicillin) usage 
was high (3.2 DID) but showed a slight decline.
There was considerable variability in the overall 
outpatient antimicrobial usage at county level (16.5 to 
28.9 DID) as shown in Figure 2. 
Hospital Antimicrobial Consumption
Forty-three public acute hospitals provided valid 
antimicrobial usage data for 2010. The median rate of 
antimicrobial consumption was 79.3 DBD (range 23.6 – 
9.2.0 Antimicrobial Consumption 
Key Points
•  The overall outpatient antimicrobial consumption in 
Ireland for 2010 was 20.3 DID, a 2% decrease from 
2009. This rate is mid-to-high in comparison with 
other European countries
•  Penicillins accounted for the largest class of 
outpatient antimicrobials used (52%), followed by 
macrolides (18%), tetracyclines (13%), cephalosporins 
6%), sulphonamides (6%) and fluoroquinolones 5%)
•  Forty-three public acute hospitals provided valid data 
for 2010
•  The median rate of hospital antimicrobial 
consumption in Ireland for 2010 was 79.3 DBD (range 
23.6 – 124.9 DBD). This represents a 4% increase on 
2009 hospital antimicrobial consumption. This rate 
is mid-to-high in comparison with other European 
countries
•  Penicillins accounted for the largest class of hospital 
antimicrobials used (40 DBD), followed by macrolides 
(10.8 DBD)
•  The fluoroquinolones was the only class of 
antimicrobials where a reduction in hospital 
consumption of 6% was recorded between 2009 and 
2010 to 5.7 DBD
•  Twenty-eight hospitals participated in a point 
prevalence study in 2010, facilitated by the Irish 
Antimicrobial Pharmacists Group. The median 
prevalence of antimicrobial use in Irish hospitals was 
36.5%, an increase from 34.4% in 2009
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124.9 DBD). This was a 4% increase from the previous 
year’s revised rate of 76.0 DBD. These levels are again 
mid-to-high in Europe.
The largest group of antimicrobials, penicillins, 
which represent 51% of all inpatient antimicrobial 
usage, showed an increased in consumption by 6% 
in 2010 to 40.0 DBD. The use of fluoroquinolones 
such as ciprofloxacin (representing 7% of all inpatient 
antimicrobial usage) decreased by 6% in 2010 to 5.7 
DBD. Fluoroquinolone usage has been decreasing 
since 2007 and is the only group of antimicrobials used 
in hospital care that showed a decline. Consumption 
of cephalosporins, monobactams and carbapenems 
(representing 9% of all inpatient antimicrobial usage) 
increased by 4% in 2010 to 6.9 DBD. Consumption 
of glycopeptides such as intravenous vancomycin, 
imidazoles such as intravenous metronidazole 
and nitrofurans (representing 10% of all inpatient 
antimicrobial usage) increased by 4% in 2010 to 8.1 
DBD. Consumption of erythromycin and related agents 
(representing 14% of all inpatient antimicrobial usage) 
increased by 3% in 2010 to 10.8 DBD. Other less 
frequently used agents in hospitals are tetracyclines, 
sulfonamides/trimethoprim, aminoglycosides and 
non-J01 systemic antimicrobials; collectively these 
drugs, representing 10% of all inpatient antimicrobial 
usage, increased by 1% in 2010 to 7.6 DBD. 
Hospital function was the main driver for the differences 
in the rates of antimicrobial consumption between 
hospitals. The rates for regional/tertiary and general 
hospitals (medians 81.5 and 81.3 DBD) centred just 
above the median for Ireland, while the rate for single 
specialist facilities (maternity, orthopaedic or paediatric) 
was much lower (median 33.9 DBD). The lower median 
consumption in single speciality hospitals probably 
reflects differences in case-mix, compared to other 
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Figure 2. Outpatient antimicrobial consumption in Ireland by 
county, in DDD per 100 inhabitants per day for 2010.
Figure 1. Outpatient antimicrobial consumption in Ireland by month, 2000-2010. 
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hospitals. However it may also reflect the fact that 
DDDs are based on adult dosing and may therefore 
underestimate antimicrobial consumption in paediatric 
settings. 
There was continued reduction in the proportionate use 
of intravenously administered specific antimicrobials 
(those with good oral bioavailability) over total use, from 
a median of 8.1% in 2009 to 7.5% in 2010. This measure 
reflects patient acuity and also the hospital function. 
The change in the level of this measure may reflect local 
antimicrobial stewardship interventions.
Hospitals Care Point Prevalence Survey 2010
Twenty-eight hospitals participated in a point prevalence 
study in June and July of 2010 which was facilitated 
by the Irish Antimicrobial Pharmacists Group (IAPG). 
Clinical records on 6,414 patients were reviewed, of 
whom 2,309 received systemic antimicrobial therapy. 
The median prevalence of antimicrobial use in Irish 
hospitals was 36.5% compared with 34.4% in 2009. 
The data collected included patient demographics, 
details of systemic antimicrobial therapy, diagnoses 
and indication, compliance with local guidelines and 
documentation of reason for therapy. In most respects 
practices in Ireland were broadly in line with other 
European hospitals in previous years, though the 
prevalence of antimicrobial use was higher in 2010. 
The increase in the number of participating hospitals 
in the 2010 study is an indication of the value of this 
methodology to monitor antimicrobial prescribing 
patterns and to identify targets for antimicrobial 
stewardship interventions. The IAPG plans to conduct a 
national point prevalence survey again in 2011.
More detailed analyses of antimicrobial usage data can 
be found on the www.hpsc.ie website, through “Topics 
A-Z”, under “ESAC”. The figures presented in this 
report may vary from previously published levels owing 
to methodological changes.
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9.3.0 Antimicrobial Resistance
Key Points
•  There were 2,170 reports of invasive E. coli infection 
submitted to the European Antimicrobial Resistance 
Surveillance Network (EARS-Net), an increase of 
5% from 2,064 reports in 2009.  Resistance to third-
generation cephalosporins (3GCs) increased slightly 
from 7.5% in 2009 to 8.3% in 2010 while extended-
spectrum beta-lactamase (ESBL)-production increased 
from 5.8% to 6.1%.  Ciprofloxacin resistance increased 
slightly from 22.3% to 23.6%. Multi-drug resistant 
(MDR) E. coli also increased from 10.4% to 11.7% over 
the same period
•  There were 1,251 reports of S. aureus bloodstream 
infection (BSI), of which 305 (24.4%) were meticillin-
resistant S. aureus (MRSA).  This represents a 
significant decrease from 27.1% reported in 2009.  
Overall, there was a 14% reduction in the number of 
MRSA BSI reports from 355 in 2009 
    For acute hospitals, the rate of MRSA BSI was 0.078 
cases per 1,000 patient bed days used, a decrease 
from 0.089 in 2009. Over the same period, the rate of 
meticillin-susceptible S. aureus (MSSA) stabilised at 
0.239 (2009, 0.237)
    Enhanced surveillance data revealed that 23% of the 
all S. aureus BSI isolates were associated with infection 
of central venous catheters (CVCs) and 6% with 
infection of peripheral venous catheters
•  There were 392 reports of E. faecium BSI compared 
with 397 in 2009.  The proportion that was 
vancomycin-resistant E. faecium (VREfm) increased 
from 38.3% in 2009 to 39.3% in 2010. MDR E. faecium 
decreased from 26.7% to 24.9% 
•  There were 326 reports of invasive K. pneumoniae 
infections compared to 323 in 2009
•  There were 314 reports of invasive S. pneumoniae 
infection compared to 356 in 2009, a decrease of 
12%.  The national rate of invasive infection was 7.4 
compared to 8.4 per 100,000 population in 2009. The 
biggest reductions in numbers of reports and rates of 
infection were seen in children 1-4 years, the target 
population for the conjugate vaccines introduced since 
September 2008
•  The proportion of penicillin-non-susceptible S. 
pneumoniae (PNSP) decreased from 20.2% in 2009 to 
18.2% in 2010; the proportion of isolates with high-
level resistance to penicillin decreased slightly from 
5.6% in 2009 to 4.8% in 2010 while intermediate level 
resistance decreased from 13.8% to 12.7%
•  Serotype data were available on 278 of 314 invasive 
pneumococcal isolates (86%) and results indicate 
good coverage for both the 23-valent polysaccharide 
(PPV23) and 13-valent conjugate (PCV13) vaccines in 
their target populations
•  There were 222 reports of invasive P. aeruginosa 
infections compared to 248 in 2009, a decrease of 10%
•  Enhanced surveillance data were provided from 
2,562 cases of invasive infection from 14 laboratories, 
representing 51% of all cases submitted to EARS-Net 
in 2010
•  See http://www.hpsc.ie for further details of EARS-Net, 
antimicrobial resistance and enhanced BSI surveillance 
in Ireland
•  European data are available at http://ecdc.europa.eu/
en/activities/surveillance/EARS-Net/Pages/Database.
aspx
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Introduction
The European Antimicrobial Resistance Surveillance 
Network (EARS-Net), previously the European 
Antimicrobial Resistance Surveillance System (EARSS), 
in Ireland collects routinely-generated antimicrobial 
susceptibility testing data on seven important bacterial 
pathogens using the EARS-Net case definition. 
Participating laboratories submit data on the “primary” 
or first isolate from blood or cerebrospinal fluid (CSF) 
per patient per quarter.  EARS-Net does not distinguish 
clinically significant isolates from contaminants and 
primarily serves as a surveillance system to measure 
national levels of antimicrobial resistance (AMR).  In 
2010, all 43 microbiology laboratories (40 by year-
end) participated in EARS-Net resulting in complete 
coverage of the Irish population.
Escherichia coli
There were 2,170 reports of invasive E. coli infection 
(2,163 from blood and seven from CSF) from 2,126 
patients, an increase of 5.1% from 2,064 reports 
in 2009.  See Table 1 for the proportion of E. coli 
isolates resistant to the four “indicator” antimicrobials/
antimicrobial classes [ampicillin, third-generation 
cephalosporins (3GCs; cefotaxime, ceftriaxone, 
ceftazidime or cefpodoxime), fluoroquinolones 
(ciprofloxacin or ofloxacin) and aminoglycosides 
(gentamicin, amikacin or tobramycin)] by year since 
2002.  
Ciprofloxacin resistance increased from 22.3% in 
2009 to 23.6% in 2010 (non-significant; Chi2=1.08, 
P=0.30).  Looking at the overall trend, the proportion 
of ciprofloxacin resistant isolates increased significantly 
between 2002 and 2008 (Chi2trend=209.5, P<0.0001) 
(Figure 1), but appears to have levelled off at 
approximately 23% over the past two years.  The 
proportion of isolates with resistance to 3GCs increased 
slightly from 7.5% in 2009 to 8.3% in 2010, with 
the proportion of 3GC-resistant isolates increasing 
significantly between 2002 and 2010 (Chi2trend=107.1, 
P<0.0001). Resistance to all aminoglycosides (including 
gentamicin) increased from 7.7% in 2009 to 9.4% in 
2010 (borderline significant; Chi2=4.2, P=0.041), with 
the proportion of aminoglycoside-resistant isolates 
increasing significantly between 2002 and 2010 
(Chi2trend=88.8, P<0.0001). 
Extended spectrum beta-lactamases (ESBLs) were 
detected in 129 (6.1%) of 2,129 isolates tested.  
Although the increase in ESBLs from 5.8% in 2009 was 
not found to be significant (Chi2=0.16, P=0.69), the 
increasing trend since 2004 (1.1%) is highly significant 
(Chi2trend=44.1, P<0.0001).  ESBLs are enzymes that 
confer resistance to most penicillins and cephalosporins 
(including 3GCs).  ESBL-producing bacteria (including 
E. coli and K. pneumoniae) are often resistant to 
other classes of antimicrobials and have emerged as 
important causes of healthcare associated infections.
Of 2,159 isolates tested against all four “indicator” 
antimicrobials, 253 (11.7%) were identified as MDR 
(defined as resistance to three or more of these), 
including 56 with resistance to all four.  The proportion 
of isolates that are MDR increased significantly 
(Chi2trend=118.2, P<0.0001) from 2.4% in 2002 when 
surveillance began. However, the increase from 10.4% 
in 2009 was not significant (Chi2=1.9, P=0.17).  
Females were approximately 1.2-times more likely to 
have an invasive E. coli infection than males (z=4.4, 
P<0.0001).  The frequency of invasive E. coli infection 
increased with age with the majority of infections 
(n=1,581; 73%) occurring in adults over 60 years.  The 
median age was 72 years (95%CI, 71-73).
Staphylococcus aureus
There were 1,251 reports of S. aureus bloodstream 
infection (BSI) from 1,207 patients, of which 305 (24.4%) 
were meticillin-resistant S. aureus (MRSA) (Table 1).  
Figure 1. Trends for E. coli – total numbers of E. coli and percentage resistance to 3GCs, 
ciprofloxacin/ofloxacin (CIP/OFX) and gentamicin/amikacin/tobramycin (GEN/AMK/TOB), 
and percentage ESBL-positive with 95% confidence intervals.
The numbers of participating laboratories by year-end are indicated above the bars
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Pathogen Year
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Number laboratories by year-end 21 27 40 41 42 44 42 43 40†
E. coli
Number of isolates
No data No data No data
741 991 1256 1445 1656 1785 1926 2064 2170
Ampicillin-R* 62.2% 61.9% 65.0% 67.6% 70.7% 68.3% 70.4% 68.7% 68.4%
3GC-R* 3.0% 2.5% 2.6% 4.1% 4.2% 6.7% 7.4% 7.5% 8.3%
ESBL-producers* 1.2% 1.3% 1.1% 2.4% 2.5% 4.1% 5.0% 5.8% 6.1%
Ciprofloxacin-R* 5.4% 9.5% 12.6% 17.3% 21.5% 22.1% 23.3% 22.3% 23.6%
Gentamicin-R* 2.7% 3.9% 5.7% 8.5% 7.7% 9.9% 10.2% 7.7% 9.4%
Gentamicin/Amikacin/Tobramycin-R* 2.9% 4.3% 6.1% 8.6% 8.6% 10.6% 11.0% 9.3% 11.8%
Imipenem/meropenem-R* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
MDR* 2.4% 3.8% 5.6% 7.7% 9.0% 11.4% 12.1% 10.4% 11.7%
Number laboratories by year-end 12 19 20 23 28 41 42 42 44 43 43 40†
S. aureus
Number of isolates 510 639 815 1042 1140 1323 1424 1412 1393 1303 1309 1251
Number Meticillin-R (or MRSA) 198 249 337 445 480 553 592 592 536 439 355 305
Meticillin-R (or MRSA) 38.8% 39.0% 41.3% 42.7% 42.1% 41.8% 41.6% 41.9% 38.5% 33.7% 27.1% 24.4%
Number VISA 0 0 0 0 0 0 0 2 1 0 0 0
VISA* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0%
Number laboratories by year-end 21 27 40 41 42 44 42 43 40†
E. faecium
Number of isolates
No data No data No data
85 135 187 224 265 330 406 397 392
Ampicillin-R* 88.9% 91.0% 95.7% 92.3% 93.9% 93.1% 95.1% 92.9% 95.6%
Vancomycin-R 11.1% 19.4% 23.2% 31.7% 37.1% 33.4% 35.7% 38.3% 39.3%
HLG-R* 16.7% 53.8% 58.0% 51.4% 44.3% 35.2% 28.1% 39.1% 39.6%
MDR* 3.7% 11.4% 18.5% 25.6% 25.6% 22.7% 16.2% 26.7% 24.9%
Number laboratories by year-end 36 39 41 42 40†
K. pneumoniae
Number of isolates
No data No data No data No data No data No data No data
217 244 310 323 326
Ampicillin-R* 97.7% 99.2% 99.7% 99.7% 99.1%
3GC-R* 10.2% 9.9% 11.4% 11.2% 10.5%
ESBL-producers* 8.6% 3.7% 7.7% 8.2% 5.0%
Ciprofloxacin-R* 15.3% 18.1% 12.8% 13.0% 10.5%
Gentamicin-R* 7.8% 9.9% 10.7% 11.1% 6.8%
Gentamicin/Amikacin/Tobramycin-R* 9.2% 11.1% 10.7% 11.1% 7.1%
Imipenem/meropenem-R* 0.0% 0.6% 0.0% 0.0% 0.0%
MDR* 11.2% 11.9% 10.6% 11.9% 8.0%
Number laboratories by year-end 12 19 20 23 28 41 42 42 44 42 43 40†
S. pneumoniae
Number of isolates 157 201 245 278 364 400 401 407 438 447 356 314
Penicillin-NS* 19.1% 12.9% 12.2% 11.5% 11.8% 10.3% 11.7% 15.7% 17.4% 23.1% 20.2% 18.2%
of which:   HLR 0.0% 3.5% 1.6% 1.4% 2.2% 1.8% 3.0% 2.9% 5.7% 6.0% 5.6% 4.8%
 Int 16.6% 8.0% 10.6% 9.7% 8.8% 7.0% 8.7% 12.5% 11.0% 16.8% 13.8% 12.7%
Erythromycin-R* 14.0% 12.0% 12.5% 12.7% 11.6% 14.4% 12.1% 16.1% 16.4% 16.7% 17.3% 15.7%
Number laboratories by year-end 21 27 40 41 42 44 42 43 40†
E. faecalis
Number of isolates
No data No data No data
168 218 242 290 294 280 301 289 298
Ampicillin-R* 8.1% 5.1% 0.8% 3.5% 4.5% 2.2% 0.7% 2.1% 2.0%
Vancomycin-R 2.4% 1.4% 1.3% 2.5% 3.7% 2.9% 3.7% 0.7% 0.3%
HLG-R* 38.5% 33.9% 41.3% 44.4% 42.4% 36.9% 30.5% 36.7% 29.7%
Number laboratories by year-end 36 39 41 42 40†
P. aeruginosa
Number of isolates
No data No data No data No data No data No data No data
128 177 199 248 222
Pipericillin/tazobactam-R* 9.4% 12.6% 9.7% 8.9% 10.0%
Ceftazidime-R* 10.6% 11.8% 8.7% 11.8% 9.2%
Imipenem/meropenem-R* 11.8% 12.2% 9.3% 10.2% 8.3%
Ciprofloxacin-R* 18.0% 22.9% 21.8% 12.1% 13.2%
Gentamicin-R* 10.2% 13.3% 9.0% 7.7% 8.7%
MDR* 9.5% 12.4% 11.1% 6.4% 6.5%
R, Resistant; NS, Non-Susceptible [includes isolates with intermediate (Int) and high-level resistance (HLR)]
MRSA, Meticillin-Resistant S. aureus; VISA, Vancomycin-Intermediate S. aureus
HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime
* Not all isolates tested
† In 2010, 3 laboratories stopped processing blood cultures, however coverage of acute hospitals remained at 100%
Table 1. Summary of EARSS data by pathogen and year, 1999-2010
This represents the lowest annual proportion since 
surveillance began in 1999.  In 2009, the proportion 
was 27.1%.  The decrease observed between 2009 
and 2010 was not significant (Chi2=2.5, P=0.11).  This 
is the fourth successive year in which a decrease has 
been observed and the overall downward trend over 
this time period is highly significant (Chi2trend=129.4, 
P<0.0001) (Figure 2).  Overall, there was a 14.1% 
reduction in the number of MRSA BSI reports compared 
with 2009 (305 vs. 355). The total number of meticillin-
susceptible S. aureus (MSSA) BSI reports levelled off in 
2010 compared to 2009 (946 vs. 954). 
Despite the decrease in numbers and proportion of 
MRSA, Ireland still had one of the higher proportions of 
MRSA in Europe in 2010 (see http://ecdc.europa.eu/en/
activities/surveillance/EARS-Net/Pages/Database.aspx 
for European data, including EARS-Net tables, charts 
and maps), but 2010 marked the first time that Ireland 
and the UK appeared in orange (with MRSA ≤25%) on 
the EARS-Net map (Figure 3). 
No MRSA isolates with reduced susceptibility to 
vancomycin were detected at the National MRSA 
Reference Laboratory.  
The MRSA rate for all acute hospitals in 2010 was 0.078 
cases per 1,000 patient bed days used, representing 
a decrease from 0.089 in 2009, while the MSSA rate 
remained relatively stable at 0.239 (2009, 0.237) 
[Note: the rates are calculated taking into account 
the denominator data (bed days used) obtained 
from the Business Intelligence Unit at the Health 
Services Executive for all acute public hospitals; and 
directly from the hospitals for private hospitals where 
available, where both numerator (MRSA numbers) and 
denominator data have been provided]. 
In patients with laboratory-confirmed S. aureus BSI, the 
probability that the infecting organism was MRSA as 
compared to MSSA was over 2-times greater in patients 
aged ≥65years than in those aged <65 years (RR=2.2, 
Chi2=58.9, P<0.0001).
Table 2. Age and gender breakdown of patients by organism with major resistance profiles (data from 16 laboratories 
participating in enhanced surveillance). Proportion of isolates detected <48 hours and >5 days post-admission is also shown.
 
Total for  2010
Percent 
female
Mean age in 
years
Percent <5 
years
Percent 65 
years or older
Detected <48 
hours after 
admission
Detected >5 
days after 
admission
MRSA 174 36% 66.4 2% 64% 36% 53%
MSSA 496 35% 57.5 4% 45% 59% 25%
PNSP 34 44% 65.6 3% 59% 91% 6%
PSSP 138 48% 58.6 9% 51% 88% 9%
FQREC 274 49% 70.4 0% 70% 59% 31%
FQSEC 863 57% 67.5 1% 63% 68% 23%
VRE 85 45% 59.8 0% 44% 8% 87%
VSE 251 43% 63.0 2% 55% 35% 53%
KPN 151 47% 61.9 1% 46% 44% 43%
PAE 96 36% 67.3 0% 59% 49% 43%
Figure 2. Trends for S. aureus – total numbers of S. aureus/MRSA and percentage MRSA 
with 95% confidence intervals
The numbers of participating laboratories by year-end are indicated above the bars
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Abbreviations used: 
FQREC, Fluoroquinolone-resistant Escherichia coli; FQSE, Fluoroquinolone-sensitive Escherichia coli; KPN, Klebsiella pneumoniae; MRSA, 
Meticillin-resistant Staphylococcus aureus; MSSA, Meticillin-sensitive Staphylococcus aureus; PAE, Pseudomonas aeruginosa; PNSP, Penicillin-
non-susceptible Streptococcus pneumoniae; PSSP,  Penicillin-susceptible Streptococcus pneumoniae; VRE, Vancomycin-resistant Enterococci; 
VSE, Vancomycin-sensitive Enterococci
Males were approximately 1.7-times more likely to get 
an invasive S. aureus infection (1.8-times for MRSA, 
z=5.1, P<0.0001; 1.7-times for MSSA, z=8.8, P<0.0001) 
than females (z=10.0, P<0.0001).  The frequency of 
invasive S. aureus infection increased with age, with 
the majority of infections (n=703; 56%) occurring in 
adults over 60 years.  The median age for patients with 
an MRSA infection was 72 years (95%CI, 70-74) while 
the median age for patients with MSSA was 59 years 
(95%CI, 57-61).  This was considered to be a significant 
difference as the confidence intervals did not overlap. 
Enterococcus faecium
There were 392 reports of E. faecium BSI from 382 
patients, a decrease of 1.3% from 397 reports in 
2009. See Table 1 for the annual proportions of 
E. faecium isolates resistant to the three “indicator” 
antimicrobials by year since 2002.  Vancomycin-resistant 
E. faecium (VREfm) accounted for 38.3% of isolates.  
This represents a slight increase from 37.3% in 2009.  
While the rate of increase in the proportion of VREfm 
appeared to slow down after 2006, the number of 
VREfm isolates increased by almost 50% between 2006 
(n=98) and 2009 (n=145). Between 2002 and 2009, 
the proportion of isolates that was VREfm increased 
significantly (Chi2trend=36.9; P<0.0001) (Figure 4).  Since 
Figure 4. Trends for E. faecium – total numbers of E. faecium and percentage resistance to 
high-level gentamicin (HLG) and vancomycin (VAN) with 95% confidence intervals
The numbers of participating laboratories by year-end are indicated above the bars
Figure 3. Distribution of MRSA in EARS-Net countries in 2010
Map downloaded from ECDC’s TESSy database on 8/11/2011:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
-124-HPSC Annual Report 2010 Healthcare Associated Infections
0% 
5% 
10% 
15% 
20% 
25% 
30% 
0 
200 
400 
600 
800 
1000 
1200 
1400 
1600 
1800 
2000 
2200 
2002 2003 2004 2005 2006 2007 2008 2009 2010 
%
R
es
is
ta
nc
e 
N
um
b
er
 o
f 
is
o
la
te
s 
Year 
Total E. coli %3GC-R %ESBL-positive 
%CIP/OFX-R %GEN/AMK/TOB-R 
0% 
10% 
20% 
30% 
40% 
50% 
0 
200 
400 
600 
800 
1000 
1200 
1400 
1600 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
%
M
R
S
A
 
N
um
b
er
 o
f 
is
o
la
te
s 
Year 
Total S.aureus MRSA %MRSA 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
2002 2003 2004 2005 2006 2007 2008 2009 2010
%
R
es
is
ta
nc
e 
N
um
b
er
 o
f 
is
o
la
te
s 
Year
Total E. faecium %HLG-R %VAN-R 
0% 
5% 
10% 
15% 
20% 
25% 
30% 
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
500 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
%
P
N
S
P
 
N
um
b
er
 o
f i
so
la
te
s 
Year 
Total S.pneumoniae PNSP %PNSP %Pen-HLR %Pen-I 
0 
10 
20 
30 
40 
50 
60 
70 
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
<1 2-4 10-14 45-64 75-79 
A
g
e-
sp
ec
ifi
c 
In
ci
d
en
ce
 R
at
e 
(A
S
IR
) 
N
um
b
er
 o
f 
is
o
la
te
s 
Age Group 
No. patients 2010 No. patients 2009 ASIR 2010 ASIR 2009 
2008, Ireland has had the highest proportion of VREfm 
in Europe. This remained the case in 2010 (38.3%), 
with the next highest proportions reported by Portugal 
(23.9%) and Greece (22.5%) (Figure 5). 
Resistance to high-level gentamicin increased 
marginally from 39.1% in 2009 to 39.6% in 2010 
(Figure 3).
Of 377 isolates tested against all three “indicator” 
antimicrobials, 94 (24.9%) were resistant to all three 
and therefore classed as multi-drug resistant (MDR).  
This represents a decrease from 26.7% in 2009 (non-
significant; Chi2=0.29; P=0.59). 
Males were approximately 1.3-times more likely to 
have an invasive E. faecium infection than females 
(z=2.75, P=0.006).  The frequency of invasive E. faecium 
infection increased with age with the majority of 
infections (n=250; 65%) occurring in adults over 60 
years.  The median age was 66 years (95%CI, 63-67).
Klebsiella pneumoniae
There were 326 reports of invasive K. pneumoniae 
infection (all from blood) from 318 patients compared 
to 323 reports in 2009.  See Table 1 for the proportion 
of K. pneumoniae isolates resistant to the four 
“indicator” antimicrobials (as for E. coli above), plus 
imipenem/meropenem, since 2006.  
There were no significant changes in the resistance 
proportions in 2010 compared to 2009. No invasive 
isolates with resistance to imipenem/meropenem were 
reported in 2010. 
Three isolates were reported as ampicillin-susceptible, 
which either represents an isolate that was misidentified 
as K. pneumoniae or misclassified as ampicillin-
susceptible, as all Klebsiella spp. are inherently resistant 
to this antimicrobial.
ESBLs were detected in 16 (5.0%) of 317 isolates tested, 
representing a decrease from 8.2% in 2009. 
Twenty-six, or 8.0%, of 324 isolates tested against all 
four “indicator” antimicrobials were identified as MDR, 
including eight with resistance to all four, a decrease 
from 11.9% in 2009.
Males were approximately 1.2-times more likely 
to have an invasive K. pneumoniae infection than 
females (z=1.67, P=0.095).  The frequency of invasive 
K. pneumoniae infection increased with age with the 
majority of infections (n=198; 61%) occurring in adults 
over 60 years.  The median age was 63 years (95%CI, 
62-66).
Streptococcus pneumoniae
There were 314 reports of invasive S. pneumoniae 
infection (303 from blood and 11 from CSF) from 
310 patients, a decrease of 11.8% from 356 reports 
in 2009.  See Table 1 for the annual proportions of 
S. pneumoniae isolates non-susceptible/resistant 
to penicillin and erythromycin by year since 1999 
when surveillance began.  Penicillin-non-susceptible 
S. pneumoniae (PNSP) accounted for 18.2% (n=57) of 
all isolates tested against penicillin (n=313) in 2010.  
Of the 57 PNSP isolates, 40 were intermediately-
resistant (Int; MIC=0.1-1.0mg/L) and 15 were high-
level resistant (HLR; MIC >1.0mg/L) to penicillin.  No 
penicillin MICs were available for two non-susceptible 
(NS) isolates. The proportion of PNSP in Ireland 
increased significantly over the four years from 10.3% 
Figure 5. Distribution of vancomycin-resistant E. faecium in EARS-Net countries in 2010
Map downloaded from ECDC’s TESSy database on 8/11/2011:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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Figure 6. Trends for S. pneumoniae – total numbers of S. pneumoniae/PNSP and 
percentage PNSP with 95% confidence intervals
HLR, High-level resistant; I, Intermediately resistant
The numbers of participating laboratories by year-end are indicated above the bars
in 2004 to 23.1% in 2008 (Chi2trend=31.5, P<0.0001) 
but has decreased over the past two years (Figure 6).  
The proportion of isolates that were HLR to penicillin 
decreased slightly from 5.6% in 2009 to 4.8% in 2010.  
Forty-six (15.7%) of 293 isolates were resistant to 
erythromycin, a decrease from 17.3% in 2009.  
In 2010, Ireland once again had one of the highest 
proportions of PNSP, and high-level resistance to 
penicillin among S. pneumoniae, in countries reporting 
to EARS-Net, although comparisons with other EARS-
Net countries is problematic due to the possibility of 
different interpretive criteria being applied to the data. 
[Note: The Clinical Laboratory Standards Institute (CLSI) 
now provides three sets of breakpoints for interpreting 
penicillin susceptibility of S. pneumoniae isolates: 
meningitis, non-meningitis and oral. In Ireland, EARS-
Net data are reported using the “oral” breakpoints 
(which correspond to the original CLSI breakpoints) for 
epidemiological purposes, and thus consistency].
Moderately high levels of erythromycin resistance 
were seen, similar to the situation observed in much of 
Southern and Central Europe. 
Of isolates tested against both penicillin and 
erythromycin (n=293), 37 (12.6%) were simultaneously 
PNSP (25 Int, 11 HLR, 1 NS) and erythromycin-resistant 
in 2010 compared with 11.9% in 2009.
Prior to the introduction of the 7-valent pneumococcal 
conjugate vaccine (PCV7) into the childhood 
immunisation schedule in September 2008, a national 
pilot project was established early in 2007 as a result 
of a collaborative initiative between the Royal College 
of Surgeons in Ireland (RCSI), Beaumont Hospital, 
Children’s University Hospital, Temple St and HPSC 
with the aim of providing baseline serotyping data 
on invasive S. pneumoniae isolates.  Thirteen valent 
pneumococcal conjugate vaccine (PCV13) replaced 
PCV7 as of September 2010. Serotype data were 
available on 278 pneumococcal isolates from 30 
laboratories (of 31 that reported pneumococcal 
isolates to EARS-Net in 2010) representing 86% of all 
pneumococcal isolates reported in 2010.  Overall, 237 
(85%) isolates belonged to serotypes covered by the 
pneumococcal polysaccharide vaccine (PPV23; target 
population: adults ≥65 years and at risk groups), while 
74 (27%) and 150 (54%) were covered by the conjugate 
vaccines (PCV7 and PCV13; target population: children 
<2 years), respectively.  From adults ≥65 years, 114 of 
139 (82%) isolates were covered by PPV23, while from 
children <2 years, 4 of 21 (19%) isolates were covered 
by PCV7 and 15 of 21 (71%) isolates were covered by 
PCV13.  Of the 50 PNSP isolates for which serotyping 
data were available, 25 of 32 (78%) from adults ≥65 
years were covered by PPV23 while the one isolate 
from a children <2 years was covered by both PCV7 
and PCV13. On-going surveillance of the predominant 
serotypes is required as strains with serotypes other 
than those in the vaccine have been reported to 
increase in prevalence following introduction of PCV7 
in other countries, hence the need for a fully resourced 
reference facility.  
The rate of invasive pneumococcal disease (IPD) in 
Ireland in 2010 was estimated to be 7.4 per 100,000 
population compared with 8.4 in 2009 (note: both 
calculated using the 2006 census data and adjusted for 
the estimated population coverage by EARS-Net for 
that year).  The highest rates of IPD were observed in 
children <1 year (24.6 per 100,000) and adults aged 75-
79 years (33.5) and ≥80 years (59.3) (Figure 7).  The rates 
in all age groups decreased compared with the data 
for 2009 with the exception of the ≥80 years group, 
which increased from 53.1 to 59.3.  The biggest drops 
were seen in the 75-79 and the 2-4 year age groups, 
-126-HPSC Annual Report 2010 Healthcare Associated Infections
0% 
5% 
10% 
15% 
20% 
25% 
30% 
0 
200 
400 
600 
800 
1000 
1200 
1400 
1600 
1800 
2000 
2200 
2002 2003 2004 2005 2006 2007 2008 2009 2010 
%
R
es
is
ta
nc
e 
N
um
b
er
 o
f 
is
o
la
te
s 
Year 
Total E. coli %3GC-R %ESBL-positive 
%CIP/OFX-R %GEN/AMK/TOB-R 
0% 
10% 
20% 
30% 
40% 
50% 
0 
200 
400 
600 
800 
1000 
1200 
1400 
1600 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
%
M
R
S
A
 
N
um
b
er
 o
f 
is
o
la
te
s 
Year 
Total S.aureus MRSA %MRSA 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
2002 2003 2004 2005 2006 2007 2008 2009 2010
%
R
es
is
ta
nc
e 
N
um
b
er
 o
f 
is
o
la
te
s  
Year
Total E. faecium %HLG-R %VAN-R 
0% 
5% 
10% 
15% 
20% 
25% 
30% 
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
500 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
%
P
N
S
P
 
N
um
b
er
 o
f i
so
la
te
s 
Year 
Total S.pneumoniae PNSP %PNSP %Pen-HLR %Pen-I 
0 
10 
20 
30 
40 
50 
60 
70 
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
<1 2-4 10-14 45-64 75-79 
A
g
e-
sp
ec
ifi
c 
In
ci
d
en
ce
 R
at
e 
(A
S
IR
) 
N
um
b
er
 o
f 
is
o
la
te
s 
Age Group 
No. patients 2010 No. patients 2009 ASIR 2010 ASIR 2009 
which decreased from 44.3 to 33.5 and 11.6 to 4.4, 
respectively. 
Males were approximately 1.2-times more likely to 
have an invasive S. pneumoniae infection [0.9-times 
for PNSP, z=0.4, P=0.69; 1.3-times for penicillin-
susceptible S. pneumoniae (PSP), z=1.89, P=0.06] than 
females (z=1.47, P=0.14). None of these findings were 
significant.  The median age was 62.5 years (95%CI, 59-
65).
Enterococcus faecalis
There were 298 reports of E. faecalis BSI from 288 
patients, an increase of 3.1% from 289 reports in 2009.  
See Table 1 for the annual proportions of E. faecalis 
isolates resistant to the three “indicator” antimicrobials 
(ampicillin, vancomycin and high-level gentamicin) by 
year since 2002 when surveillance began.  Vancomycin-
resistant E. faecalis (VREfa) accounted for 0.3% of 
isolates, a decrease from 0.7% in 2009 (non-significant; 
Chi2=0.37; P=0.54).  
Six isolates were reported as ampicillin-resistant, which 
suggests that these isolates were either misidentified 
as E. faecalis or misclassified as ampicillin-resistant, as 
resistance to ampicillin is rare in E. faecalis.
Males were approximately 1.3-times more likely to have 
an invasive E. faecalis infection than females (z=1.96, 
P=0.054).  The frequency of invasive E. faecalis infection 
increased with age with the majority of infections 
(n=182; 65%) occurring in adults over 60 years.  The 
median age was 66 years (95%CI, 64-71).
Pseudomonas aeruginosa
There were 222 reports of invasive P. aeruginosa 
infection (220 from blood and two from CSF) from 
219 patients, a decrease of 10.5% from 248 reports in 
2009.  See Table 1 for the proportion of P. aeruginosa 
isolates resistant to the five “indicator” antimicrobials/
antimicrobial classes [piperacillin-tazobactam, 
ceftazidime, carbapenems (meropenem or imipenem), 
fluoroquinolones (ciprofloxacin or ofloxacin) and 
gentamicin] since 2006.  There were no significant 
changes in the resistance proportions in 2010 compared 
to 2009.
Fourteen (6.5%) of 215 isolates tested against all five 
“indicator” antimicrobials were MDR, including one with 
resistance to all five (2009, 6.4%).
Males were approximately 1.2-times more likely to have 
an invasive P. aeruginosa infection than females (non-
significant; z=1.21, P=0.23).  The frequency of invasive 
P. aeruginosa infection increased with age with the 
majority of infections (n=143; 64%) occurring in adults 
over 60 years.  The median age was 68 years (95%CI, 
65-71).
Enhanced Surveillance
The enhanced surveillance programme involves 
voluntary participation by hospitals that provide 
additional demographic, risk factor and clinical data 
on invasive pathogens causing BSI. The enhanced 
surveillance programme was established in 2004. In 
2010, there were 2,562 individual records (cases or 
isolates under the EARS-Net definition) submitted 
from 14 participating laboratories (compared to 2,228 
submitted in 2009). The total number of records thus 
far for 2010 represents 51% of the total core EARS-Net 
dataset. Demographic and other basic data for the 
major resistance profiles of EARS-Net pathogens are 
shown in Table 2. 
A detailed analysis of the changes over time of 
the factors affecting S. aureus BSI showed that the 
decrease in clinically significant MRSA BSI acquired 
in the reporting hospital (representing 75% of all 
MRSA isolates) over the previous three years was 
predominantly among older age groups. The decrease 
in MRSA BSI was also among cases in which central 
venous catheters (CVCs) or respiratory tract infections 
were primary sources. There was a corresponding 
increase in MSSA rates over the same time. The rates of 
change for both MRSA and MSSA stabilised in 2010.
Enhanced surveillance can offer input into future 
infection control measures both nationally and in those 
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Figure 7. Numbers and age-specific incidence rates of patients with invasive 
S. pneumoniae infection in 2010 compared with 2009
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hospitals that participate in the surveillance scheme. 
One aspect of participation in enhanced surveillance is 
that it can help to put into context levels of preventable 
infections. For example, in 2010, 23% of the all S. 
aureus BSI isolates were associated with infection 
of CVCs and 6% with infection of peripheral venous 
catheters. 
For further details, go to the HPSC website (http://www.
hpsc.ie) and click on “Topics A-Z”, then “Enhanced 
Bacteraemia Surveillance”.
Conclusion
Improvements in infection prevention and control 
resources and interventions, along with hospital 
antimicrobial stewardship programmes, may have 
contributed to reducing the burden of MRSA BSI in 
Ireland since 2006. The introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7) into the 
childhood immunisation program in September 2008 
has already resulted in a reduction in the burden of 
invasive pneumococcal disease in children.  Despite 
these successes, antimicrobial resistance remains a 
major problem in this country. Of particular concern, 
are the high numbers and proportions of vancomycin 
resistant E. faecium as Ireland has by far the highest 
level of resistance in the EU. In addition, the 
proportion of E. coli isolates that exhibit resistance to 
fluoroquinolones has increased.  ESBL production has 
increased in E. coli and K. pneumoniae.
AMR is also an issue in other bacterial species as well 
as in sites other than blood and/or CSF for which 
national surveillance data are not currently available in 
Ireland. There are continued threats posed by emerging 
resistance mechanisms in these and other bacterial 
pathogens (e.g. carbapenemases in Enterobacteriaceae, 
and vancomycin resistance in S. aureus). 
These current problems and future threats highlight the 
on-going commitment and resources that are necessary 
to reduce the burden of AMR and healthcare-associated 
infection in this country, as outlined in the Strategy 
for the control of Antimicrobial Resistance in Ireland 
(SARI) in 2001, and in particular measures to promote 
more prudent antimicrobial use in both hospital and 
community settings. 
HPSC thanks all the microbiology laboratories for their 
continued participation and enthusiasm for the EARS-
Net project.
The data presented in this report were taken from the 
EARS-Net database on 1st September 2011. For further 
details of EARS-Net and antimicrobial resistance in 
Ireland see http://www.hpsc.ie 
European data are available at http://ecdc.europa.eu/
en/activities/surveillance/EARS-Net/Pages/Database.
aspx
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Computerised Infectious Disease 
Reporting System (CIDR)
Nearly 13,000 notifications were recorded in CIDR in 
2010. This was a significant drop on 2009 when figures 
peaked due to the H1N1 influenza pandemic in that 
year. On the other hand the enhanced surveillance 
dataset on a number of diseases was extended, 
requiring work to enable this to be captured through 
the CIDR application but also to allow it to be retrieved 
through reporting.
CIDR training
In parallel with continuing CIDR operations and 
additional implementations, the CIDR training 
programme continued through the year with a number 
of sessions for 29 Public Health and laboratory users 
through the year.
New developments through the year
2010 saw the development and deployment of a major 
upgrade to the CIDR application software. CIDR release 
2.3 included a number of significant enhancements to 
the CIDR application including breaking up enhanced 
surveillance datasets into sections / pages to improve 
usability but also to reduce the volume of network 
traffic that had proved problematic towards the latter 
stages of the containment phase of the H1N1 influenza 
pandemic in 2009. The validation process for laboratory 
data uploaded to CIDR was also improved. This release 
also provided improved compatibility for the use of 
web browsers other than Internet Explorer 6 (including 
IE7 and 8 as well as Firefox).  There were also changes 
to the CIDR ‘History’ database to potentially facilitate 
future archiving of data as well a number of bugfixes. 
CIDR Impementations
Three areas of significant CIDR implementation activity 
through 2010 included the ongoing effort to complete 
implementation in the laboratories. Three clinical 
microbiology hospital laboratories went ‘live’ on CIDR 
10. Computerised Infectious Disease 
 Reporting (CIDR)
Summary
•  2010 represented the 7th year of continued CIDR 
live operation
•  Although the number of notifications in 2010 
was lower than previous two years  an increased 
amount of information was collected on a 
number of these diseases as increased enhanced 
surveillance was implemented on CIDR
•  CIDR implementations continued through 2010 at 
lab and public health levels as well as including TB 
notifications from the beginning of 2011
•  The CIDR application software was significantly 
upgraded during the year to improve the usability 
of the system and to increase performance.  The 
efficiency of software development was much 
improved by relocating this within HPSC
•  ISO 27001 accreditation for Information Security 
Management was retained following a full re-
certification audit
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in 2010 (Naas, Loughlinstown and Limerick Regional 
Hospitals). The CIDR implementation in the National 
Salmonella Reference Laboratory in Galway needed 
to be revisited when that laboratory moved from a 
MS Access-based system to the iSOFT Laboratory 
Information Management System. The TB laboratory 
in St James’s Hospital was set up on CIDR as a new 
reference laboratory as part of the preparation for TB 
notifications on CIDR.
CIDR implementation in the Department of Public 
Health in the Mid West continued to be held up by 
resourcing difficulties in that region but a partial 
implementation was agreed that allowed the clinical 
microbiology lab in the Regional Hospital to begin to 
upload their notifications from October. Designated 
staff within HPSC managed this surveillance / 
notification data in CIDR on behalf of the Department 
of Public Health in the Mid West pending resolution of 
their local issues.
The partial CIDR go-live in the Mid West allowed the 
work to proceed on preparing for TB notifications to 
be included on CIDR from the beginning of 2011. In 
addition to the work already mentioned with the TB 
Reference Laboratory, this involved setting up TB as 
a disease within CIDR together with the enhanced 
surveillance questions associated with this disease and 
the reporting changes to enable this information to be 
retrieved.
As well as preparing enhanced surveillance data 
questions for TB, 2010 also saw the implementation of 
enhanced surveillance on CIDR for cryptosporidiosis, 
brucellosis and botulism. It also saw the ‘normalisation’ 
of influenza enhanced surveillance on CIDR for the 
2010/2011 influenza season after the particular 
challenges of the H1N1 influenza pandemic in 2009.
A further significant development in 2010 was the 
implementation of a reporting solution to allow 
salmonella laboratory results uploaded to CIDR from 
the National Salmonella Reference Laboratory to 
be retrieved through reporting. Although CIDR was 
originally designed and built to record and retrieve 
information about cases / events of infectious disease, 
there has been an increasing need to be able to retrieve 
lab data at lab test / result level.
CIDR Information Governance
A major achievement in 2010 was the retention 
of ISO 27001 certification for Information Security 
Management following a full 3 yearly accreditation 
audit. This accreditation underscores the recognition 
of the need to protect the sensitive health information 
in CIDR and it has proved useful in reassuring patient 
groups and health professionals that the confidentiality 
of this information is appropriately managed.
Communications
The CIDR National Steering Group and the CIDR User 
Group continued to convene by teleconference through 
2010 to provide governance and user feedback to the 
CIDR team. 2010 saw the retirement of Dick McMahon 
from the Steering Group after 8 years of valuable 
contribution to CIDR. Niall Sinnott from the HSE ICT 
Programme Management Office took up Dick’s position 
on the Steering Group from the beginning of 2011.
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Appendix 1
Notifiable Infectious Diseases in Ireland
Notes:
Figures for the year 2010 presented in this appendix were extracted from the Computerised Infectious Disease Reporting 
(CIDR) system in September 2011. These figures may differ from those published previously due to ongoing updating of 
notification data on CIDR.
Figures on EARSS pathogens, tuberculosis and sexually transmitted infections are not presented here, since these diseases 
were not reported via the CIDR system during 2010. Separate databases are used to collate data on these diseases. Details on 
the epidemiology of these diseases can be found in separate chapters in this document.
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Table  A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2010) under Infectious 
Diseases (Amendment) (No. 3) Regulations 2003 (S.I. No. 707 of 2003)
Infectious Disease Causative Pathogen(s)
Acute anterior poliomyelitis Polio virus
Acute infectious gastroenteritis
Ano-genital warts
Anthrax Bacillus anthracis
Bacillus cereus food-borne infection/intoxication Bacillus cereus
Bacterial meningitis (not otherwise specified)
Botulism Clostridium botulinum
Brucellosis Brucella species
Campylobacter infection Campylobacter species
Chancroid Haemophilus ducreyi
Chlamydia trachomatis infection (genital) Chlamydia trachomatis
Cholera Vibrio cholerae
Clostridium perfringens (type A) food-borne disease Clostridium perfringens
Creutzfeldt Jakob disease
Creutzfeldt Jakob disease (new variant)
Cryptosporidiosis Cryptosporidium parvum
Diphtheria Corynebacterium diphtheriae
Echinococcosis Echinococcus species
Enterococcal bacteraemia Enterococcus species (blood)
Enterohaemorrhagic Escherichia coli Escherichia coli of serogroup known to be toxin-producing
Escherichia coli infection (invasive) Escherichia coli (blood, CSF)
Giardiasis Giardia lamblia
Gonorrhoea Neisseria gonorrhoeae
Granuloma inguinale
Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF or other normally sterile site)
Hepatitis A (acute) Hepatitis A virus
Hepatitis B (acute and chronic) Hepatitis B virus
Hepatitis C Hepatitis C virus
Herpes simplex (genital) Herpes simplex virus
Influenza Influenza A and B virus
Legionellosis Legionella species
Leptospirosis Leptospira species
Listeriosis Listeria monocytogenes
Lymphogranuloma venereum
Malaria Plasmodium falciparum, P. vivax, P. ovale, P. malariae
Measles Measles virus
Meningococcal disease Neisseria meningitidis
Mumps Mumps virus
Non-specific urethritis
Noroviral infection Norovirus
Paratyphoid Salmonella paratyphi
Pertussis Bordetella pertussis
Plague Yersinia pestis
Q fever Coxiella burnetii
Rabies Rabies virus
Rubella Rubella virus
Salmonellosis Salmonella enterica
Severe Acute Respiratory Syndrome (SARS) SARS-associated coronavirus
Shigellosis Shigella species
Smallpox Variola virus
Staphylococcal food poisoning Enterotoxigenic Staphylococcus aureus
Staphylococcus aureus bacteraemia Staphylococcus aureus (blood)
Streptococcus group A infection (invasive) Streptococcus pyogenes (blood, CSF or other normally sterile site)
Streptococcus pneumoniae infection (invasive) Streptococcus  pneumoniae (blood, CSF or other normally sterile site)
Syphilis Treponema pallidum
Tetanus Clostridium tetani
Toxoplasmosis Toxoplasma gondii
Trichinosis Trichinella species
Trichomoniasis Trichomonas vaginalis
Tuberculosis Mycobacterium tuberculosis complex
Tularemia Francisella tularensis
Typhoid Salmonella typhi
Typhus Rickettsia prowazekii
Viral encephalitis
Viral haemorrhagic fevers Lassa virus, Marburg virus, Ebola virus, Crimean-Congo haemorrhagic fever virus
Viral meningitis
Yellow fever Yellow fever virus
Yersiniosis Yersinia enterocolitica, Yersinia pseudotuberculosis
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Table A1.2 Number of notifiable infectious diseases, 2008-2010 and crude incidence rates of diseases, 2010
Infectious Disease 2008 2009 2010 CIR* 2010
Acute infectious gastroenteritis 4169 4357 4290 101.18
Bacillus cereus food-borne infection or intoxication 0 1 0 0.00
Bacterial meningitis (not otherwise specified) 40 40 42 0.99
Botulism 7 0 0 0.00
Brucellosis 3 0 2 0.05
Campylobacter infection 1736 1807 1661 39.18
Clostridium perfringens (type A) food-borne disease 1 1 0 0.00
Creutzfeldt Jakob disease 2 5 3 0.07
Cryptosporidiosis 415 445 294 6.93
Echinococcosis 2 1 1 0.02
Enterohaemorrhagic Escherichia coli 238 255 224 5.28
Giardiasis 71 61 57 1.34
Haemophilus influenzae disease (invasive) 22 43 28 0.66
Hepatitis A (acute) 42 50 46 1.08
Hepatitis B (acute and chronic) 919 803 645 15.21
Hepatitis C 1516 1241 1239 29.22
Influenza 473 484** 210 4.95
Legionellosis 48 9 11 0.26
Leptospirosis 29 24 17 0.40
Listeriosis 13 10 10 0.24
Malaria 82 90 82 1.93
Measles 55 162 403 9.51
Meningococcal disease 168 147 114 2.69
Mumps 1380 3620 293 6.91
Noroviral infection 1768 1634 1927 45.45
Pandemic H1N1 (2009)† 0 4571 65 1.53
Paratyphoid 8 10 5 0.12
Pertussis 104 78 114 2.69
Q fever 13 17 9 0.21
Rubella 40 19 24 0.57
Salmonellosis 449 333 356 8.40
Shigellosis 75 70 60 1.42
Staphylococcal food poisoning 1 1 0 0.00
Streptococcus group A infection (invasive) 70 60 68 1.60
Streptococcus pneumoniae infection (invasive) 465 432 391 9.22
Tetanus 2 0 0 0.00
Toxoplasmosis 49 37 37 0.87
Typhoid 5 9 8 0.19
Viral encephalitis 5 5 22 0.52
Viral meningitis 97 142 169 3.99
Yersiniosis 3 3 3 0.07
Total 14585 20593 12930
*Crude incidence rate per 100,000 total population
** 134 of these influenza cases in 2009 were possibly due to 2009 pandemic influenza as they occurred between weeks 17 and 52, 2009, but were 
reported as influenza.
†The influenza A (H1N1) 2009 pandemic was declared over by the WHO on 10/08/2010. Any new influenza A (H1N1) 2009 cases since that time 
are notified under the disease Influenza. The disease Pandemic (H1N1) 2009 was only relevant for the pandemic period, 25/04/2009 – 10/08/2010.
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Table A1.3 Number of notifiable infectious diseases by HSE area, 2010
Infectious Disease HSE-E HSE-M HSE-MW HSE-NE HSE-NW HSE-SE HSE-S HSE-W Total
Acute infectious gastroenteritis 1132 391 205 218 330 741 670 603 4290
Bacterial meningitis (not otherwise 
specified)
13 2 4 1 6 6 4 6 42
Brucellosis * * * * * * * * 2
Campylobacter infection 534 126 159 106 92 208 242 194 1661
Creutzfeldt Jakob disease * * * * * * * * 3
Cryptosporidiosis 18 24 31 15 31 55 51 69 294
Echinococcosis * * * * * * * * 1
Enterohaemorrhagic Escherichia coli 28 20 44 8 39 18 40 27 224
Giardiasis 19 1 4 6 0 4 14 9 57
Haemophilus influenzae disease (invasive) 9 1 2 2 1 5 7 1 28
Hepatitis A (acute) 19 3 3 1 1 1 16 2 46
Hepatitis B (acute and chronic) 412 24 36 43 11 34 53 32 645
Hepatitis C 940 71 41 51 16 35 49 36 1239
Influenza 98 17 13 10 22 8 13 29 210
Legionellosis 7 0 1 1 0 2 0 0 11
Leptospirosis 6 0 0 0 1 3 4 3 17
Listeriosis 2 1 0 1 0 3 2 1 10
Malaria 40 6 3 7 6 7 7 6 82
Measles 150 6 51 6 12 12 117 49 403
Meningococcal disease 42 4 10 10 11 18 15 4 114
Mumps 141 12 34 14 10 25 17 40 293
Noroviral infection 725 109 250 173 67 121 222 260 1927
Pandemic H1N1 (2009)† 16 6 9 4 3 8 12 7 65
Paratyphoid 2 0 1 0 0 0 2 0 5
Pertussis 25 1 5 4 67 3 9 0 114
Q fever 0 0 2 0 0 0 7 0 9
Rubella 13 0 1 0 1 5 2 2 24
Salmonellosis 129 46 28 30 16 33 40 34 356
Shigellosis 21 2 7 5 2 4 15 4 60
Streptococcus group A infection (invasive) 22 2 6 7 8 5 12 6 68
Streptococcus pneumoniae infection 
(invasive)
110 21 33 16 14 113 57 27 391
Toxoplasmosis 13 4 3 2 2 0 8 5 37
Typhoid 7 0 0 0 0 0 1 0 8
Viral encephalitis 5 1 1 2 2 3 3 5 22
Viral meningitis 68 3 17 10 23 18 14 16 169
Yersiniosis * * * * * * * * 3
*Data not reported to HSE area level when total number in Ireland <5 cases
†The influenza A (H1N1) 2009 pandemic was declared over by the WHO on 10/08/2010. Any new influenza A (H1N1) 2009 cases since that 
time are notified under the disease Influenza. The disease Pandemic (H1N1) 2009 was only relevant for the pandemic period, 25/04/2009 – 
10/08/2010.
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Table A1.4 Number of notifiable infectious diseases by age group (years), 2010
Infectious Disease 0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ Unknown Total
Acute infectious gastroenteritis 2497 69 21 22 23 84 88 99 178 1204 5 4290
Bacterial meningitis (not otherwise 
specified)
21 2 1 2 3 1 3 0 3 6 0 42
Brucellosis 0 0 0 0 0 1 0 1 0 0 0 2
Campylobacter infection 418 109 72 61 150 233 185 154 107 166 6 1661
Creutzfeldt Jakob disease 0 0 0 0 0 0 0 1 2 0 0 3
Cryptosporidiosis 182 56 20 5 8 12 2 3 3 3 0 294
Echinococcosis 0 0 0 0 0 0 1 0 0 0 0 1
Enterohaemorrhagic Escherichia coli 97 24 15 8 7 19 21 9 13 11 0 224
Giardiasis 9 2 1 1 4 17 7 10 2 3 1 57
Haemophilus influenzae disease 
(invasive)
4 1 1 1 2 3 2 2 0 12 0 28
Hepatitis A (acute) 5 7 4 4 6 6 7 2 3 2 0 46
Hepatitis B (acute and chronic) 6 3 3 20 95 292 151 41 20 14 0 645
Hepatitis C 9 0 0 18 72 521 375 165 58 20 1 1239
Influenza 19 10 15 15 25 60 23 23 11 8 1 210
Legionellosis 0 0 0 0 1 0 0 3 2 5 0 11
Leptospirosis 0 0 0 2 3 3 2 3 2 2 0 17
Listeriosis 1 0 0 0 0 3 1 0 2 3 0 10
Malaria 2 6 3 3 3 19 28 15 3 0 0 82
Measles 201 72 49 41 8 24 4 4 0 0 0 403
Meningococcal disease 74 8 4 12 1 4 0 1 3 7 0 114
Mumps 31 30 29 45 41 47 29 21 9 8 3 293
Noroviral infection 215 24 24 13 29 83 52 94 137 1224 32 1927
Pandemic H1N1 (2009)† 7 3 5 5 5 15 10 9 3 3 0 65
Paratyphoid 0 0 1 0 3 0 1 0 0 0 0 5
Pertussis 62 7 16 6 2 6 7 3 5 0 0 114
Q fever 0 0 0 1 0 1 3 2 0 2 0 9
Rubella 22 2 0 0 0 0 0 0 0 0 0 24
Salmonellosis 75 17 24 10 40 57 33 31 29 40 0 356
Shigellosis 8 1 0 2 3 21 11 8 4 2 0 60
Streptococcus group A infection 
(invasive)
6 4 0 2 1 5 13 7 7 22 1 68
Streptococcus pneumoniae infection 
(invasive) 37 2 1 7 4 18 26 42 53 201 0 391
Toxoplasmosis 1 0 0 2 4 15 10 3 2 0 0 37
Typhoid 0 0 0 0 0 6 1 1 0 0 0 8
Viral encephalitis 2 0 1 0 0 2 2 3 3 9 0 22
Viral meningitis 61 12 7 20 13 36 15 3 1 1 0 169
Yersiniosis 0 0 0 0 0 1 0 1 0 1 0 3
Total 4072 471 317 328 556 1615 1113 764 665 2979 50 12930
†The influenza A (H1N1) 2009 pandemic was declared over by the WHO on 10/08/2010. Any new influenza A (H1N1) 2009 cases since that 
time are notified under the disease Influenza. The disease Pandemic (H1N1) 2009 was only relevant for the pandemic period, 25/04/2009 – 
10/08/2010.
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Table A1.5 Number of notifiable infectious diseases by gender, 2010
Infectious Disease Male Female Unknown Total
Acute infectious gastroenteritis 2055 2230 5 4290
Bacterial meningitis (not otherwise specified) 21 21 0 42
Brucellosis 2 0 0 2
Campylobacter infection 882 773 6 1661
Creutzfeldt Jakob disease 2 1 0 3
Cryptosporidiosis 143 151 0 294
Echinococcosis 0 1 0 1
Enterohaemorrhagic Escherichia coli 114 110 0 224
Giardiasis 26 31 0 57
Haemophilus influenzae disease (invasive) 16 12 0 28
Hepatitis A (acute) 24 22 0 46
Hepatitis B (acute and chronic) 341 297 7 645
Hepatitis C 833 396 10 1239
Influenza 94 115 1 210
Legionellosis 6 5 0 11
Leptospirosis 16 1 0 17
Listeriosis 2 8 0 10
Malaria 43 38 1 82
Measles 203 200 0 403
Meningococcal disease 68 46 0 114
Mumps 158 133 2 293
Noroviral infection 893 1032 2 1927
Pandemic H1N1 (2009)† 35 29 1 65
Paratyphoid 4 1 0 5
Pertussis 52 62 0 114
Q fever 3 6 0 9
Rubella 11 13 0 24
Salmonellosis 182 174 0 356
Shigellosis 35 25 0 60
Streptococcus group A infection (invasive) 36 32 0 68
Streptococcus pneumoniae infection (invasive) 215 176 0 391
Toxoplasmosis 13 24 0 37
Typhoid 4 4 0 8
Viral encephalitis 9 13 0 22
Viral meningitis 82 87 0 169
Yersiniosis 3 0 0 3
Total 6626 6269 35 12930
 †The influenza A (H1N1) 2009 pandemic was declared over by the WHO on 10/08/2010. Any new influenza A (H1N1) 2009 cases since that 
time are notified under the disease Influenza. The disease Pandemic (H1N1) 2009 was only relevant for the pandemic period, 25/04/2009 – 
10/08/2010.
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 Table A1.6 Number of notifiable infectious diseases by case classification, 2010
Infectious Disease Confirmed Probable Possible Not Specified Total
Acute infectious gastroenteritis 4196 92 0 2 4290
Bacterial meningitis (not otherwise specified) 21 7 14 0 42
Brucellosis 1 1 0 0 2
Campylobacter infection 1659 0 0 2 1661
Creutzfeldt Jakob disease 3 0 0 0 3
Cryptosporidiosis 294 0 0 0 294
Echinococcosis 1 0 0 0 1
Enterohaemorrhagic Escherichia coli 222 2 0 0 224
Giardiasis 57 0 0 0 57
Haemophilus influenzae disease (invasive) 26 0 2 0 28
Hepatitis A (acute) 40 3 3 0 46
Hepatitis B (acute and chronic) 645 0 0 0 645
Hepatitis C 1239 0 0 0 1239
Influenza 191 0 19 0 210
Legionellosis 11 0 0 0 11
Leptospirosis 17 0 0 0 17
Listeriosis 10 0 0 0 10
Malaria 82 0 0 0 82
Measles 299 0 104 0 403
Meningococcal disease* 98 0 16 0 114
Mumps 109 11 173 0 293
Noroviral infection 1841 86 0 0 1927
Pandemic H1N1 (2009)† 65 0 0 0 65
Paratyphoid 5 0 0 0 5
Pertussis 45 11 58 0 114
Q fever 9 0 0 0 9
Rubella 1 0 23 0 24
Salmonellosis 349 7 0 0 356
Shigellosis 60 0 0 0 60
Streptococcus group A infection (invasive) 65 3 0 0 68
Streptococcus pneumoniae infection (invasive) 302 2 87 0 391
Toxoplasmosis 37 0 0 0 37
Typhoid 8 0 0 0 8
Viral encephalitis 21 0 1 0 22
Viral meningitis 149 8 11 1 169
Yersiniosis 3 0 0 0 3
Total 12181 233 511 5 12930
Case classifications are assigned to notifications as per the Case Definitions for Notifiable Diseases booklet, available at http://www.hpsc.ie. 
*As per the case definitions, meningococcal disease notifications are classified as definite, presumed and possible. For convenience they are 
reported in this table as confirmed, probable and possible, respectively.
†The influenza A (H1N1) 2009 pandemic was declared over by the WHO on 10/08/2010. Any new influenza A (H1N1) 2009 cases since that time 
are notified under the disease Influenza. The disease Pandemic (H1N1) 2009 was only relevant for the pandemic period, 25/04/2009 – 10/08/2010.
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Table A2.1 Immunisation uptake (%) at 12 months of age in 2010 (i.e. cohort born 01/01/2009-31/12/2009), based on available data
HSE Area
Local Health Office/HSE 
Area
Number 
in cohort 
for BCG *
Number in 
cohort for 
D3 & T3*
Immunisation Uptake (%)*
BCG D3 Hib3 Polio3 HepB3 MenC2 PCV2
HSE-E
Dublin South na 1700 na 87 87 87 87 87 87
Dublin South East na 1529 na 89 89 89 89 89 89
Dublin South City na 1767 na 92 92 92 92 92 92
Dublin South West na 2705 na 91 91 91 91 91 91
Dublin West na 2965 na 87 87 87 87 87 87
Dublin North West na 3910 na 78 78 78 78 78 78
Dublin North Central na 1775 na 90 90 90 90 90 90
Dublin North na 4499 na 90 90 90 90 90 90
Kildare/West Wicklow na 4304 na 88 88 88 88 88 89
Wicklow na 2081 na 85 85 85 85 85 85
HSE-E Total na 27235 na 87 87 87 87 87 87
HSE-M
Laois/Offaly 1497 1497 93 88 88 88 88 88 88
Longford/Westmeath 1137 1137 93 89 89 89 89 89 89
HSE-M Total 2634 2634 93 89 89 89 89 89 89
HSE-MW
Clare 1916 1927 98 93 93 93 93 93 93
Limerick 2161 2133 97 92 92 92 92 92 92
Tipperary NR/East Limerick 2058 2086 97 92 92 92 92 92 92
HSE-MW Total 6135 6146 97 92 92 92 92 92 92
HSE-NE
Cavan/Monaghan na 1625 na 95 95 95 94 93 93
Louth na 1607 na 92 92 92 92 90 90
Meath na 2733 na 92 92 92 92 91 91
HSE-NE Total na 5965 na 93 93 93 93 91 91
HSE-NW
Donegal 2523 2523 95 94 93 94 93 93 93
Sligo/Leitrim 1501 1501 96 92 93 93 92 92 93
HSE-NW Total 4024 4024 95 93 93 93 93 93 93
HSE-SE
Carlow/Kilkenny 2091 2091 95 88 88 88 88 88 88
South Tipperary 1563 1563 96 91 91 91 91 90 90
Waterford 2127 2127 95 91 91 91 91 91 92
Wexford 2395 2395 96 91 91 91 91 90 91
HSE-SE Total 8176 8176 96 90 90 90 90 90 90
HSE-S
North Cork 396 787 74 87 87 87 87 86 86
North South Lee 1485 3048 91 88 88 88 88 86 86
West Cork 195 426 87 81 82 81 81 78 78
Kerry 535 1075 90 88 89 88 88 86 86
HSE-S Total 2611 5336 88 87 88 87 87 86 86
HSE-W
Galway na 4076 na 88 88 88 88 88 89
Mayo na 1844 na 84 84 84 84 84 85
Roscommon na 978 na 96 96 96 95 96 96
HSE-W Total na 6898 na 88 88 88 88 88 89
Ireland 23580 66414 95 89 89 89 89 89 89
na=not available 
Since T3 and P3 uptake identical to D3 uptake only D3 uptake figures are presented       
* The 2010 data for those at 12 months are incomplete as the following were unavailable: the Quarter 1 2010 HSE-M and HSE-S data and the 
HSE-MW MenC2 data; the Quarter 2 2010 HSE-M data and HSE-S data and; the Quarter 4 2010 HSE-NE data.  The available 2010 national 12 
month D3, T3, P3 (n=66,415), Hib3 (n=66,421), HepB3 (n=66,414), Polio3 (n=66,414) and PCV2 (n=66,418) cohort data may be around 87% (this figure 
is an estimate only) of the 2010 national birth cohort and the available MenC2 (n=64,895) cohort may be around 85% (this figure is an estimate 
only) of the 2010 national birth cohort.  BCG uptake data were available for the HSE-MW, HSE-NW, and HSE-SE Areas in Quarters 1-4 2010, for 
the HSE-M Area in Quarters 3 and 4 2010 and the HSE-SA Area in Quarter 4 2010.  The available 2010 national BCG cohort data may be around 
31% (this figure is an estimate only) of the national birth cohort.  
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here 
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Table A2.2 Immunisation uptake (%) at 24 months of age in 2010 (i.e. cohort born 01/01/2008-31/12/2008*), based on available data
HSE Area
Local Health Office/HSE 
Area
Number in 
cohort for D3 
& T3†
Immunisation Uptake (%)†
D3 Hib3 Hibb HepB3 MenC3 PCV3 MMR1
HSE-E
Dublin South 1605 95 95 84 94 83 84 89
Dublin South East 1461 96 96 81 95 85 89 92
Dublin South City 1669 96 96 85 95 88 90 92
Dublin South West 2612 96 95 87 95 88 90 93
Dublin West 2818 92 92 81 92 83 86 87
Dublin North West 3882 91 91 78 92 81 83 84
Dublin North Central 1672 94 93 84 94 86 86 90
Dublin North 4396 94 94 87 94 88 90 91
Kildare/West Wicklow 4397 93 93 83 96 87 91 89
Wicklow 2095 92 92 79 92 81 82 85
HSE-E Total 26607 93 93 83 94 85 87 89
HSE-M
Laois/Offaly 1457 93 93 82 93 79 88 89
Longford/Westmeath 1100 93 93 86 93 85 91 91
HSE-M Total 2557 93 93 84 93 82 89 90
HSE-MW
Clare 1835 95 95 91 95 90 90 93
Limerick 2111 94 94 88 95 86 91 91
Tipperary NR/East 
Limerick 2053 95 95 90 95 89 92 92
HSE-MW Total 5999 94 94 89 95 88 91 92
HSE-NE
Cavan/Monaghan 1723 95 95 93 95 93 94 94
Louth 1695 95 95 92 95 92 92 93
Meath 2749 95 95 91 95 92 90 92
HSE-NE Total 6167 95 95 92 95 92 92 93
HSE-NW
Donegal 2480 96 96 89 95 88 90 91
Sligo/Leitrim 1464 96 95 91 94 87 86 94
HSE-NW Total 3944 96 95 90 95 88 88 92
HSE-SE
Carlow/Kilkenny 2197 95 95 92 94 87 89 93
South Tipperary 1463 95 94 94 96 89 91 93
Waterford 2242 93 93 93 93 88 89 93
Wexford 2532 95 95 94 95 89 91 94
HSE-SE Total 8434 94 94 93 94 88 90 93
HSE-S
North Cork 1203 92 93 79 92 81 86 86
North South Lee 4493 94 95 82 92 84 88 91
West Cork 609 88 89 71 87 74 75 79
Kerry 1592 93 94 81 93 84 87 89
HSE-S Total 7897 93 94 80 92 83 87 89
HSE-W
Galway 4245 92 92 79 91 83 84 86
Mayo 1904 94 93 77 95 82 84 86
Roscommon 1000 99 98 95 98 96 96 96
HSE-W Total 7149 93 93 80 93 85 85 88
Ireland 68754 94 94 85 94 86 88 90
Since T3, P3 and Polio3 uptake identical to D3 uptake only D3 uptake figures are presented
* Since September 1st 2008 the new primary childhood immunisation schedule has been implemented.   The changes to the primary schedule 
for children born on or after 1st July 2008 include introduction of a hepatitis B vaccine (as part of a 6 in 1 vaccine) given at 2, 4, 6 months of age 
and introduction of pneumococcal conjugate vaccine given at 2, 6 and 12 months of age.  Therefore, HepB3 and PCV3 uptake data presented 
here are only for those born between 01/07/2008 and 31/12/2008.
†The 2010 data for those at 24 months are incomplete as the following were unavailable: the Quarter 1 2010 HSE-M and HSE-S data and the 
HSE-E Dublin North Hibb data; the Quarter 2 2010 HSE-M data and; the Quarter 4 2010 HSE-NE data.  The available 2010 national 24 month 
D3, T3, P3 (n=68,754), Hib3 (n=68,760), Hibb (n=67,726), HepB3 (n=36,602), Polio3 (n=68,753), MenC3 (n=68,688), PCV3 (n=36,551) and MMR1 
(n=68,788) cohort data may be around 89-90% (this figure is an estimate only) of the national birth cohort.
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here 
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Table A2.3 Local Health Office (LHO) abbreviations used in the immunisation uptake chapter of this document
Local Health Office Abbreviations Local Health Office
CE Clare
CN/MN Cavan/Monaghan
CW/KK Carlow/Kilkenny
DL Donegal
DN Dublin North
DNC Dublin North Central
DNW Dublin North West
DS Dublin South
DSC Dublin South City
DSE Dublin South East
DSW Dublin South West
DW Dublin West
G Galway
KE/WW Kildare/West Wicklow 
KY Kerry
L Limerick
LD/WD Longford/Westmeath
LH Louth
LS/OY Laois/Offaly
MH Meath
MO Mayo
NC North Cork
NSL* North South Lee*
RN Roscommon
SO/LM Sligo/Leitrim
TN/EL Tipperary North /East Limerick
TS South Tipperary
WC West Cork
WD Waterford
WX Wexford
WW Wicklow 
*Please note while North Lee and South Lee are two separate LHOs their combined immunisation uptake data are reported
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Explanatory Notes
Glossary of Terms
Notifiable Infectious Diseases
Computerised Infectious Disease Reporting (CIDR) 
system
For the majority of the notifiable infectious diseases 
(see Appendix 1), data were collated using the 
Computerised Infectious Disease Reporting (CIDR) 
system.  During 2010, notification data were inputted 
directly by areas using the system.  For areas not yet on 
CIDR, data were forwarded weekly to HPSC for input to 
CIDR.  Enhanced surveillance was undertaken for certain 
diseases and these data collated on CIDR.   Outbreak 
data were also collated on CIDR using the same process 
outlined above.  Since 4th May 2008, new cases of 
Clostridium difficile-associated disease (CDAD) were 
notified on CIDR under the category ‘acute infectious 
gastroenteritis’ (AIG). Weekly Reports on infectious 
disease notifications (including a separate report for AIG 
with the emphasis on C. difficile) and outbreaks were 
produced by HPSC and published on the HPSC website, 
www.hpsc.ie.   Throughout the year data were cleaned 
and validated on an ongoing basis and final data checks 
and cleaning were undertaken following year end by 
HPSC and the Departments of Public Health.  Data 
analysis was performed using CIDR Business Objects 
Reporting and MS Excel.  Figures for the relevant 
chapters within this report were extracted from CIDR 
between July and October 2011.  These figures may 
differ from those previously published due to ongoing 
updating of data on CIDR.
Data on the notifiable infectious diseases not yet on 
CIDR were collated as follows:
National Tuberculosis Surveillance System (NTBSS)
TB notification data (including enhanced information) 
for 2009 were collated in the regional Departments of 
Public Health, where data were entered on the Epi2000 
NTBSS database.  Each HSE Area provided finalised 
2009 data (with outcome information) and provisional 
2010 data to HPSC in mid-2011.  Data were validated 
and cleaned with each area and the national data were 
collated.  Validation of the 2009 TB data was concluded 
during September 2011.
Sexually Transmitted Infections (STIs)
Clinicians and laboratories notified their respective 
Departments of Public Health of probable and 
confirmed cases of STIs.  Notifications were anonymised 
prior to notification.  Data for 2-009 were collated 
and analysed by Departments of Public Health and 
aggregated data were reported to HPSC.  National 
data were collated on an MS Access database, analysis 
preformed and reports produced by HPSC.
An enhanced surveillance system is in place for syphilis 
since 2000.  Enhanced forms were completed by 
clinicians and forwarded to the appropriate Department 
of Public Health from where they were sent to HPSC.  
An MS Access database was used at HPSC for collation 
and analysis of the national syphilis case-based data.
Other Surveillance Systems
Influenza Surveillance
Since 2000, HPSC has worked in collaboration with 
the NVRL, the ICGP and the Departments of Public 
Health on the influenza sentinel surveillance project. 
Sixty general practices (located in all HSE-Areas and 
representing 6.2% of the population) were recruited 
to report electronically, on a weekly basis, the number 
of patients who consulted with influenza-like illness 
(ILI).  ILI is defined using the EU case definition for ILI 
which is sudden onset of symptoms AND at least one 
of the following four systemic symptoms: fever, malaise, 
headache, myalgia; AND at least one of the following 
three respiratory symptoms: cough, sore throat, 
shortness of breath. 
Sentinel GPs were requested to send a combined nasal 
and throat swab on one to two ILI patients per week to 
the NVRL. The NVRL also tested respiratory non-sentinel 
specimens, referred mainly from hospitals. Other 
surveillance systems set up to monitor ILI/influenza 
activity include a network of sentinel hospitals reporting 
admissions data and sentinel schools reporting 
absenteeism. The Departments of Public Health also 
notified HPSC weekly of all cases of influenza, all 
influenza/ILI outbreaks and enhanced surveillance data 
on all hospitalised cases of confirmed influenza in 0-14 
year olds. HPSC was notified of all registered deaths on 
a daily basis from the General Register Office.
Several surveillance projects that were initiated/
augmented during the 2009 influenza pandemic were 
continued during the 2010/2011 influenza season: 
•  Surveillance of all calls to GP out-of-hours (OOHs) 
centres were monitored for self-reported influenza. 
•  Surveillance of all confirmed influenza notifications, 
including hospitalisation status.
•  Surveillance of all confirmed influenza adult and 
paediatric cases admitted to critical care.
•  Enhanced surveillance of all confirmed influenza 
deaths.
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At HPSC, data were collated from the various sources, 
analysed and weekly reports were produced. Influenza 
surveillance reports were posted on the HPSC website 
www.hpsc.ie. Aggregated clinical and virological data 
and anonymised data on confirmed influenza cases 
admitted to ICU and influenza-associated deaths were 
reported weekly to the European Centre for Disease 
Prevention and Control (ECDC).
HIV
HIV and AIDS surveillance in Ireland is voluntary 
and anonymised and operates in co-operation with 
laboratories, clinicians and Departments of Public 
Health.  In 2010, clinicians completed surveillance forms 
on newly diagnosed HIV cases, AIDS cases and AIDS 
related deaths and forwarded these to the appropriate 
Department of Public Health who in turn forwarded 
them to HPSC where national data were collated on an 
MS Access database.  Bi-annual analysis of these data 
were performed at HPSC and reports produced.  
Immunisation Uptake
Each HSE Area maintains a childhood immunisation 
database.  In 2010, HSE Areas provided HPSC with 
immunisation uptake data for their area and for each 
of the Local Health Offices in their area on a quarterly 
basis.  National data were collated and analysed at 
HPSC using a MS Excel database.  Quarterly reports 
were produced and are available on the HPSC website.  
For further details on methods used, please see the 
immunisation uptake chapter within this report.
European Antimicrobial Resistance Surveillance 
Network (EARS-Net)
Data were collected by participating EARS-Net (formerly 
the European Antimicrobial Resistance Surveillance 
System, EARSS) laboratories in 2010 on the first invasive 
isolate per patient per quarter on Staphylococcus 
aureus and Enterococcus faecalis from blood only 
and on Streptococcus pneumoniae, Escherichia coli, 
Klebsiella pneumoniae and Pseudomonas aeruginosa 
from blood and cerebrospinal fluid (CSF).  Data 
were reported quarterly to HPSC and collated in the 
WHONET database. Quarterly and annual reports were 
produced.
Note:  In general, invasive infections due to K. 
pneumoniae and P. aeruginosa are not notifiable but 
these pathogens are now included for surveillance 
under the EARS-Net project.
Antimicrobial consumption
Community (outpatient) consumption data were 
obtained from IMS Health and represent wholesaler 
to retail pharmacy sales figures for Ireland. Hospital 
(inpatient) consumption data were obtained directly 
from clinical pharmacies and validated with the support 
of the Irish Antimicrobial Pharmacists Association. 
Quarterly and annual consumption trends by named 
public acute hospitals are published on the HPSC 
website.  All data were stored at the HSPC in an MS 
Access database, and interpreted using the WHO 
Anatomical Therapeutic Chemicals index (www.whocc.
no/atcddd/) in line with European Surveillance of 
Antimicrobial Consumption (ESAC) methodology. See 
relevant section for notes on the denominator data.
Healthcare associated infections
Data were collected by participating general ICUs on 
MRSA colonisation/infection in the critical care setting. 
Data were reported monthly to the HPSC and stored in 
an MS Access database. Quarterly and annual reports 
were produced.  Data were also collected on the total 
volume of alcohol-based hand rub used per hospital 
per year/quarter, excluding that used for pre-operative 
surgical “scrub”.  See relevant section for notes on the 
denominator data. The rate of usage per hospital was 
calculated as the total volume of hand rub consumed (in 
litres) per 1000 bed days used, and quarterly and annual 
reports were produced for publication on the HPSC 
website.
Denominator Data
To calculate disease incidence rates, Census of 
Population data were used as the denominator 
(available from the Central Statistics Office, http://www.
cso.ie).  Population figures were applied as follows: 
Census 2006 for analysis of 2004 2010 data, Census 
2002 for 2000-2003 data and Census 1996 for 1999 
data. 
Monthly population changes were estimated between 
1993 and 2010 using a curve interpolation method for 
the calculation of outpatient antibiotic consumption 
rates. These are based on April 2011 update of the 
mid-year population estimates published by the CSO.  
Bed-days used and other activity data for public acute 
hospitals were provided by the Performance Monitoring 
Unit of the HSE and used to calculate rates of MRSA 
and hospital antibiotic consumption.
HSE Areas
Although organisational changes have taken place 
in the Health Services, the term HSE Areas are used 
in this report when analysing and presenting data by 
geographical area (equating to the eight former health 
board regions/areas).  This is because operationally 
the surveillance, prevention and control of infectious 
diseases are still managed by eight Departments of 
Public Health, one in each HSE Area.
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CIDR Computerised Infectious Diseases Reporting
DoHC Department of Health and Children
EARS-Net European Antimicrobial Resistance Surveillance Network 
ECDC European Centre for Disease Prevention and Control
EISN European Influenza Surveillance Network
FSAI Food Safety Authority of Ireland
FSPB Food Safety Promotion Board
ICGP Irish College of General Practitioners
IDU Injecting Drug User
IMMRL Irish Meningococcal and Meningitis Reference Laboratory
IPD Invasive pneumococcal disease
HCAI Healthcare associated infections
HPSC Health Protection Surveillance Centre
HSE Health Services Executive
HSE E HSE Eastern Region
HSE M HSE Midland Area
HSE MW HSE Mid-Western Area
HSE NE HSE North Eastern Area
HSE NW HSE North Western Area
HSE SE HSE South Eastern Area
HSE S HSE Southern Area
HSE W HSE Western Area
MRSA Meticillin Resistant Staphylococcus aureus
MSM Men who have Sex with Men
NSRL National Salmonella Reference Laboratory
NVRL National Virus Reference Laboratory
STIs Sexually Transmitted Infections
TB Tuberculosis
WHO World Health Organisation
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